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A B S T R A C T
Background
Acute psychotic illness, especially when associatedwith agitated or violent behaviour, can require urgent pharmacological tranquillisation
or sedation. In several countries, clinicians often use benzodiazepines (either alone or in combination with antipsychotics) for this
outcome.
Objectives
To examine whether benzodiazepines, alone or in combination with other pharmacological agents, is an effective treatment for psy-
chosis-induced aggression or agitation when compared with placebo, other pharmacological agents (alone or in combination) or non-
pharmacological approaches.
Search methods
We searched the Cochrane Schizophrenia Group’s register (January 2012, 20 August 2015 and 3 August 2016), inspected reference
lists of included and excluded studies, and contacted authors of relevant studies.
Selection criteria
We included all randomised controlled trials (RCTs) comparing benzodiazepines alone or in combination with any antipsychotics,
versus antipsychotics alone or in combination with any other antipsychotics, benzodiazepines or antihistamines, for people who were
aggressive or agitated due to psychosis.
Data collection and analysis
We reliably selected studies, quality assessed them and extracted data. For binary outcomes, we calculated standard estimates of risk ratio
(RR) and their 95% confidence intervals (CI) using a fixed-effect model. For continuous outcomes, we calculated the mean difference
(MD) between groups. If there was heterogeneity, this was explored using a random-effects model. We assessed risk of bias and created
a ’Summary of findings’ table using GRADE.
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Main results
Twenty trials including 695 participants are now included in the review. The trials compared benzodiazepines or benzodiazepines plus
an antipsychotic with placebo, antipsychotics, antihistamines, or a combination of these. The quality of evidence for the main outcomes
was low or very low due to very small sample size of included studies and serious risk of bias (randomisation, allocation concealment
and blinding were not well conducted in the included trials, 30% of trials (six out of 20) were supported by pharmaceutical institutes).
There was no clear effect for most outcomes.
Benzodiazepines versus placebo
One trial compared benzodiazepines with placebo. There was no difference in the number of participants sedated at 24 hours (very
low quality evidence). However, for the outcome of global state, clearly more people receiving placebo showed no improvement in the
medium term (one to 48 hours) (n = 102, 1 RCT, RR 0.62, 95% CI 0.40 to 0.97, very low quality evidence).
Benzodiazepines versus antipsychotics
When compared with haloperidol, there was no observed effect for benzodiazepines for sedation by 16 hours (n = 434, 8 RCTs, RR
1.13, 95% CI 0.83 to 1.54, low quality evidence). There was no difference in the number of participants who had not improved in
the medium term (n = 188, 5 RCTs, RR 0.89, 95% CI 0.71 to 1.11, low quality evidence). However, one small study found fewer
participants improved when receiving benzodiazepines compared with olanzapine (n = 150, 1 RCT, RR 1.84, 95% CI 1.06 to 3.18,
very low quality evidence). People receiving benzodiazepines were less likely to experience extrapyramidal effects in the medium term
compared to people receiving haloperidol (n = 233, 6 RCTs, RR 0.13, 95% CI 0.04 to 0.41, low quality evidence).
Benzodiazepines versus combined antipsychotics/antihistamines
When benzodiazepine was compared with combined antipsychotics/antihistamines (haloperidol plus promethazine), there was a higher
risk of no improvement in people receiving benzodiazepines in the medium term (n = 200, 1 RCT, RR 2.17, 95% CI 1.16 to 4.05,
low quality evidence). However, for sedation, the results were controversial between two groups: lorazepam may lead to lower risk of
sedation than combined antipsychotics/antihistamines (n = 200, 1 RCT, RR 0.91, 95% CI 0.84 to 0.98, low quality evidence); while,
midazolam may lead to higher risk of sedation than combined antipsychotics/antihistamines (n = 200, 1 RCT, RR 1.13, 95% CI 1.04
to 1.23, low quality evidence).
Other combinations
Data comparing benzodiazepines plus antipsychotics versus benzodiazepines alone did not yield any results with clear differences; all
were very low quality evidence.When comparing combined benzodiazepines/antipsychotics (all studies compared haloperidol) with the
same antipsychotics alone (haloperidol), there was no difference between groups in improvement in themedium term (n = 185, 4 RCTs,
RR 1.17, 95% CI 0.93 to 1.46, low quality evidence), but sedation was more likely in people who received the combination therapy
(n = 172, 3 RCTs, RR 1.75, 95% CI 1.14 to 2.67,very low quality evidence). Only one study compared combined benzodiazepine/
antipsychotics with antipsychotics; however, this study did not report our primary outcomes. One small study compared combined
benzodiazepines/antipsychotics with combined antihistamines/antipsychotics. Results showed a higher risk of no clinical improvement
(n = 60, 1 RCT, RR 25.00, 95% CI 1.55 to 403.99, very low quality evidence) and sedation status (n = 60, 1 RCT, RR 12.00, 95% CI
1.66 to 86.59, very low quality evidence) in the combined benzodiazepines/antipsychotics group.
Authors’ conclusions
The evidence from RCTs for the use of benzodiazepines alone is not good. There were relatively few good data. Most trials were too
small to highlight differences in either positive or negative effects. Adding a benzodiazepine to other drugs does not seem to confer clear
advantage and has potential for adding unnecessary adverse effects. Sole use of older antipsychotics unaccompanied by anticholinergic
drugs seems difficult to justify. Much more high-quality research is still needed in this area.
P L A I N L A N G U A G E S U M M A R Y
Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis
Review question
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The aim of this review was to compare the tranquillising (calming) or sedative (sleepiness) effects of benzodiazepines, given alone or
combined with other drugs compared with the effect of placebo (a pretend treatment), other drugs or non-drug treatments for people
who are aggressive or agitated because they are experiencing psychoses.
Background
Acute psychosis is a rapid worsening of a person’s mental state where touch with reality is often lost. People may experience frightening
delusions or hallucinations which are distressing and may cause agitated or aggressive behaviour. In urgent cases, this agitation or
aggression may cause harm to the person experiencing the psychoses or others around them. To avoid such harm, rapid tranquillisation
or sedation with medicines may be required. The most common medicines used to achieve a state of calmness or sedation are
benzodiazepines and these can be given either alone or in combination with antipsychotics.
Searching
The original search for this review was carried out in January 2012 and subsequently two further update searches were run in August
2015 and August 2016. In total, these searches found 2497 records, which the review authors checked for inclusion or exclusion from
the review. Authors included records only if they were randomised trials (clinical studies where people are randomly put into one of two
or more treatment groups) that allocated people with acute psychosis who presented with agitation, violence aggressive behaviour (or a
combination of these) to receive benzodiazepines either given alone or combined with any antipsychotics, versus placebo, antipsychotics
alone or in combination with other antipsychotics/benzodiazepines/antihistamines or non-drug treatments.
Evidence found
In total, 20 trials were included. Overall, the quality of evidence was low or very low due to serious risk of bias and very small size of
included trials. There was no clear difference in improvement between benzodiazepines and placebo, benzodiazepines and antipsychotics
or benzodiazepines plus antipsychotics and benzodiazepines alone or antipsychotic alone. When benzodiazepines were compared with
combined antipsychotics/antihistamines, there was a higher risk of no improvement in people receiving benzodiazepine alone but
the evidence was of low quality. Only one study showed lower effect of combined benzodiazepines/antipsychotics versus combined
antihistamines/antipsychotics. However, the evidence was of very low quality. In terms of side effects, people receiving benzodiazepines
compared to antipsychotics had lower risk of presenting with symptoms such as shaking, tremors and slurred speech whereas the results
for the sedation caused were unclear.
Conclusions
The existing trials are not informative enough to support or refute the use of benzodiazepines alone or in additional to other medicines
when urgent tranquillisation or sedation with medicines is required. Although benzodiazepines alone may cause fewer side effects
compared to older antipsychotics, when they are added on to othermedicines this may lead to unnecessary side effects. Further studies are
needed to provide good-quality evidence with robust conclusions to inform clinical practice and policies around rapid tranquillisation
for people with psychoses who are aggressive or agitated.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Benzodiazepines compared to placebo for psychosis- induced aggression or agitation
Patient or population: people with psychosis-induced aggression or agitat ion
Settings: hospitals (Romania and US)
Intervention: benzodiazepines
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Benzodiazepines
Tranquilli-
sation or asleep: seda-
tion - medium term
Number of part icipants
sedated
Follow-up: 24 hours
59 per 10001 98 per 1000
(25 to 389)
RR 1.67
(0.42 to 6.61)
102
(1 study)
⊕©©©
V ery low2,3,4
-
Global state: no im-
provement - medium
term
As def ined in each
study
Follow-up: 24 hours
569 per 10001 353 per 1000
(227 to 552)
RR 0.62
(0.40 to 0.97)
102
(1 study)
⊕©©©
Very low2,3,4
-
Global state: need for
additional medication -
medium term
Number of part ici-
pants requiring addi-
t ional medicat ion
Follow-up: 24 hours
529 per 10001 529 per 1000
(365 to 762)
RR 1.00
(0.69 to 1.44)
102
(1 study)
⊕©©©
Very low2,3,4
-
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Adverse effects/
events: extrapyramidal
symptoms - medium
term
Number of instances of
extrapyramidal symp-
toms
Follow-up: 24 hours
59 per 10001 19 per 1000
(2 to 182)
RR 0.33
(0.04 to 3.1)
102
(1 study)
⊕©©©
Very low2,3,4
-
Satisfaction with treat-
ment: f rom the per-
spect ive of consumer,
family and informal car-
ers or professionals/
carers at any point dur-
ing the acute manage-
ment stage
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Economic out-
comes: cost-ef fect ive-
ness - clinically impor-
tant
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Assumed risk: mean baseline risk presented for single study. Equates with that of control group.
2Risk of bias: ’very serious’ - 90% of trial authors and coauthors were employed by trial sponsors at the t ime of the study -
downgraded by 1.
3Risk of bias: ’serious’ - randomisat ion poorly described - downgraded by 1.5
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4Imprecision: ’serious’ - small sample size - downgraded by 1.
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B A C K G R O U N D
Description of the condition
Acutely psychotic people may exhibit agitated and aggressive be-
haviour that canpresent a danger to themselves or others. To ensure
a safe and therapeutic environment where the patients have their
dignity and privacy respected, de-escalation techniques should be
used to calm the patient (NICE 2015; Rocca 2006). Frequently,
however, the behaviour may be too disturbed or agitated for these
methods to be effective, and it might prove imperative that further
action in the form of rapid tranquillisation is given usually as a
last resort because the risk to the person or other people is too
high (NICE 2015; Rocca 2006). The aim of rapid tranquillisation
is to achieve a state of calm that is sufficient to minimise risk of
harm to the agitated person themselves, or to others around them,
and allow treatment of the underlying condition (Battaglia 2005;
NICE 2015). Rapid tranquillisation may serve as primary therapy
in such instances but may also be used in conjunction with other
de-escalation methods (Marder 2006; NICE 2015).
Description of the intervention
Rapid tranquillisation is commonly used in emergency settings
in general and psychiatric hospitals worldwide (Goedhard 2006;
Marder 2006). Three major classes of drugs are used to achieve
rapid tranquillisation: typical antipsychotics, benzodiazepines
and, more recently, atypical antipsychotics (Marder 2006). Intra-
muscular (IM) injections of typical antipsychotics and benzodi-
azepines, alone or in combination, have been the treatment of
choice for several decades. One review of the research literature re-
ported that the typical antipsychotic, haloperidol, and the benzo-
diazepine, lorazepam, were the most widely used drugs (Battaglia
2005). However, the drugs used for rapid tranquillisation may
vary widely in different countries. One survey in Rio de Janeiro,
Brazil, showed that a haloperidol/promethazine mixture was com-
monly used (Huf 2002), while one survey of African psychiatrists
found that chlorpromazine and diazepam were most commonly
prescribed, although the choice of drug tended to be governed by
availability rather than preference (James 2011). With the intro-
duction of parenteral forms of the atypical antipsychotics, these
are also gaining in popularity as the first-line treatment for agita-
tion in the psychiatric emergency setting (Marder 2006; Mintzer
2006).
The benzodiazepine family is large (Table 1), and with different
characteristics of metabolism (Table 2).
How the intervention might work
Among other actions, benzodiazepines enhance the effect of the
inhibitory neurotransmitter gamma-aminobutyric acid (GABA),
which results in sleep inducing, sedative, antianxiety, muscle re-
laxant and amnesic effects. First discovered in 1955, through long
experience, it is clear that these drugs are effective for managing
aggression, but it is unclear just how effective and, if they are better
or worse than other compounds or combinations of compounds.
Why it is important to do this review
Guidance suggests benzodiazepines are at least as effective as an-
tipsychotics in controlling severely agitated behaviour (Allen 2000;
NICE 2015; Rocca 2006), and indeed this was the finding of the
original Cochrane review (Gillies 2005). Some authors suggest
that the combination of antipsychotics with benzodiazepines may
be more advantageous than either drug alone (Rocca 2006), but
there was inadequate evidence of this in the original Cochrane re-
view (Gillies 2005). This update includes all new trials comparing
benzodiazepines (alone or combined with antipsychotics) with an-
tipsychotics (alone or in combination with benzodiazepines). In
addition, in this update, we included trials that compared benzo-
diazepines alone or in combination with antipsychotics, compared
to other antipsychotics, benzodiazepines or antihistamines.
While there is evidence that both benzodiazepines and antipsy-
chotics are effective in decreasing agitation, both can cause unde-
sirable adverse effects. Acute phase treatment with typical antipsy-
chotic drugs may result in debilitating extrapyramidal symptoms
(EPS) including Parkinson’s-like symptoms, hypotension, lower-
ing of the seizure threshold, cardiac arrhythmia and neuroleptic
malignant syndrome (Battaglia 2005; NICE 2015; Rocca 2006).
Benzodiazepines produce EPS less frequently, but can cause res-
piratory depression, ataxia, excessive sedation, memory impair-
ment and paradoxical disinhibition (Battaglia 2005;Marder 2006;
Rocca 2006). The adverse effect profile of combined therapy with
benzodiazepines and antipsychotics is as yet unclear (Gillies 2005),
although it has been suggested that combination therapy may de-
crease the incidence of adverse effects (Battaglia 2005). It is also
thought that the broader activity profile of atypical antipsychotics
may mean they are less likely to produce the EPS adverse effects
of the typical antipsychotics (Duggan 2005; Essali 2009; Silveira
da Mota Neto 2002), but there have been reports of severe ad-
verse events associated with the IM administration of these drugs
(Battaglia 2005).
This is one of a series of similar reviews (Table 3).
O B J E C T I V E S
To examine whether benzodiazepines, alone or in combination
with other pharmacological agents, is an effective treatment for
psychosis-induced aggression or agitation when compared with
placebo, other pharmacological agents (alone or in combination)
or non-pharmacological approaches.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all relevant randomised controlled trials (RCTs). We
excluded quasi-randomised trials, such as those allocating by days
of the week. If a trial was described as ’double blind’ but implied
randomisation, we included such trials in a sensitivity analysis (see
Sensitivity analysis). If their inclusiondidnot result in a substantive
difference, they remained in the analyses. If their inclusion resulted
in a clear effect, we did not add the data from these lower-quality
studies to the results of the better-designed trials, but presented
such data within a subcategory.
Types of participants
Any people presenting to the adult services with acutely disturbed/
aggressive/agitated behaviour thought to be secondary to psychotic
illnesses such as schizophrenia, schizoaffective disorder, mixed af-
fective disorders, manic phase of bipolar disorder or brief psychotic
episode. For the purposes of this review, we defined ’acute’ as where
authors of trials stated or implied that the behavioural disturbance
was of sudden onset or extreme in nature, or both.Where trials in-
cluded people with organic illnesses or people abusing substances,
we only included these trials if over 60% of participants were ex-
hibiting disturbed behaviour resulting from a psychotic episode.
Types of interventions
Benzodiazepines - given alone
Benzodiazepines included: alprazolam, bretazenil, bromazepam,
chlordiazepoxide, cinolazepam, clonazepam, clorazepate, cloti-
azepam, cloxazolam, delorazepam, diazepam, estazolam, flu-
nitrazepam, halazepam, loprazolam, lorazepam, lormetazepam,
medazepam, midazolam, nimetazepam, nitrazepam, nordazepam,
oxazepam, phenazepam, pinazepam, prazepam, premazepam,
quazepam, temazepam, tetrazepam, triazolam (Table 1).
Any dose, any means of administration.
Compared with the following:
1. Placebo
2. Other benzodiazepine - given alone
Any dose, any means of administration.
3. Antipsychotics
First generation/typical, including: chlorpromazine, chlorproth-
ixene, clopenthixol, cyamemazine, droperidol, flupentixol/flu-
penthixol, fluphenazine, haloperidol, levomepromazine, loxapine,
mesoridazine, molindone, periciazine, perphenazine, pimozide,
prochlorperazine, promazine, promethazine, thioridazine, thioth-
ixene, trifluoperazine, triflupromazine, zuclopenthixol.
Second generation/atypical, including: amisulpride, aripiprazole,
asenapine, clozapine, clothiapine, clotiapine, iloperidone, lurasi-
done, mosapramine, olanzapine, paliperidone, perospirone, queti-
apine, remoxipride, risperidone, sertindole, sulpiride, ziprasidone,
zotepine.
Any dose, any means of administration.
4. Other combinations of drugs
4.1. Benzodiazepines plus antipsychotics (where the benzodi-
azepine is the same in both groups).
4.2. Antipsychotics plus antihistamine/anticholinergic drugs.
Antihistamines including: azelastine, brompheniramine, bu-
clizine, bromodiphenhydramine, carbinoxamine, cetirizine, cy-
clizine, chlorpheniramine, chlorodiphenhydramine, clemastine,
cyproheptadine, desloratadine, dexbrompheniramine, deschlor-
pheniramine, dexchlorpheniramine, dimenhydrinate, dimethin-
dene, diphenhydramine, doxylamine, ebastine, embramine, fex-
ofenadine, levocetirizine, loratadine, meclozine, olopatadine,
orphenadrine, phenindamine, pheniramine, phenyltoloxamine,
promethazine, pyrilamine, rupatadine, tripelennamine, triproli-
dine.
Any dose, any means of administration.
5. Non-pharmacological approaches
Benzodiazepines plus antipsychotics
Compared with the following.
1. Placebo
2. Any antipsychotics (where the antipsychotic was the same
in both groups)
Any dose, any means of administration.
3. Other combinations of drugs
3.1. Benzodiazepines plus antipsychotics (where the antipsychotic
was the same in both groups).
3.2. Antipsychotics plus antihistamines (where the antipsychotic
was the same in both groups).
4. Non-pharmacological approaches
Types of outcome measures
We divided into immediate term (zero to 15 minutes), short term
(15 minutes to one hour) and medium term (one to 48 hours).
We chose 48 hours as a maximum follow-up as most benzodi-
azepines act rapidly (see Table 2), and for this review our primary
outcome was tranquillisation or asleep, which we considered not
to be a long-term outcome. We recognise some outcomes such as
mental state and adverse effects need longer-term follow-up and
will include long-term data in future updates of this review.
Primary outcomes
1. Tranquillisation or asleep
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1.1. Tranquil or asleep - by up to 30 minutes.
1.2. Repeated need for rapid tranquillisation.
Secondary outcomes
1. Tranquillisation or asleep
1.1. Not tranquil - over 30 minutes.
1.2. Not asleep - over 30 minutes.
1.3. Time to tranquillisation/sleep.
1.4. Time to tranquillisation.
1.5. Time to sleep.
2. Behaviours
2.1. Specific behaviours
2.1.1. Self-harm, including suicide.
2.1.2. Injury to others.
2.2. Agitation.
2.2.1. Another episode of agitation by 24 hours.
2.2.2. Clinically important change in agitation.
2.2.3. Change in agitation.
2.2.4. Mean endpoint in agitation score.
2.2.5. Mean change in agitation scores.
2.3. Aggression.
2.3.1. Another episode of aggression by 24 hours.
2.3.2. Clinically important change in aggression.
2.3.3. Change in aggression.
2.3.4. Mean endpoint in aggression score.
2.3.5. Mean change in aggression scores.
2.4. General.
2.4.1. Clinically important change in behaviour.
2.4.2. Mean endpoint/change score behaviour scale.
3. Global state
3.1. General.
3.1.1. Clinically important change in global state - as defined by
individual studies.
3.1.2. Any change in global state - as defined by individual studies.
3.1.3. Mean endpoint/change score global state scale.
3.1.4. Need for additional medication.
3.1.5. Change in medication dosage.
4. Mental state
4.1. General.
4.1.1. Clinically important change in general mental state scores.
4.1.2. Mean endpoint general mental state score.
5. Adverse effects/events
5.1. General.
5.1.1. Incidence of adverse effects, general or specific.
5.1.2. Severity of symptoms.
5.1.3. Measured acceptance of treatment.
5.1.4. Sudden or unexpected death.
5.2. Specific.
5.2.1. Extrapyramidal symptoms (EPS).
5.2.2. Use of medication for EPS.
6. Hospital and service outcomes
6.1. Hospitalisation.
6.1.1. Time to hospitalisation.
6.1.2. Hospitalisation of people in the community.
6.1.3. Duration of hospital stay.
6.1.4. Changes in services provided by community teams.
6.2. Seclusion.
6.2.1. Time in seclusion.
6.2.2. Changes in hospital status (e.g. changes from voluntary to
involuntary care, changes in level of observation, use of seclusion).
7. Satisfaction with treatment
7.1. Specific.
7.1.1. Consumers.
7.1.2. Family and informal carers.
7.1.3. Professionals/carers.
8. Economic outcomes
8.1. Specific.
8.1.1. Direct costs - as defined by trial authors.
8.1.2. Indirect costs - as defined by trial authors.
8.1.3. Cost-effectiveness - as defined by trial authors.
9. Leaving the study early
10. ’Summary of findings’ tables
Weused theGRADEapproach to interpret findings (Schünemann
2008) and used GRADE profiler (GRADEpro) to import data
fromReviewManager 5 (Review Manager) to create ’Summary of
findings’ tables. These tables provide outcome-specific informa-
tion concerning the overall quality of evidence from each included
study in the comparison, the magnitude of effect of the interven-
tions examined and the sum of available data on all outcomes we
rated as important to patient care and decision making. We se-
lected the following main outcomes for inclusion in the ’Summary
of findings’ table.
1. Tranquillisation or asleep: sedation - medium term.
2. Global state: no improvement - medium term.
3. Global state: need for additional medication - medium
term.
4. Adverse effects/events: clinically important - EPS - medium
term.
5. Satisfaction with treatment: from the perspective of
consumer, family and informal carers or professionals/carers at
any point during the acute management stage.
6. Economic outcomes: cost-effectiveness.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Trials Register
On3 August 2016, the information specialist searched the register
using the following search strategy:
(*All_Aggression* AND *ALL_Benzodizepines*) in Keyword
Field of REFERENCE
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In such a study-based register, searching the major concept re-
trieves all the relevant keywords and studies because all the stud-
ies have already been organised based on their interventions and
linked to the relevant topics.
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including MED-
LINE, Embase, AMED, BIOSIS, CINAHL, PsycINFO, PubMed
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature and conference proceedings (see Group
Module). There is no language, date, document type or publica-
tion status limitations for inclusion of records into the register.
For previous searches, see Appendix 1.
Searching other resources
1. Reference searching
We inspected references of all included studies for further relevant
studies.
2. Handsearching
We sought additional relevant trials by handsearching reference
lists of included and excluded trials.
3. Requests for additional data
We attempted to contact authors of relevant trials to inquire about
other sources of relevant information.
Data collection and analysis
Selection of studies
Material downloaded from electronic sources included details of
author, institution or journal of publication. One review author
(HZ) inspected all reports, which were then inspected the other
review authors (DG, TS, SJS, FC, JX or SZ) to ensure reliable
selection.We resolved any disagreements by discussion, and where
there was still doubt, we acquired the full article for further in-
spection. Once the full articles were obtained, we decided whether
the studies met the review criteria. If disagreement could not be
resolved by discussion, we sought further information and added
these trials to the list of those awaiting assessment.
Data extraction and management
1. Extraction
The review authors (DG, TS, SJS, FC or SZ) independently ex-
tracted data from all included studies. In addition, to ensure reli-
ability, one review author (JX) independently extracted data from
a random sample of these studies, comprising 10% of the total.
Any disagreements were discussed, decisions documented and, if
necessary, we contacted authors of studies for clarification. With
remaining problems, one review author (CA) helped clarify issues
and these final decisions were documented. Data presented only in
graphs and figures were extracted whenever possible, but included
only if two review authors independently had the same result. We
attempted to contact authors through an open-ended request to
obtain missing information or for clarification whenever neces-
sary. If studies were multi-centre, where possible, we extracted data
relevant to each component centre separately.
2. Management
2.1. Forms
We extracted binary, continuous and other data onto standard,
simple forms.
2.2. Scale-derived data
We included continuous data from rating scales only if:
• the psychometric properties of the measuring instrument
were described in a peer-reviewed journal (Marshall 2000); and
• the measuring instrument had not been written or modified
by one of the trialists for that particular trial.
Ideally, the measuring instrument was a self-report or was com-
pleted by an independent rater or relative (not the therapist). We
realise that this is not often reported clearly; in Description of
studies, we noted if this was the case or not.
2.3. Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. However, calculation of change needs two assessments
(baseline and endpoint), which can be difficult in unstable and
difficult-to-measure conditions such as schizophrenia.We decided
primarily to use endpoint data, and only use change data if end-
point data were not available. Because endpoint and change data
are combined in the analysis, we used mean differences (MD)
rather than standardised mean differences (SMD) throughout
(Higgins 2011).
2.4. Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the problemof applying parametric
tests to non-parametric data, we aimed to apply the following
standards to all data before inclusion:
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• standard deviations (SDs) and means were reported in the
paper or obtainable from the authors;
• when a scale starts from the finite number zero, the SD is
more than the mean, this is considered strong evidence of skew
(Higgins 2011);
• if a scale started from a positive value (such as the Positive
and Negative Syndrome Scale (PANSS) which can have values
from 30 to 210), we modified the calculation described above to
take the scale starting point into account. In these cases, skew is
present if SD > (S - Smin), where S is the mean score and Smin is
the minimum score. Where skewed data were present, we
presented results in a separate table.
Skewed endpoint data from trials of fewer than 200 participants
were entered in additional tables rather than into an analysis.
Skewed endpoint data pose less of a problem when looking at
means if the sample size is large (over 200 participants) and these
were entered into syntheses.
When continuous data are presented on a scale that includes the
possibility of negative values (such as change data), it is difficult
to determine whether data are skewed or not; we entered change
data from both large and small trials.
2.5. Common measure
To facilitate comparison between trials, we intended to convert
variables that could be reported in differentmetrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month) if necessary.
2.6. Direction of graphs
We entered data in such a way that the area to the left of the line
of no effect indicated a favourable outcome for benzodiazepines
alone, or (in the absence of a benzodiazepine alone) benzodi-
azepines in combination with antipsychotics.
Assessment of risk of bias in included studies
Two review authors (HZ and JX) independently assessed risk of
bias using criteria described in theCochrane Handbook for Systemic
reviews of Interventions to assess trial quality (Higgins 2011). This
set of criteria is based on evidence of associations between over-
estimate of effect and high risk of bias of the article such as se-
quence generation, allocation concealment, blinding, incomplete
outcome data and selective reporting.
Where the raters disagreed, the final rating was made by consen-
sus, with the involvement of another member of the review group.
Where inadequate details of randomisation and other character-
istics of trials were provided, we contacted authors of the trials
to obtain further information. Non-concurrence in quality assess-
ment was reported, but where disputes arose as to which category
a trial was to be allocated, we resolved issues by discussion.
The level of risk of bias was noted in both the text of the review
and in the ’Summary of findings’ tables.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ra-
tios and that odds ratios tend to be interpreted as RR by clini-
cians (Deeks 2000). If heterogeneity was identified (Assessment of
heterogeneity), we used a random-effectsmodel to explorewhether
this had an effect on findings. For statistically significant results, we
used ’Summary of findings’ tables to calculate the number needed
to treat for an additional beneficial or harmful outcome and its
95% CI.
2. Continuous data
For continuous outcomes, we calculated estimated MD between
groups as change and endpoint data were combined. If scales of
considerable similarity had been used, we would have presumed
there was a small difference in measurement, calculated the effect
size and transformed the effect back to the units of one or more
of the specific instruments. However, data of this type were not
identified.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ cluster randomisation (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. First, authors often fail to account
for intraclass correlation in clustered trials, leading to a ’unit of
analysis’ error (Divine 1992) whereby P values are spuriously low,
CIs unduly narrow and statistically significant difference overesti-
mated. This causes type I errors (Bland 1997; Gulliford 1999).
None of the present included trials used cluster randomisation.
For the purposes of future updates of this review, where clustering
is not accounted for in primary studies, we will present data in
a table, with an * symbol to indicate the presence of a probable
unit of analysis error. In subsequent versions of this review, we will
seek to contact first authors of trials to obtain intraclass correlation
coefficients for their clustered data and to adjust for this by us-
ing accepted methods (Gulliford 1999). Where clustering may be
incorporated into the analysis of primary studies, we will present
these data as if from a non-cluster randomised study, but adjust
for the clustering effect.
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2. Cross-over trials
None of the present included trials employed a cross-over trial
design; for the purposes of future updates of this review, a major
concern of cross-over trials is the carry-over effect. It occurs if an
effect (e.g. pharmacological, physiological or psychological) of the
treatment in the first phase is carried over to the second phase.
As a consequence, on entry to the second phase the participants
can differ systematically from their initial state despite a washout
phase. For the same reason, cross-over trials are not appropriate
if the condition of interest is unstable (Elbourne 2002). As both
effects are very likely in severe mental illness, we will only use data
of the first phase of cross-over trials.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if two or
more of the interventionswere similar, we pooled data. If datawere
binary, these were simply added. If data were continuous, we com-
bined data following the formula in Section 7.7.3.8 (Combining
groups) of the Cochrane Handbook for Systemic reviews of Interven-
tions (Higgins 2011). Where the additional treatment arms were
not relevant, we did not use these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for in either group, we would
not present these data or use them within analyses (except for the
outcome ’leaving the study early’).
2. Binary
Where attrition for a binary outcome was between 0% and 50%,
we presented data on a ’once-randomised-always-analyse’ basis (an
intention-to-treat analysis) by including those leaving the study
early in the denominator.
3. Continuous
3.1. Attrition
Where attrition for a continuous outcome was between 0% and
50%, and data only from people who completed the study to that
point were reported, we presented and used these data.
3.2. Standard deviations
If SDs were not reported, we first tried to obtain the missing val-
ues from the authors. If not available, where there were missing
measures of variance for continuous data, but an exact standard
error (SE) and CIs available for group means, and either P value
or t value available for differences in mean, we could calculate
them according to the rules described in the Cochrane Handbook
for Systemic reviews of Interventions (Higgins 2011).When only the
SE was reported, SDs were calculated by the formula SD = SE ×
square root (n). Sections 7.7.3 and 16.1.3 of the Cochrane Hand-
book for Systemic reviews of Interventions present detailed formulae
for estimating SDs from P values, t or F values; CIs; ranges or
other statistics (Higgins 2011). If these formulae did not apply, we
calculated the SDs according to a validated imputation method,
which is based on the SDs of the other included trials (Furukawa
2006). Although some of these imputation strategies can intro-
duce error, the alternative would be to exclude a given study’s out-
come and thus to lose information. Where the only variance given
was range (Diazepam 1979, IL), SDs were also estimated from the
difference between the upper and lower value divided by four.
3.3. Last observation carried forward
We anticipated that some trials would employ the method of last
observation carried forward (LOCF) within the study report. As
with all methods of imputation to deal with missing data, LOCF
introduces uncertainty about the reliability of the results (Leucht
2007). Therefore, where LOCF data were used in the trial, if less
than 50% of the data had been assumed, we would have presented
and used these data and indicated that they were the product
of LOCF assumptions. Where LOCF were not used, data were
analysed as they were presented in the original publications.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included trials initially, without seeing compar-
ison data, to judge clinical heterogeneity. We simply inspected all
trials for clearly outlying people or situations that we had not pre-
dicted would arise. When such situations or participant groups
arose, these implications were covered in the Discussion.
2. Methodological heterogeneity
We considered all included trials initially, without seeing compar-
ison data, to judge methodological heterogeneity. We simply in-
spected all trials for clearly outlying methods that we had not pre-
dicted would arise. When such methodological differences arose,
these were considered in the Discussion.
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3. Statistical heterogeneity
3.1. Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2. Employing the I2 statistic
Heterogeneity between trials was investigated by considering the
I2 statistic alongside the Chi2 statistic (P > 0.10). The I2 statistic
provides an estimate of the percentage of inconsistency thought
to be due to chance (Higgins 2008). The importance of the ob-
served value of I2 statistic depends on the magnitude and direc-
tion of effects and the strength of evidence for heterogeneity (e.g.
P value from the Chi2 test, or a CI for the I2 statistic). An I
2 statistic estimate of 50% or greater accompanied by a statisti-
cally significant Chi2 statistic is interpreted as evidence of substan-
tial levels of heterogeneity (Section 9.5.2; Higgins 2011). When
there were substantial levels of heterogeneity in the primary out-
come, we explored reasons for heterogeneity (Subgroup analysis
and investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research find-
ings is influenced by the nature and direction of results. These are
described in section 10.1 of the Cochrane Handbook for Systemic
reviews of Interventions (Higgins 2011). We attempted to locate
protocols of included randomised trials. If the protocol was avail-
able, outcomes in the protocol and in the published report were
compared. If the protocol was not available, outcomes listed in the
methods section of the trial report were compared with actually
reported results.
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We did not
use funnel plots for outcomes where there were 10 or fewer trials,
or where all trials were of similar sizes. In other cases, where funnel
plots were possible, we sought statistical advice in their interpre-
tation. Because there were more data available for the secondary
outcome of sedation, we completed a funnel plot analysis for this
outcome (Figure 1).
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Figure 1. Funnel plot of comparison: 2 benzodiazepines versus antipsychotics, outcome: 2.1 Tranquillisation
or asleep: 1. sedation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different trials are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between trials even if there is no statistically
significant heterogeneity. However, there is a disadvantage to the
random-effects model as it puts added weight onto small trials,
which often are the most biased ones. Depending on the direction
of effect, these trials can either inflate or deflate the effect size. We
chose a fixed-effect model for all analyses, and if heterogeneity was
identified, we used a random-effects model.
As this is a reviewof the effects on acute psychosis, we included only
those outcomes up to and including 48 hours after the initial dose
of medication. Where data were for more than one time interval
within the immediate (zero to 15minutes), short term (15minutes
to one hour) and medium term (one to 48 hours) categories, we
used the earlier data. The only exception to this were the data from
Diazepam 1979, IL; this trial reported Clinical Global Impression
(CGI) data at four and 24 hours (medium term) but because the
loss to follow-up was more than 50% for one group at four hours
and complete at 24 hours, we used the latter data.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
Subgroup analyses were carried out for different antipsychotics.
2. Investigation of heterogeneity
If inconsistency was high, this was reported. First, we investigated
whether data had been entered correctly. Second, if data were cor-
rect, we visually inspected the graph and if the results of trials
were clearly different, these data were not pooled. Where there
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was evidence of substantial statistical heterogeneity data (Analysis
5.1; Analysis 5.5; Analysis 2.9), these were also analysed using a
random-effects model and any differences in the results of fixed-
effect and random-effects models covered in the Discussion. Pos-
sible reasons for identified heterogeneity are also considered in the
Discussion.
Sensitivity analysis
1. Implication of randomisation
If trials were described in some way as to imply randomisation,
we undertook a sensitivity analyses for the primary outcome. We
included these studies in the analyses and if there was no substan-
tive difference when the implied randomised studies were added
to those with better description of randomisation, then we used
relevant data from these studies.
2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up (see Dealing with missing data), we compared the findings of
the primary outcome when we used our assumption compared
with completer data only. If there was a substantial difference, we
reported and discussed these results but continued to employ our
assumption.
Where assumptions had to be made regarding missing SDs data
(see Dealing with missing data), we compared the findings of the
primary outcome when we used our assumption compared with
completer data only. We undertook a sensitivity analysis testing
how prone results were to change when ’completer’ data only were
compared to the imputed data using the above assumption. If
there was a substantial difference, we reported and discussed these
results but continued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that we judged to be at
high risk of bias across one or more of the domains of randomisa-
tion for the meta-analysis of the primary outcome (see Assessment
of risk of bias in included studies). If the exclusion of trials at high
risk of bias did not substantially alter the direction of effect or the
precision of the effect estimates, we included data from these trials
in the analysis
4. Imputed values
We undertook a sensitivity analysis to assess the effects of includ-
ing data from trials where we used imputed values for intraclass
correlation coefficients in calculating the design effect in cluster
randomised trials. If we found substantial differences in the direc-
tion or precision of effect estimates, we did not pool data from the
excluded trials with the other trials contributing to the outcome,
but presented them separately.
5. Fixed and random effects
We synthesised data using a fixed-effect model, however, we also
synthesised data for the primary outcome using a random-effects
model to evaluate whether this altered the significance of the re-
sults.
R E S U L T S
Description of studies
Results of the search
The update searches were undertaken on two occasions; August
2015 (75 references) and August 2016 (three references), totalling
78 new references.With the addition of the previous search results,
we screened 2497 references. Of which, 2428 references were ex-
cluded after viewing the titles and abstracts and 84 full-text reports
were obtained for further screening. Forty-eight studies (with 52
full-text reports) were excluded due to ineligible study design, par-
ticipants or comparisons. Finally, 20 studies (with 32 full-text re-
ports) were included in the review (see Figure 2).
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Figure 2. Study flow diagram.
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Included studies
See Characteristics of included studies table for descriptions of
each study. This updated review adopted a different means of pre-
senting included studies. We decided to present included studies
in such a way as to describe the type of benzodiazepine employed
in the study, as well as the year and country in which the study was
undertaken. For example, in the study that was referenced in the
previous review as ’Qu 1999’, participants received either clon-
azepam 2 mg or haloperidol 10 mg and the study was undertaken
in China in 1999; therefore, it is now presented as Clonazepam
1999, CHN. We felt that this method, although unconventional,
would be most suitable way to present the findings in a logical
and concise manner, as results are clustered in graphs for ease of
understanding.
The review included 20 trials. This is the total of the 17 trials from
the previous review and three after the latest search (Clonazepam
2007a, CHN; Lorazepam 2009, SK; Lorazepam 2010, IN). In
this 2016 update, we changed the inclusion criteria to include
the comparison of antihistamines/anticholinergics in combination
with antipsychotics, as we considered that a review of the effect
of benzodiazepines for psychosis-induced aggression should take
into account the potential use of antihistamines for the treatment
of psychosis-induced aggression due to its potential sedative and
anticholinergic properties and the widespread use of this com-
bination. The inclusion criteria were clarified to specify the in-
clusion of benzodiazepines either alone or in combination with
any other antipsychotic drug, versus placebo, non-pharmacolog-
ical approaches, other benzodiazepines or antipsychotics alone,
or combined with any other antipsychotic, antihistaminic/anti-
cholinergic drugs or other benzodiazepine. The inclusion criteria
were further refined to ensure that the benzodiazepine was the
same in the intervention and comparator arm of the trials where
benzodiazepine alone was compared to benzodiazepine combined
with antipsychotic. This enabled us to detect whether the appar-
ent effect was due to combination with an antipsychotic. Where
a combination of benzodiazepine with an antipsychotic was com-
pared to another benzodiazepine combined with an antipsychotic,
it was ensured that the antipsychotic was the same in both the
intervention and the comparator arm. This allowed us to detect
whether the apparent effect was due to the superiority of one ben-
zodiazepine over another. Moreover, this had the result of permit-
ting the exclusion of previously included studies, which were ex-
cluded due to comparing benzodiazepines plus antipsychotics ver-
sus different antipsychotics (Han 2005; Wang 2004; Yang 2003;
Zhang 2007).
One trial compared benzodiazepines with placebo (Lorazepam
2001, RO andUSA); 11 trials compared benzodiazepines with an-
tipsychotics (Clonazepam 1993, CA; Clonazepam 1999, CHN;
Clonazepam 2007a, CHN; Diazepam 1979, IL; Flunitrazepam
1999, IL; Lorazepam 1989, USA; Lorazepam 1991, USA;
Lorazepam 1997a, USA; Lorazepam 1997b, USA; Lorazepam
2001, RO and USA; Midazolam 2006, AU); five trials compared
benzodiazepines combinedwith antipsychotics with the same ben-
zodiazepines alone (Clonazepam 2007a, CHN;Lorazepam1997a,
USA; Lorazepam 1998, USA; Lorazepam 1989, USA; Lorazepam
2006, USA); six trials compared benzodiazepines combined with
antipsychotics with the same antipsychotics alone (Alprazolam
1992, USA; Clonazepam 2007a, CHN; Lorazepam 1989, USA;
Lorazepam 1997a, USA; Lorazepam 2009, SK; Midazolam 2011,
BZ); four trials compared benzodiazepines with antihistamines
combined with antipsychotics (Lorazepam 2004, IN; Lorazepam
2010, IN; Midazolam 2003, BZ; Midazolam 2011, BZ); one
trial compared benzodiazepines combined with antipsychotics
versus two different antipsychotics (Lorazepam 1998, SA); and
one trial compared benzodiazepines combined with antipsy-
chotics versus antipsychotics and antihistamines (Midazolam
2011, BZ). Seven trials had with multiple treatment arms (
Clonazepam 2007a, CHN; Lorazepam 1989, USA; Lorazepam
1997a, USA; Lorazepam 2001, RO and USA; Lorazepam 2006,
USA; Lorazepam 2009, SK; Midazolam 2011, BZ).
1. Setting
Three trials were set in general emergency departments (
Lorazepam 1997a, USA; Lorazepam 2006, USA; Midazolam
2006, AU); five trials were set in psychiatric hospitals (Diazepam
1979, IL; Lorazepam 1989, USA; Lorazepam 1998, SA;
Lorazepam 2004, IN; Midazolam 2003, BZ); one was implied
as having taken place in a psychiatric hospital (Flunitrazepam
1999, IL); and one within a general hospital (Lorazepam 2001,
RO and USA). Five trials were conducted in psychiatric emer-
gency departments (Alprazolam 1992, USA; Clonazepam 1993,
CA; Lorazepam 1997b, USA; Lorazepam 1998, USA; Midazolam
2011, BZ); one trial took place in a locked intensive care unit
(Lorazepam 1991, USA); two trials were implied as having
taken place in a Chinese hospital (Clonazepam 1999, CHN;
Clonazepam 2007a, CHN); one trial was conducted in a institute
of mental health in India (Lorazepam 2010, IN), one trial did not
state the settings of enrolling participants (Lorazepam 2009, SK).
The majority of these trials took place in the Americas, followed
by China, India, Israel, Canada, Australia, Romania, South Africa
and South Korea.
2. Length of trials
The duration of included trials varied from one hour (Lorazepam
1989, USA) to sevendays (Lorazepam 1998, SA; Lorazepam1998,
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USA), and two weeks (Lorazepam 2004, IN; Midazolam 2003,
BZ), although only data up to 48 hours were included for this
review.
3. Participants
Participants in seven of the included trials appeared to have been
inpatients (Clonazepam 1999, CHN; Clonazepam 2007a, CHN;
Flunitrazepam 1999, IL; Lorazepam 1989, USA; Lorazepam
1991, USA; Lorazepam 2001, RO and USA; Lorazepam 2004,
IN), while in 12 trials, participants appeared to have been
newly admitted (Alprazolam 1992, USA; Diazepam 1979, IL;
Lorazepam 1997a, USA; Lorazepam 1997b, USA; Lorazepam
1998, SA; Lorazepam 1998, USA; Lorazepam 2004, IN;
Lorazepam 2006, USA; Lorazepam 2010, IN; Midazolam 2003,
BZ; Midazolam 2006, AU; Midazolam 2011, BZ), and in one
trial, participants were a mixture of inpatients and new admissions
(Clonazepam 1993, CA).
In most trials, participants were of mixed diagnoses (Clonazepam
1993, CA; Clonazepam 1999, CHN; Diazepam 1979, IL;
Flunitrazepam 1999, IL; Lorazepam 1989, USA; Lorazepam
1991, USA; Lorazepam 1997a, USA; Lorazepam 1997b, USA;
Lorazepam 1998, SA; Lorazepam 1998, USA; Lorazepam 2001,
RO and USA; Lorazepam 2004, IN; Lorazepam 2006, USA;
Lorazepam 2009, SK; Midazolam 2003, BZ; Midazolam 2011,
BZ). Participants in Alprazolam 1992, USA were diagnosed as
having schizophrenia and in Clonazepam 2007a, CHN, partici-
pants had schizophrenia with agitation/aggression. In Midazolam
2006, AU and Lorazepam 2010, IN, the diagnosis was not explicit
but was described as a ’mental illness/psychotic diagnosis.’
4. Trial size
The overall sample size in all the included trials was generally
small. The total number of participants in each trial ranged from
16 (Clonazepam 1993, CA) to 301 (Midazolam 2003, BZ).
5. Interventions
5.1. Benzodiazepines versus placebo
Wewere able to include one trial comparing benzodiazepines with
placebo (Lorazepam 2001, RO and USA). This trial compared
one to three IM injections of lorazepam (2 mg to 5 mg) with IM
placebo.
5.2. Benzodiazepines versus antipsychotics
Eleven trials compared benzodiazepines with antipsychotics. Four
trials compared lorazepam with haloperidol (Lorazepam 1989,
USA; Lorazepam1991, USA; Lorazepam1997a, USA; Lorazepam
1997b, USA); three trials compared lorazepam 2 mg versus
haloperidol 5 mg (Lorazepam 1997a, USA; Lorazepam 1997b,
USA; Lorazepam 1991, USA); and one trial compared lorazepam
4 mg to haloperidol 5 mg (Lorazepam 1989, USA). In all these
trials, both interventions were given as an IM injection, although
in the trial by Lorazepam 1997b, USA, participants were able to
receive the administered dose as an oral concentrate. Medications
were given as a single injection in the trials by Lorazepam 1989,
USA andLorazepam 1991, USA. In the trial by Lorazepam1997b,
USA, doses were administered every 30 minutes for four hours or
until the participant was sedated. Additional doses could be given
in the trial by Lorazepam 1991, USA, where the mean number of
doses of lorazepamwas 1.13 andhaloperidol was 1.10. Participants
in Lorazepam 1997a, USA could have been given up to six doses
over eight hours although the majority (71% of participants re-
ceiving haloperidol and 74% receiving lorazepam) received fewer
than three doses. Lorazepam 2001, RO and USA compared lo-
razepam 2 mg to 5 mg IM with olanzapine 10 mg to 25 mg IM.
In this trial, participants received one to three doses based on the
clinical judgement of ’the investigator.’
In the remaining trials that compared benzodiazepines with an-
tipsychotics, three compared IM clonazepam with IM haloperidol
(Clonazepam 1993, CA; Clonazepam 1999, CHN; Clonazepam
2007a, CHN). Clonazepam 1993, CA compared clonazepam 1
mg to 2 mg with haloperidol 5 mg to 10 mg at 0 minutes, 30
minutes and one hour. Clonazepam 1999, CHN compared clon-
azepam 2 mg with haloperidol 10 mg. Clonazepam 2007a, CHN
compared clonazepam 2 mg to 6 mg with haloperidol 5 mg to
15 mg. Flunitrazepam 1999, IL compared single doses of fluni-
trazepam 1 mg with haloperidol 5 mg . The trial by Diazepam
1979, IL compared diazepam (mean dose 35 mg over three hours)
with high-dose haloperidol (35 mg over three hours) and low-
dose haloperidol (20 mg over three hours) and Clonazepam 1999,
CHNcompared clonazepam2mg IMwith haloperidol 10mg IM.
Midazolam 2006, AU comparedmidazolam 5mgwith droperidol
10 mg, both of which were given intravenously, with repeat doses
given until sedation was achieved.
5.3. Benzodiazepines plus antipsychotics versus same
benzodiazepines
Five trials compared a combination of lorazepam with haloperidol
versus lorazepam alone. Lorazepam 1997a, USA and Lorazepam
1998, USA compared lorazepam 2mg plus haloperidol 5 mg with
lorazepam 2 mg alone while Lorazepam 1989, USA compared lo-
razepam 4 mg plus haloperidol 5 mg with lorazepam 4 mg. All
were given by IM injection. Lorazepam 2006, USA compared lo-
razepam 2 mg IM plus risperidone 2 mg oral, or lorazepam 2 mg
IM plus haloperidol 5 mg oral with lorazepam 2 mg IM (plus
oral placebo). Clonazepam 2007a, CHN compared clonazepam
2 mg to 6 mg IM plus haloperidol 5 mg to 15 mg IM with
clonazepam 2 mg to 6 mg IM (plus placebo). Lorazepam 1989,
USA and Lorazepam 2006, USA gave single doses. Participants in
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Lorazepam 1998, USA could receive a second dose within the first
hour, and in Lorazepam 1997a, USA participants could be given
up to six doses over eight hours. In Clonazepam 2007a, CHN,
the participant received at least one dose but no more than three
doses. However, majority of participants received fewer than three
doses.
5.4. Benzodiazepines plus antipsychotics versus same
antipsychotics
We found six trials comparing combinedbenzodiazepines/antipsy-
chotics with the same antipsychotics alone. In each study, ben-
zodiazepines were combined with and compared with haloperi-
dol; Alprazolam 1992, USA compared alprazolam 1 mg plus
haloperidol 5 mg with haloperidol 5 mg plus placebo; Lorazepam
1997a, USA compared lorazepam 2 mg plus haloperidol 5 mg
with haloperidol 5 mg alone; and Lorazepam 1989, USA com-
pared lorazepam 4 mg plus haloperidol 5 mg with haloperidol 5
mg. Clonazepam 2007a, CHN compared clonazepam 2 mg to 6
mg IM plus haloperidol 5 mg to 15 mg IM with haloperidol 5 mg
to 15 mg IM (plus placebo). All drugs were administered as an IM
injection. In the trials by Lorazepam 1989, USA single doses were
given; in Alprazolam 1992, USA medications were administered
as a daily oral dose although additional doses could be given if the
psychosis scores were high; and in Lorazepam 1997a, USA, 9% of
the participants receiving both drugs and 29% of the participants
receiving haloperidol were given three or more doses. Midazolam
2011, BZ compared midazolam 15 mg combined with haloperi-
dol 5 mg IM versus haloperidol 5 mg IM.
5.5. Benzodiazepines versus antipsychotics plus
antihistamines
We found three trials comparing benzodiazepines versus antipsy-
chotics plus antihistamines (Lorazepam 2004, IN; Lorazepam
2010, IN; Midazolam 2003, BZ). Two were large, higher-quality
trials that compared the effects of benzodiazepines versus com-
bined haloperidol/promethazine. In Midazolam 2003, BZ, mida-
zolam 15 mg IM (with flumazenil made available for use in the
event of midazolam toxicity) was compared with haloperidol 5
mg to 10 mg IM (77 participants received 5 mg, 71 participants
received 10 mg) combined with promethazine 25 mg to 50 mg
IM (147 participants received 50 mg, one participant received 25
mg). Similarly, Lorazepam 2004, IN compared lorazepam 4 mg
IM with haloperidol 10 mg IM combined with promethazine 25
mg to 50 mg IM (96 participants received 50 mg, four partici-
pants received 25 mg); all doses were given at the discretion of the
treating physician. Lorazepam 2010, IN compared lorazepam 4
mg IM with haloperidol 10 mg IM.
5.6. Benzodiazepines plus antipsychotics versus
antipsychotics plus antipsychotics
One trial compared benzodiazepines plus antipsychotics versus an-
tipsychotics plus antipsychotics (Lorazepam 1998, SA). The trial
compared lorazepam 4 mg IM with clotiapine 40 mg IM given
at six hourly intervals ’if warranted.’ Both groups also received
haloperidol 10 mg IM at the same time.
5.7. Benzodiazepines plus antipsychotics versus
antipsychotics plus antihistamines
One trial compared benzodiazepines plus antipsychotics versus an-
tipsychotics plus antihistamines (Midazolam 2011, BZ). The trial
compared midazolam 15 mg plus haloperidol 5 mg (each admin-
istered IM) with promethazine 50 mg plus haloperidol 5mg (each
administered IM). After the initial dose, only additional doses of
combined haloperidol/promethazine could be used, according to
clinical judgement. If a participant needed another intervention,
he or she were immediately removed from the study.
6. Outcomes scales
The trials used the following outcome scales.
6.1. Global state
1.1. Clinical Global Impression (CGI, Busner 2007; Guy 1970)
(high = worse).
TheCGI scale was designed to quantify severity of illness and over-
all clinical improvement in people with a psychiatric disorder. A 7-
point scoring system is usually used for severity and improvement
with lower scores indicating decreased severity or greater recovery,
or both. Alprazolam 1992, USA; Diazepam 1979, IL; Lorazepam
1997b, USA; and Lorazepam 2001, RO and USA used this scale.
Lorazepam 1998, USA dichotomised scores by defining a reduc-
tion of at least 3 points on the CGI as improvement. Lorazepam
2004, IN dichotomised the outcomes of this scale to present out-
comes of those clinically improved.
6.1.2. Ramsay Sedation Scale (RSS, Ramsay 1974)
The RSS is a six-item rating scale used to assess levels of sedation
by selecting the most appropriate level of response. A rating of one
indicates an agitated, anxious state, and a rating of six indicates an
unresponsive state. Midazolam 2011, BZ reported data using this
scale.
6.2. Behaviour
6.2.1. Agitated Behaviour Scale (ABS, Corrigan 1988) (high =
worse)
The ABS was originally developed in response to the need to make
serial assessments of agitation during the acute period following
traumatic brain injury (Caplan 1999). It originally consisted of 39
items, but was subsequently reduced to 14 items following valida-
tion and includes a range of agitated behaviour, such as short at-
tention span, impulsiveness, violence/threatening violence, unco-
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operativeness, restlessness and repetitive behaviour. The 14-item
ratings range on a scale of one to four, with one indicating the
absence of agitated behaviour, and four indicating the extreme
presence of agitated behaviour. Lorazepam 2001, RO and USA
used this scale. Lorazepam 1997a, USA also used this scale, but
presented skewed data (see Data and analyses).
6.2.2. Overt Aggression Scale (OAS, Yudofsky 1986) (high =
worse)
The OAS is designed to assess observable aggressive or violent be-
haviour and consists of four categories: verbal aggression, physi-
cal aggression against objects, physical aggression against self and
physical aggression against other people. Within each category,
there are four types of aggressive behaviour listed. Clonazepam
1999, CHN;Lorazepam1998, SA; andMidazolam 2011, BZused
this scale. Flunitrazepam 1999, IL defined improvement as a re-
duction of at least 4 points on theOAS and Lorazepam 1998, USA
defined improvement as a decrease of 50% or more. Lorazepam
1991, USA also used this scale, defining improvement as a ’greater
than mean decrease’ in scores at two hours.
6.2.3. Overt Agitation Severity Scale (OASS, Yudofsky 1997)
(high = worse)
The OASS is designed to define and objectively rate the severity
of agitated behaviour and confines its rating exclusively to observ-
able behavioural manifestations of agitation. This comprises three
categories: vocalisations and oral/facial movements, upper torso
and upper extremitymovements, and lower extremitymovements,
each with four types of agitated behaviour listed. These types of
behaviour are rated on a 0- to 4-point scale, with 0 = not present
and 4 = always present. Midazolam 2011, BZ reported data using
this scale.
6.2.4. Positive and Negative Symptom Scale (PANSS, Kay 1987)
(high = worse)
PANSS was developed from the Brief Psychiatric Rating Scale
(BPRS) and the Psychopathology Rating Scale. It is used to
evaluate positive, negative and other symptom dimensions in
schizophrenia. The scale has 30 items, each measured on a 7-
point scoring system varying from one (absent) to seven (extreme).
Lorazepam 2006, USA; however, data were skewed for Lorazepam
2006, USA. Lorazepam 2001, RO and USA each reported data
from the PANSS-Excited Component subscale (PANSS-EC);
Lorazepam 2001, RO and USA defined a reduction of 40% or
more on the PANSS-EC as a measure of improvement.
6.3. Mental state
6.3.1. Brief Psychiatric Rating Scale (BPRS, Overall 1967; Shafer
2005) (high = worse)
The BPRS lists a range of psychiatric symptoms generally asso-
ciated with the domains of anxiety and depression, hostility and
suspiciousness, thought disturbance and withdrawal/motor retar-
dation. The original scale has 16 items, but a revised 18-item
scale is commonly used. Each item is rated on a 7-point scale
varying from ’not present’ to ’extremely severe.’ Alprazolam 1992,
USA, Clonazepam 1999, CHN; and Lorazepam 1997b, USA re-
ported data from this scale. Alprazolam1992, USAandLorazepam
1997a, USA also reported data using the 11 psychosis-anxiety
items from the BPRS, classified as the BPRS-psychosis subscale
(Faustman 1989). Lorazepam 2006, USA reported skew data from
this scale.
6.3.2. Inpatient Multidimensional Psychiatric Scale (IMPS,
Cairns 1983; Lorr 1963)
The IMPS measures psychotic symptom scales in psychiatric in-
patients. It originally consisted of 75 items and 10 domains. The
addition of another 15 items resulted in 12 domains: excitement,
hostile belligerence, grandiose expansiveness, paranoid projection,
perceptual distortions, anxious depression, retardation and apa-
thy, conceptual disorganisation, motor disturbances, disoriented
behaviour, impaired functioning and obsessive-phobic. The IMPS
was used by Clonazepam 1993, CA who reported a reduction of
at least 50% as improvement.
Excluded studies
We excluded 48 studies (with 52 full-text reports). See
Characteristics of excluded studies table.
• Four trials did not appear to be randomised (Arana 1986;
Liang 2003; Simpson 2003; Yu 2006).
• Participants in eight trials were agitated without psychosis,
retarded catatonia or not acutely psychotic (Gharabawi 2003;
Lenox 1992; Nestoros 1982; Nobay 2004; Richards 1998;
Wetzel 1997). Martel 2005 was excluded because agitation
appeared to be due to alcohol intoxication in 93% of
participants. Isbister 2010 was excluded because it enrolled
participants with acutely disturbed/aggressive/agitated behaviour
believed to be secondary to psychotic illnesses.
• 19 trials had ineligible comparisons (Currier 2000; Currier
2004; Han 2005; Hou 2011; Huf 2007; Hwang 2012; Kinon
2002; Kinon 2004; NCT00797277; NCT00859872; Veraksa
2016; Wang 2004; Wu 2006; Yang 2003; Yang 2006; Zhang
2007; Zhong 2006; Zhou 2014; Zhu 2005).
• None of the outcomes of interest were reported in 17 trials
within the 48-hour time period (Chen 2012; Davis 2008; Deng
2004; Ge 2004; Guz 1972; Hankoff 1962; Hanlon 1970; He
2011; Kang 2006; Mei 2006; Stevens 1992; Tang 2007; Wan
2005; Wyant 1990; Zhang 2008; Zhou 2012).
Risk of bias in included studies
For a summary of the overall risk of bias in included trials, see
Figure 3 and Figure 4.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 4. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All 20 included trials were described as randomised but overall
the description of allocation and concealment was poor. Only
Lorazepam 2004, IN, Midazolam 2006, AU, and Midazolam
2003, BZ adequately described the process used for randomisation
and the concealment of allocation. Four trials stated that a table of
random numbers was used to allocate participants (Clonazepam
2007a, CHN; Flunitrazepam 1999, IL; Lorazepam 1997a, USA;
Lorazepam 1998, USA). Diazepam 1979, IL was described as a
randomised trial but also referred to alternate allocation. There
was no description of the method of allocation and concealment
in the remaining trials.
Blinding
1. Blinding of participants
Twelve of the included trials were described as double blinded;
however, the method of blinding was unclear (Alprazolam
1992, USA; Clonazepam 1993, CA; Clonazepam 2007a, CHN;
Lorazepam 1991, USA; Lorazepam 1997a, USA; Lorazepam
1997b, USA; Lorazepam 1998, SA; Lorazepam 1998, USA;
Lorazepam 2001, RO and USA; Lorazepam 2006, USA;
Midazolam 2006, AU; Midazolam 2011, BZ), with only three
trials explaining blinding methods (Alprazolam 1992, USA;
Lorazepam 1991, USA; Lorazepam 1997a, USA).
Four trials were single/observer blinded (Diazepam 1979, IL;
Flunitrazepam 1999, IL; Lorazepam 2004, IN; Midazolam 2003,
BZ). Midazolam 2003, BZ and Lorazepam 2004, IN were blind
up until point of treatment assignment. Lorazepam 1989, USA
and Lorazepam 2010, IN were not blinded. Clonazepam 1999,
CHN and Lorazepam 2009, SK did not state whether blinding
was used.
Incomplete outcome data
High loss to follow-up was where the number of participants
lost to follow-up was more than 5% in the first two hours or
between 25% and 50% overall. In six of the trials, there was
a high loss to follow-up rate observed (Alprazolam 1992, USA;
Clonazepam 1993, CA; Diazepam 1979, IL; Lorazepam 1991,
USA; Lorazepam 2006, USA; Midazolam 2006, AU), and 12
trials had a low loss to follow-up (Clonazepam 1999, CHN;
Clonazepam 2007a, CHN; Flunitrazepam 1999, IL; Lorazepam
1989, USA; Lorazepam 1997a, USA; Lorazepam 1997b, USA;
Lorazepam 1998, SA; Lorazepam 1998, USA; Lorazepam 2001,
RO and USA; Lorazepam 2004, IN; Midazolam 2003, BZ;
Midazolam2011, BZ).Two trials hadunclear rate of loss to follow-
up, as only abstracts of these two trials are available (Lorazepam
2009, SK; Lorazepam 2010, IN; see Table 4).
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Selective reporting
Most of the studies were rated as low risk of bias in this domain as
all measured outcomes of each study were reported. In Lorazepam
1998, USA, there was a higher risk of bias noted, as the trial au-
thors changed the criteria for ’improvement’ (using a visual ana-
logue scale (VAS) post-study, after analysis had taken place. We
considered there were potential risks of selective reporting in four
trials: Alprazolam 1992, USA did not report the data measured by
Simpson-Angus Side Effects Profile. Lorazepam 1991, USA did
not report the SD of BPRS and CGI. Lorazepam 2009, SK and
Lorazepam 2010, IN were reported as abstracts, so it is unclear
whether there was selective reporting.
Other potential sources of bias
Funding sources
Six trials were funded by pharmaceutical companies:
Alprazolam 1992, USA was supported in part by a grant from
The Upjohn Company (now Pfizer); Clonazepam 1993, CA was
partially funded by Hoffmann La Roche Ltd; Lorazepam 1991,
USA was supported in part by Wyeth Laboratories; Lorazepam
1997a, USA was supported in part by a grant from Wyeth-Ayerst
Research (now also part of Pfizer); and Lorazepam 2006, USA was
funded by a grant from Janssen Pharmaceutica. However, as the
study did not reveal more information, we are unsure whether the
pharmaceutical companies were involved in the study design and
reporting process. Lorazepam 2001, RO and USA was funded by
Lilly Research Laboratories, Indiana, and developed a rating scale
for use in the study (which was excluded from analysis); 90% of
the trial authors of this study were also employed by the same
pharmaceutical company. Therefore, the company was probably
involved in the study design and reporting process, and we suspect
there is conflict of interests.
Other sources of funding include support from the National Al-
liance for Research on Schizophrenia and Depression (Lorazepam
1997b, USA); a postgraduate scholarship from the National
Health and Medicine Research Council and a research grant from
the Australasian College for EmergencyMedicine (Morson Taylor
Award, Midazolam 2006, AU); a grant from the Gralnick Foun-
dation, High Point Hospital, Port Chester, New York (Diazepam
1979, IL); funding from Fundação Oswaldo Cruz, the British
Council, CAPES (Coordenação de Aperfeiçoamento de Pessoal
de Nível Superior) and FAPERJ (Fundação de Amparo à Pesquisa
do Estado do Rio de Janeiro, Midazolam 2003, BZ); funding
by intramural research grants from Fluid Research Fund (Chris-
tian Medical College, Vellore), and the Cochrane Schizophrenia
Group general fund (Lorazepam 2004, IN). American John M
Davis Funding supported the Clonazepam 2007a, CHN study.
Eight trials did not reveal information about funding source:
Clonazepam 1999, CHN; Flunitrazepam 1999, IL; Lorazepam
1989, USA; Lorazepam 1998, SA; Lorazepam 1998, USA;
Lorazepam 2009, SK; Lorazepam 2010, IN; Midazolam 2011,
BZ.
Effects of interventions
See: Summary of findings for the main comparison
Benzodiazepines compared to placebo for psychosis-induced
aggression or agitation; Summary of findings 2 Benzodiazepines
compared to antipsychotics for psychosis-induced aggression or
agitation; Summary of findings 3 Benzodiazepines compared
to antihistamines plus antipsychotics for psychosis-induced
aggression or agitation; Summary of findings 4 Benzodiazepines
+ antipsychotics compared to same enzodiazepines for psychosis-
induced aggression or agitation; Summary of findings
5 Benzodiazepines + antipsychotics compared to same
antipsychotics for psychosis-induced aggression or agitation;
Summary of findings 6 Benzodiazepines plus antipsychotics
compared to antipsychotics plus antipsychotics for psychosis-
induced aggression or agitation; Summary of findings 7
Benzodiazepines plus antipsychotics compared to antihistamines
plus antipsychotics for psychosis-induced aggression or agitation
Comparison 1: Benzodiazepines versus placebo
All data for this comparison came from Lorazepam 2001, RO and
USA) (n = 102). This comparison has 11 outcomes.
1.1 Tranquillisation or asleep
There was no clear difference between the benzodiazepine and
placebo groups in the number of people who were sedated (n =
102, RR 1.67, 95% CI 0.42 to 6.61, Analysis 1.1, very low quality
evidence).
1.2. Behaviours
There was a clear difference with ABS scores in favour of partici-
pants allocated to benzodiazepine (n = 101, MD -3.61, 95% CI -
5.92 to -1.30, Analysis 1.2).
1.3 to 1.5 Global state
There was no clear difference in the number of people who had
not improved in the short term (n = 102, RR 0.89, 95% CI 0.69
to 1.16) but fewer people receiving benzodiazepines were rated
as not improved in the medium term (n = 102, RR 0.62, 95%
CI 0.40 to 0.97, Analysis 1.3, very low quality evidence). There
was no clear difference between benzodiazepine and placebo in
the number of people who needed additional medication (n =
102, RR 1.00, 95% CI 0.69 to 1.44, Analysis 1.4, very low quality
evidence). The mean change in CGI scores was also comparable (n
= 76, MD 0.07, 95% CI -0.46 to 0.60, Analysis 1.5).
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1.6 to 1.7 Mental state
There was no clear difference between groups in the change in
PANSS (n = 99, MD -2.57, 95% CI -6.23 to 1.09, Analysis 1.6)
or PANSS excited component scores (n = 101, MD -1.91, 95%
CI -3.83 to 0.01, Analysis 1.7).
1.8 to 1.10 Adverse effects/events
There was no clear difference between benzodiazepine and placebo
in EPS (n = 102, RR 0.33, 95%CI 0.04 to 3.10, Analysis 1.8, very
low quality evidence) or receiving medication for EPS (n = 102,
RR 0.33, 95% CI 0.04 to 3.10, Analysis 1.9) There was no clear
difference in dizziness, nausea and vomiting (Analysis 1.10).
1.11 Leaving study early
There was no clear difference in leaving the study early for any
reason (n = 102, RR 0.60, 95% CI 0.15 to 2.38, Analysis 1.11).
Missing outcomes
For this comparison, none of the studies reported hospital and ser-
vice outcomes, satisfaction with treatment or economic outcomes.
Comparison 2: Benzodiazepines versus antipsychotics
We included 11 trials comparing benzodiazepines with an-
tipsychotics (Clonazepam 1993, CA; Clonazepam 1999, CHN;
Clonazepam 2007a, CHN; Diazepam 1979, IL; Flunitrazepam
1999, IL; Lorazepam 1989, USA; Lorazepam 1991, USA;
Lorazepam 1997a, USA; Lorazepam 1997b, USA; Lorazepam
2001, RO and USA; Midazolam 2006, AU).
2.1 Tranquillisation or asleep
There was no clear difference in the number of people sedated
when benzodiazepines were compared with haloperidol in the
short term (n = 44, 1 RCT, RR 1.17, 95% CI 0.53 to 2.59) or
medium term (n = 434, 8 RCTs, RR 1.13, 95% CI 0.83 to 1.54,
low quality evidence) or olanzapine in the medium term (n = 150,
1 RCT, RR 0.75, 95% CI 0.28 to 1.98). However, people receiv-
ing benzodiazepines were more likely to be sedated in the short
term when compared with people receiving droperidol (n = 153,
1 RCT, RR 2.71, 95% CI 1.55 to 4.73). The differences between
subgroups were significant (Chi2 = 8.77, P = 0.03, I2 = 66%, Anal-
ysis 2.1.
2.2 to 2.3 Behaviours
People receiving olanzapine scored significantly lower on the Agi-
tated Behaviour Scale (ABS) in the medium term (n = 149,1 RCT,
MD 2.91, 95% CI 0.80 to 5.02) but there was no difference when
haloperidol was compared with lorazepam (n = 66,1 RCT, MD
1.80, 95% CI -2.39 to 5.99, Analysis 2.2). There was no signifi-
cant difference in OAS scores at medium term when clonazepam
was compared with haloperidol (n = 46, 1 RCT, MD 0.20, 95%
CI -0.57 to 0.97, Analysis 2.3).
2.4 to 2.7 Global state
More people in the benzodiazepines group were likely to be rated
as not improved in the medium term (n = 150, 1 RCT, RR 1.84,
95% CI 1.06 to 3.18,very low quality evidence) when compared
with olanzapine but there was no clear difference in the short
term (n = 150, 1 RCT, RR 1.26, 95% CI 0.95 to 1.66) or when
benzodiazepines were compared with haloperidol in the medium
term (n = 188, 5 RCTs, RR 0.89, 95%CI 0.71 to 1.11, low quality
evidence). Analysis 2.4
People receiving benzodiazepines were no more likely to need ad-
ditional medication compared with those receiving droperidol in
the short term (n = 153, 1 RCT, RR 1.87, 95% CI 0.83 to 4.19)
or haloperidol in the medium term (n = 66, 1 RCT, RR 0.87,
95% CI 0.70 to 1.09, very low quality evidence). However, partic-
ipants receiving lorazepam were more likely to require additional
medication than those receiving olanzapine in the medium term
(n = 150, 1 RCT, RR 2.02, 95% CI 1.33 to 3.07, very low quality
evidence); Analysis 2.5.
CGI change/endpoint scores for the short term favoured lo-
razepam when compared with haloperidol (n = 37, 1 RCT, MD -
0.67, 95% CI -1.09 to -0.25). Because of the marked heterogene-
ity of medium-term data, these were not pooled. Results clearly
favoured lorazepam compared with haloperidol (n = 37, 1 RCT,
MD -0.81, 95% CI -1.37 to -0.25). There was no clear difference
when diazepam was compared with haloperidol (n = 40, 1 RCT,
MD 0.60, 95% CI -0.17 to 1.37) or when olanzapine was com-
pared with lorazepam (n = 147, 1 RCT, MD 0.14, 95% CI -0.15
to 0.43). (All in Analysis 2.6). There was also no clear difference
in IMPS scores in the medium term when clonazepam was com-
pared with haloperidol (n = 16, 1 RCT, MD 2.60, 95% CI -3.04
to 8.24, Analysis 2.7).
2.8 to 2.14 Mental state
When no clinical improvement was defined as the decrease rate of
BPRS score less than 30%, there was no clear difference between
clonazepam and haloperidol (n = 30, 1 RCT, RR 0.93, 95% CI
0.73 to 1.18, Analysis 2.8). There was no clear difference in BPRS
scores in the short term (n = 37, 1 RCT, MD -3.26, 95% CI -
10.65 to 4.13) or medium term (n = 123, 3 RCTs, MD 1.67,
95% CI -1.84 to 5.18), Analysis 2.9). As the medium-term data
were heterogenous (Chi2 = 4.43, P = 0.11, I2 = 55%), we used a
random-effects model but these results were also equivocal (n =
123, 3 RCTs, MD 1.18, 95% CI -4.18 to 6.53). In the medium
term, there was no difference between people receiving lorazepam
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or haloperidol in BPRS psychosis subscale scores (n = 66, 1 RCT,
MD = 0.70, 95% CI -7.20 to 8.60, Analysis 2.10). For BPRS
positive subscale and excited component subscale, there was no
clear difference between clonazepam and haloperidol (n = 30, 1
RCT, MD 0.80, 95% CI -1.83 to 3.43, Analysis 2.11; n = 30, 1
RCT, MD 1.27, 95% CI -0.49 to 3.03, Analysis 2.12). For people
receiving antipsychotics, the change in PANSS (n = 146, 1 RCT,
MD5.64, 95%CI2.20 to 9.08, Analysis 2.13) andPANSS excited
component scores were significantly better for people receiving
olanzapine compared to those receiving lorazepam (n = 149, 1
RCT, MD 2.85, 95% CI 1.14 to 4.56, Analysis 2.14).
2.15 to 2.17 Adverse effects/events
EPS were significantly lower in the group receiving benzodi-
azepines compared with those receiving haloperidol (n = 233, 6
RCTs, RR 0.13, 95% CI 0.04 to 0.41, low quality evidence) and
cumulatively (n = 536, 8 RCTs, RR 0.15, 95% CI 0.06 to 0.39).
There was no difference in the single trials where lorazepam was
compared with olanzapine (n = 150, 1 RCT, RR 0.24, 95% CI
0.03 to 1.89) and midazolam was compared with droperidol (n =
153, 1RCT,RR0.15, 95%CI 0.01 to 2.90), Analysis 2.15. People
receiving antipsychotics were no more likely to require medication
for EPS (n = 216, 2 RCT, RR 0.40, 95% CI 0.15 to 1.05) or the
single trials that compared lorazepam with haloperidol (n = 66, 1
RCT, RR 0.50, 95% CI 0.17 to 1.47) or olanzapine (n = 150, 1
RCT, RR 0.24, 95% CI 0.03 to 1.89). Analysis 2.16.
There were no differences in the number of people experiencing
specific adverse effects: airway management, akathisia, ataxia, low
blood pressure, dizziness, dry mouth, drowsiness, hypoxia, high
or low heart rates, nausea or vomiting, seizures, speech disorder
or tremor when compared with people receiving antipsychotics.
However, these results all came from single trials (Analysis 2.17).
2.18 Leaving study early
There was no clear difference between groups at medium term for
leaving the study early (n = 339, 3 RCTs, RR 1.48, 95% CI 0.70
to 3.13, Analysis 2.18).
Missing outcomes
For this comparison, none of the studies reported hospital and ser-
vice outcomes, satisfaction with treatment or economic outcomes.
Comparison 3: Benzodiazepines versus antipsychotics
plus antihistamines
Two trials compared benzodiazepines versus antipsychotics + an-
tihistamines (Lorazepam 2004, IN; Midazolam 2003, BZ).
3.1 Tranquillisation or asleep
The two trials presented conflicting results for sedation (
Midazolam 2003, BZ; Lorazepam 2004, IN). People receiving lo-
razepam were less likely to be sedated compared with haloperidol
and promethazine in the immediate term (n = 200, 1 RCT, RR
0.88, 95%CI 0.77 to 0.99), short term (n = 200, 1 RCT, RR 0.85,
95% CI 0.77 to 0.95) and medium term (n = 200, 1 RCT, RR
0.91, 95% CI 0.84 to 0.98, low quality evidence), while people re-
ceivingmidazolam weremore likely to be sedated in the short term
(n = 301, 1 RCT, RR 1.32, 95% CI 1.16 to 1.49) and medium
term (n = 301, 1 RCT, RR 1.13, 95% CI 1.04 to 1.23, Analysis
3.1, low quality evidence) compared to those receiving combined
haloperidol/promethazine mix. Because of the high degree of het-
erogeneity (short term: Chi2 = 30.06; I2 = 97%; medium term:
Chi2 = 14.31; I2 = 93%), data from these trials were not pooled
(see Summary of main results).
3.2 to 3.4 Global state
One study reported most of these outcomes (Lorazepam 2004,
IN). More people receiving lorazepam had not improved com-
pared to those receiving combined haloperidol/promethazine in
the immediate term (n = 200, 1 RCT, RR 1.79, 95% CI 1.36
to 2.37), short term (n = 200, 1 RCT, RR 2.47, 95% CI 1.51
to 4.03), and medium term (n = 200, 1 RCT, RR 2.17, 95% CI
1.16 to 4.05, low quality evidence). Analysis 3.2. Neither group
required additional medication in the immediate term and there
was no clear difference between groups in the short term (n = 200,
RR 3.00, 95% CI 0.12 to 72.77) and medium term (n = 200, RR
1.33, 95% CI 0.31 to 5.81, low quality evidence). Analysis 3.3.
One study reported mean CGI scores (Lorazepam 2004, IN). The
scores were higher in participants receiving combined haloperidol/
promethazine than participants receiving benzodiazepines alone
in the immediate term (n = 200, 1 RCT, MD 0.49, 95% CI 0.23
to 0.75) and short term (n = 200, 1 RCT, MD 0.60, 95% CI 0.34
to 0.86), but not the medium term (n = 200, 1 RCT, MD 0.23,
95% CI -0.05 to 0.51). Analysis 3.4.
3.5 Adverse effects/events
There were no clear differences in the specific adverse events: air-
way management (n = 501, 2 RCTs, RR 2.99, 95% CI 0.31 to
28.54), nausea (n = 200, 1 RCT, RR 3.00; 95% CI 0.12 to 72.77)
or seizure (n = 301, 1 RCT, RR 0.33, 95% CI 0.01 to 8.06) when
midazolam or lorazepam were compared with combined haloperi-
dol/promethazine. Analysis 3.5
3.6 Hospital and service outcomes
There was no clear difference in the number of people ’not dis-
charged’ in each treatment group (n = 200,medium termRR1.13,
95% CI 0.86 to 1.48, Analysis 3.6).
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3.7 Leaving study early
There was no clear difference in people lost to follow-up when mi-
dazolam and lorazepam were compared with combined haloperi-
dol/promethazine (n = 501, 2 RCTs, RR 0.43, 95% CI 0.06 to
2.87, Analysis 3.7).
Missing outcomes
For this comparions, non of the studies reported data for mental
state, hospital and service outcomes, satisfaction with treatment
or economic outcomes.
Comparison 4: Benzodiazepines plus antipsychotics
versus same benzodiazepines
Five trials reported data comparing benzodiazepines plus antipsy-
chotics versus same benzodiazepines (Clonazepam 2007a, CHN;
Lorazepam 1997a, USA; Lorazepam 1998, USA; Lorazepam
1989, USA; Lorazepam 2006, USA).
4.1 Tranquillisation or asleep
Sedationwas higher in the combined lorazepam/haloperidol group
than the lorazepam only group in the short term (n = 47, 1 RCT,
RR 1.92, 95% CI 1.10 to 3.35), although there was no difference
in the medium term (n = 110, 2 RCTs, RR 0.84, 95% CI 0.59 to
1.19, low quality evidence). Analysis 4.1.
4.2 Behaviours
Medium-term ABS scores for people receiving lorazepam were
similar to those receiving combined lorazepam/haloperidol treat-
ment (n = 63, 1 RCT, RR -1.60, 95% CI -5.94 to 2.74, Analysis
4.2).
4.3 to 4.4 Global state
There was no clear difference in improvement when people who
received combined lorazepam/haloperidol were compared to peo-
ple receiving lorazepam in the short term (n = 20, 1 RCT, RR 0.11,
95%CI 0.01 to 1.74) ormedium term (n = 113, 3 RCTs, RR 0.96,
95% CI 0.76 to 1.20, low quality evidence), or compared to people
receiving combined lorazepam/risperidone in the medium term
(n = 20, 1 RCT, RR 0.86, 95% CI 0.45 to 1.64, low quality evi-
dence). Analysis 4.3. There was no clear difference in the number of
participants requiring additional medication when lorazepam was
compared with combined lorazepam/haloperidol in the medium
term (n = 103, 3 RCTs, RR 1.02, 95%CI 0.79 to 1.32, low quality
evidence), with no instances reported when comparing combined
lorazepam/risperidone with lorazepam alone. Analysis 4.4.
4.5 to 4.12 Mental state
When no clinical improvement was defined as the decrease rate of
BPRS score less than 30%, there was no clear difference between
clonazepam and haloperidol (n = 30, 1 RCT, RR 1.00 CI 0.76 to
1.32, Analysis 4.5).
There was no clear difference between people who received com-
bined lorazepam/antipsychotics compared with people who re-
ceived lorazepam alone for BPRS (short term: n = 20, 1 RCT,MD
1.10, 95% CI -23.17 to 25.37; medium term: n = 20, 1 RCT,
MD -1.70, 95% CI -24.26 to 20.86). Analysis 4.6. BPRS psy-
chosis subscale (n = 63, 1 RCT, MD 1.20, 95% CI -6.28 to 8.68,
Analysis 4.10), BPRS positive subscale (n = 30, 1 RCT, MD 0.06,
95% CI -2.73 to 2.85, Analysis 4.11), BPRS excited component
scale (n = 30, 1 RCT, MD -0.80, 95% CI -2.41 to 0.81, Analysis
4.12) and PANSS (short term: n = 20, 1 RCT, MD 6.40, 95% CI
-36.50 to 49.30; medium term: n = 20, 1 RCT, MD 3.20, 95%
CI -29.41 to 35.81, Analysis 4.8) . Data from Lorazepam 2006,
USA could not be added to the meta-analysis for BPRS (Analysis
4.7) and PANSS scores (Analysis 4.9) because data appeared to be
skewed.
4.13 to 4.15 Adverse effects/events
There was no clear difference in EPS when comparing combined
lorazepam/haloperidol with lorazepam alone (n = 83, 2 RCTs, RR
1.94, 95% CI 0.18 to 20.30, Analysis 4.13, low quality evidence),
but Lorazepam 1998, USA reported no instances of EPS in their
study. There was also no clear difference in the need formedication
for EPS (n = 63, 1 RCT, RR 0.73, 95% CI 0.18 to 2.99, Anal-
ysis 4.14), or any clear difference in the specific adverse events;
akathisia, ataxia, dizziness, drowsiness, dry mouth or speech dis-
order, Analysis 4.15).
4.16 Leaving study early
There was no clear difference in the number of people leaving
the study early when lorazepam was compared with combined
lorazepam/haloperidol (n = 40, 2 RCTs, RR 0.71, 95% CI 0.34
to 1.50) or combined lorazepam/risperidone (n = 20, 1 RCT, RR
0.86, 95% CI 0.45 to 1.64). Analysis 4.16.
Missing outcomes
For this comparison, none of the studies reported hospital and ser-
vice outcomes, satisfaction with treatment or economic outcomes.
Comparison 5: Benzodiazepines plus antipsychotics
versus same antipsychotics
Six trials compared benzodiazepines plus antipsychotics ver-
sus same antipsychotics (Alprazolam 1992, USA; Clonazepam
2007a, CHN; Lorazepam 1989, USA; Lorazepam 1997a, USA;
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Lorazepam 2009, SK; Midazolam 2011, BZ). All trials compared
combined benzodiazepine/haloperidol with haloperidol alone.
5.1 Tranquillisation or asleep
Sedation was significantly more likely in the combined benzo-
diazepines/haloperidol group compared with haloperidol in the
short term (n = 45, 1 RCT, RR 2.25, 95% CI 1.18 to 4.30) and
medium term (n = 172, 3 RCTs, RR 1.75, 95% CI 1.14 to 2.67,
very low quality evidence) when using a fixed-effect model. How-
ever, the medium-term results were highly heterogeneous (Chi2
= 6.90, P = 0.03, I2 = 71%) and no longer significant when a
random-effects model was used (n = 172, 3 RCTs, RR 1.67, 95%
CI 0.67 to 4.12). Analysis 5.1.
5.2 to 5.4 Behaviours
There was no clear difference in ABS agitation scores when lo-
razepam plus haloperidol was compared with haloperidol (n = 67,
1 RCT, MD -0.20, 95% CI -5.05 to 4.65, Analysis 5.2). OAS ag-
gression scores were also not different when combinedmidazolam/
haloperidol was compared with haloperidol in the short term (n =
60, 1 RCT, MD 1.20, 95% CI -0.04 to 2.44) but in the medium
term favoured the haloperidol only group (n = 60, 1 RCT, MD
2.40, 95% CI 0.59 to 4.21). Analysis 5.3. Agitation scores using
the OASS were significantly higher in the midazolam/haloperidol
group compared with haloperidol in the short term (n = 60, 1
RCT, MD 8.50, 95% CI 7.07 to 9.93) and medium term (n = 60,
1 RCT, MD 6.70, 95% CI 5.94 to 7.46, Analysis 5.4).
5.5 to 5.8 Global state
In the medium term, people who received combined benzodi-
azepines/haloperidol were no more likely to improve than those
receiving haloperidol alone (n = 185, 4 RCTs, RR 1.17, 95% CI
0.93 to 1.46, Analysis 5.5,low quality evidence). These results were
heterogeneous (Chi2 = 11.15, P = 0.01, I2 = 73%) but this was due
to one small study contributing only 2.9% of weight to the anal-
ysis. The findings using a random-effects model were very similar
(n = 185, 4 RCTs, RR 1.04 CI 0.67 to 1.62). In the medium term,
people receiving haloperidol alone were no more likely to require
additional medication than those receiving combined lorazepam/
haloperidol (n = 67, 1 RCT, RR 0.95, 95% CI 0.79 to 1.15).
Analysis 5.6, low quality evidence). There was also no clear differ-
ence inmean doses of additionalmedicationwhenmidazolamplus
haloperidol was compared with midazolam (n = 60, 1 RCT, MD
0.20, 95% CI -0.33 to 0.73, Analysis 5.7). Mean change scores
for the RSS were significantly higher in the combined midazolam/
haloperidol group when compared with haloperidol in the short
term (n = 60, 1 RCT, MD 0.50, 95% CI -0.01 to 1.01) although
this was not different in the medium term (n = 60, 1 RCT, MD
0.10, 95% CI -0.36 to 0.56). Analysis 5.8.
5.9 to 5.13 Mental state
When clinical improvement was defined as the decrease rate of
BPRS score less than 30%, there was no clear difference between
clonazepam and haloperidol (n = 30, 1 RCT, RR 0.93, 95%
CI 0.73 to 1.18, Analysis 5.9). Alprazolam 1992, USA reported
medium-term BPRS scale data, with no significant difference be-
tween (n = 28, MD 0.01, 95% CI -7.26 to 7.28, Analysis 5.10).
There was no different between groups receiving the combined
treatment compared to benzodiazepine alone in the medium term
for BPRS psychosis subscale scores (n = 95, 2 RCTs, MD -1.19,
95% CI -4.60 to 2.23, Analysis 5.11), BPRS positive scores (n =
30, 1 RCT, MD 0.86, 95% CI -1.62 to 3.34, Analysis 5.12) and
BPRS excited component scores (n = 30, 1 RCT, MD 0.47, 95%
CI -1.32 to 2.26). Analysis 5.13.
5.14 to 5.16 Adverse effects/events
There was no clear difference in the rate of EPS (n = 127, 2
RCTs, RR 0.44, 95% CI 0.16 to 1.17, Analysis 5.14, low quality
evidence) or medication for EPS (n = 95, 2 RCTs, RR 0.52, 95%
CI 0.27 to 1.01, Analysis 5.15) when people receiving combined
benzodiazepines/haloperidol were compared with those receiving
haloperidol alone. There was no clear difference between groups
when assessing specific adverse events (Analysis 5.16).
5.17 Hospital and service outcomes
In Alprazolam 1992, USA, there was no difference in participants
who had not been discharged in the medium term (n = 28, 1 RCT,
RR 0.90, 95% CI 0.54 to 1.50, Analysis 5.17).
Missing outcomes
For this comparison, none of the studies reported leaving the study
early, satisfaction with treatment or economic outcomes.
Comparison 6: Benzodiazepines plus antipsychotics
versus antipsychotics plus antipsychotics
One study compared benzodiazepines plus antipsychotics versus
antipsychotics plus antipsychotics (Lorazepam 1998, SA).
6.1 Behaviour
There was no clear difference in medium-term OAS scores when
combined lorazepam/haloperidol was compared with combined
clothiapine/haloperidol (n = 60, 1 RCT, MD -5.83, 95% CI -
27.60 to 15.94, Analysis 6.1).
6.2 Leaving the study early
The study reported no participants left the study early (Analysis
6.2).
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Missing outcomes
For this comparison, none of the studies reported data for tran-
quilisation or asleep, global state, mental state, adverse effects/
events, hospital and service outcomes, satisfaction with treatment
or economic outcomes.
Comparison 7: Benzodiazepines plus antipsychotics
versus antipsychotics plus antihistamines
One study compared benzodiazepines plus antipsychotics versus
antipsychotics plus antihistamines (Midazolam 2011, BZ).
7.1 Tranquillisation or asleep
Medium-term sedation was higher in the midazolam/haloperidol
group (n = 60, 1 RCT, RR 12.00, 95% CI 1.66 to 86.59, very low
quality evidence, Analysis 7.1).
7.2 to 7.3 Behaviours
OAS aggression scores in people receiving combined midazolam/
haloperidol were significantly lower than scores in the combined
promethazine/haloperidol group in the short term (n = 60, 1 RCT,
MD -3.30, 95% CI -5.25 to -1.35), but there was no clear dif-
ference in the medium term (n = 60, 1 RCT, MD 1.70, 95% CI
-0.06 to 3.46). Analysis 7.2. People who received combined mi-
dazolam/haloperidol scored lower on the OASS agitation scale in
the short term (n = 60, 1 RCT, MD -16.00, 95% CI -18.98 to -
13.02) and medium term (n = 60, 1 RCT, MD -2.70, 95% CI -
3.73 to -1.67). Analysis 7.3.
7.4 to 7.6 Global state
In themedium term,more people receiving combinedmidazolam/
haloperidol had not improved (n = 60, 1 RCT, RR 25.00, 95%
CI 1.55 to 403.99, very low quality evidence, Analysis 7.4) and
were given a higher dose of additional medication compared with
the combined promethazine/haloperidol group (n = 60, 1 RCT,
MD 0.63, 95% CI 0.15 to 1.11, Analysis 7.5). Short-term RSS
sedation scores (n = 60, 1 RCT, MD short term 0.60, 95% CI
0.07 to 1.13) were higher in the midazolam/haloperidol group,
although there was no clear difference inmedium-term RSS scores
(n = 60, 1 RCT, MD 0.00, 95% CI -0.46 to 0.46). Analysis 7.6.
7.7 to 7.8 Adverse events
There was no clear difference between groups in the incidence of
EPS in the medium-term (n = 60, 1 RCT, RR 0.60, 95% CI 0.16
to 2.29, very low quality evidence, Analysis 7.7) or hypotension (n
= 60, 1 RCT, RR 1.67, 95% CI 0.44 to 6.36, Analysis 7.8).
Missing outcomes
For this comparison, none of the studies reported data for leaving
the study early, hospital and service outcomes, satisfaction with
treatment or economic outcomes.
Sensitivity analyses
We conducted sensitivity analyses for Comparison 2 (benzodi-
azepines versus antipsychotics) for the primary outcome of our pri-
mary outcome tranqulisation or asleep (sedation) and additional
outcomes of global state ’improvement’ and adverse effects ’ex-
trapyramidal symptoms’ as these analyses had the most available
data.
8. Sensitivity analysis - Randomised sequence generation
In trials rated as low risk of bias, people receiving benzodiazepines
were significantly more likely to be sedated compared with people
receiving antipsychotics (n = 247, 3 RCTs, RR 2.22, 95% CI
1.52 to 3.25) with slight heterogeneity (Chi2 = 2.26, P = 0.32, I
2 = 11%); there was no clear difference between groups in trials
where the method of sequence generation was unclear (n = 340, 6
RCTs, RR 0.84, 95% CI 0.56 to 1.26, Analysis 8.1). The test for
differences between subgroups was significant and demonstrated
high heterogeneity (Chi2 = 11.86, P = 0.0006, I2 = 91.6%).
In trials rated as low risk of bias, there was no clear difference
between groups in the numbers who had not improved (n = 124,
3 RCTs, RR 1.01, 95% CI 0.80 to 1.28, Analysis 8.2), neither
was there any clear difference between groups in trials where the
method of sequence generation was unclear (n = 214, 3 RCTs,
RR 1.13, 95% CI 0.78 to 1.63); however, heterogeneity was high
(Chi2 = 9.34, P =.009, I2 = 79%). The test for differences between
subgroups was not significant (Chi2 = 0.06, P = 0.81, I2 = 0%).
The estimates of EPS were similar in trials with a low risk of
bias (n = 247, 3 RCTs, RR 0.16, 95% CI 0.03 to 0.85) and for
trials that were unclear (n = 285, 5 RCTs, RR 0.15, 95% CI
0.05 to 0.47); both trials demonstrating a clear difference between
benzodiazepines and antipsychotics (Analysis 8.3). There was no
significant difference between subgroups (Chi2 = 0.00, P = 0.95,
I2 = 0%).
9. Sensitivity analysis - Allocation concealment
People receiving benzodiazepines were more likely to be sedated
in the one trial rated at low risk of bias for allocation concealment
(n = 153, RR 2.71, 95% CI 1.55 to 4.73), although there was no
clear difference between groups for those trials rated as unclear (n
= 434, 8 RCTs, RR 1.08, 95% CI 0.79 to 1.48, Analysis 9.1). The
difference between subgroups was clear and demonstrated high
heterogeneity (Chi2 = 7.86, P = 0.005, I2 = 87.3%).
All trials reporting improvement/no improvement were rated as
having an unclear risk of bias. There was no clear difference in ’no
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improvement’ (n = 338, 6 RCTs, RR 1.07, 95% CI 0.86 to 1.32);
however, results displayed high heterogeneity (Chi2 = 11.33, P =
0.05, I2 = 56%, Analysis 9.2).
The risk of EPS was similar in the benzodiazepine and antipsy-
chotics group in one study at a low risk of bias (n = 153, RR 0.15,
95% CI 0.01 to 2.90) and slightly reduced in the seven trials with
an unclear risk of allocation bias (n = 379, 7 RCTs, RR 0.15, 95%
CI 0.06 to 0.41, Analysis 9.3). There was no significant difference
between subgroups (Chi2 = 0.00, P = 1.00, I2 = 0%).
10. Sensitivity analysis - Blinded outcome measurement
There was a clear difference in the amount of people who were
sedated in the benzodiazepines group in those trials that were rated
at low risk of bias (n = 119, 2 RCTs, RR 1.66, 95% CI 1.05
to 2.64), but not in trials rated at unclear risk of bias (n = 424,
6 RCTs, RR 1.34, 95% CI 0.93 to 1.94) for blinded outcome
measurement. There was also no clear change in trials exhibiting
a high risk (n = 44, 1 RCT, RR 1.14, 95% CI 0.56 to 2.34);
however, heterogeneity was high (Analysis 10.1). There was no
clear difference between subgroups (Chi2 = 0.89, P = 0.64, I2 =
0%).
In trials rated as having an unclear risk of bias, the rate of no im-
provement was similar between people receiving benzodiazepines
and people receiving antipsychotics (n = 224, 4 RCTs, RR 1.18,
95% CI 0.88 to 1.59), the heterogeneity was high (Chi2 = 12.97,
P = 0.005; I2 = 77%) and in trials rated at low risk of bias, there
was no clear difference in improvement between groups (n = 114,
2 RCTs, RR 0.80, 95% CI 0.60 to 1.07), but heterogeneity was
high (Chi2 = 3.15, P = 0.08, I2 = 68%); differences between sub-
groups were significant with high heterogeneity (Chi2 = 3.36, P =
0.07, I2 = 70.2%, Analysis 10.2).
There was a clearly decreased risk of EPS in people receiving ben-
zodiazepines, irrespective of whether trials were rated as low risk of
bias (n = 106, 2 RCTs, RR 0.12, 95% CI 0.03 to 0.48) or unclear
risk of bias (n = 426, 6 RCTs, RR 0.19, 95% CI 0.05 to 0.68)
for blinded outcome measurement (Analysis 10.3). There was no
significant difference between subgroups (Chi2 = 0.21, P = 0.64,
I2 = 0%).
11. Sensitivity analysis - Incomplete outcome data (attrition
bias)
There was no clear difference in sedation whether trials were rated
at low risk of bias (n = 260, 4 RCTs, RR 1.30, 95% CI 0.83
to 2.03) or at unclear risk of bias (n = 134, 3 RCTs, RR 1.07,
95% CI 0.62 to 1.83). Where risk of bias was high, there was a
difference in favour of antipsychotics, but heterogeneity between
trials was high (n = 193, 2 RCTs, RR 1.78, 95% CI 1.15 to 2.75,
Analysis 11.1). Apparent differences between subgroups were not
significant (Chi2 = 2.23, P = 0.33, I2 = 10.1%).
Trials rated as a low risk of attrition bias were more likely to
find similar rates of no improvement in people receiving benzodi-
azepines compared with people receiving antipsychotics (n = 290,
5 RCTs, RR 1.23, 95% CI 0.98 to 1.56), whereas, in the one trial
rated at unclear risk of bias, there was a lower rate of no improve-
ment in people receiving benzodiazepines identified (n = 48, RR
0.56, 95 %CI 0.32 to 0.97). There was a clear difference between
these subgroups (Chi2 = 6.65, P = 0.01, I2 = 85.0%, Analysis
11.2).
The finding that the incidence of EPSwas lower in people receiving
benzodiazepines was clearly identified in low risk of bias trials (n =
302, 5 RCTs, RR 0.18, 95% CI 0.06 to 0.60) and in unclear risk
of bias trials (n = 77, 2 RCTs, RR 0.09, 95% CI 0.01 to 0.65),
but not in high risk of bias trials (n = 153, 1 RCT, RR 0.15, 95%
CI 0.01 to 2.90, Analysis 11.3). However, this apparent difference
between subgroups was not significant (Chi2 = 0.44, P = 0.93, I2
= 0%).
Publication bias
Sedation data from the comparison of benzodiazepines versus an-
tipsychotics were used to investigate whether there was evidence
of systematic small trial bias in a funnel plot analysis. There was a
small number of trials and it was difficult to be sure of any asym-
metry (Figure 1). We think it inadvisable to read too much into
this exploratory, low-powered technique of investigation. What is
needed are more trials with a wide spread of findings.
29Benzodiazepines for psychosis-induced aggression or agitation (Review)
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Benzodiazepines compared to antipsychotics for psychosis- induced aggression or agitation
Patient or population: people with psychosis-induced aggression or agitat ion
Settings: hospitals (US, Canada, Israel, China, Australia)
Intervention: benzodiazepines
Comparison: ant ipsychot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Antipsychotics Benzodiazepines
Tranquilli-
sation or asleep: seda-
tion - medium term vs
haloperidol
Number of part icipants
sedated
Follow-up: mean 16
hours
Low RR 1.13
(0.83 to 1.54)
434
(8 studies)
⊕⊕©©
Low1,2
-
100 per 1000 113 per 1000
(83 to 154)
Moderate5
227 per 1000 257 per 1000
(189 to 350)
High
500 per 1000 565 per 1000
(415 to 770)
Global state:
no improvement - vs
haloperidol - medium
term
As def ined in each
study
Follow-up: 24 hours
Low RR 0.89
(0.71 to 1.11)
188
(5 studies)
⊕⊕©©
Low1,2
-
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77 per 1000 68 per 1000
(55 to 85)
Moderate3
619 per 1000 551 per 1000
(439 to 687)
High
933 per 1000 830 per 1000
(662 to 1000)
Global state: no im-
provement - vs olanza-
pine - medium term
As def ined in each
study
Follow-up: 24 hours
192 per 1000 353 per 1000
(203 to 610)
RR 1.84
(1.06 to 3.18)
150
(1 study)
⊕©©©
Very low1,2,7
-
Global state: need for
additional medication -
medium term
Number of part ici-
pants requiring addi-
t ional medicat ion
Follow-up: 24 hours
See comment See comment Not est imable 216
(2 studies)
⊕©©©
Very low1,2,4
High levels of het-
erogeneity between in-
cluded studies (Chi2 =
16.41; I2 = 94%) - data
not pooled.4
Ad-
verse effects/ events:
extrapyramidal symp-
toms - vs haloperidol -
medium term
Number of instances of
extrapyramidal symp-
toms
Follow-up: 21 hours
Low RR 0.13
(0.04 to 0.41)
233
(6 studies)
⊕⊕©©
Low1,2
-
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0 per 1000 0 per 1000
(0 to 0)
Moderate6
186 per 1000 24 per 1000
(7 to 76)
High
500 per 1000 65 per 1000
(20 to 205)
Satisfaction with treat-
ment: f rom the per-
spect ive of consumer,
family and informal
care givers or profes-
sionals/ carers at any
point during the acute
management stage
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Economic outcomes:
cost-effectiveness
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1Risk of bias: ’serious’ - most trials received funding f rom a pharmaceut ical inst itute and there was potent ial risk of select ion
bias.
2Imprecision: ’serious’ - conf idence intervals for best est imate of ef fect included both ’no ef fect ’ and appreciable benef it /
harm.
3Assumed risk: calculated f rom the included studies - presented three risks based on the control group risks - ’moderate’ risk
equates with that of control group (61.9%).
4Inconsistency: ’serious’ - one study indicated signif icant favour of ant ipsychot ics, while the other study indicated favour for
benzodiazepines (non-signif icant).
5Assumed risk: calculated f rom the included studies - presented three risks based on the control group risks - ’moderate’ risk
equates with that of control group (22.7%).
6Assumed risk: calculated f rom the included studies - presented three risks based on the control group risks - ’moderate’ risk
equates with that of control group (18.6%).
7Only one small study report ing data.
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Benzodiazepines compared to antihistamines + antipsychotics for psychosis- induced aggression or agitation
Patient or population: people with psychosis-induced aggression or agitat ion
Settings: psychiatric hospitals (US, Canada, Israel, China, Australia)
Intervention: benzodiazepines
Comparison: ant ihistamines + ant ipsychot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Antihistaimes + an-
tipsychotics
Benzodiazepines
Tranquil-
lisation or asleep: se-
dation - medium term -
lorazepam vs haloperi-
dol + promethazine
Number of part icipants
sedated
Follow-up: 2 weeks
970 per 10001 883 per 1000
(815 to 951)
RR 0.91
(0.84 to 0.98)
200
(1 study)
⊕⊕©©
Low2,3
-
Tranquillisa-
tion or asleep: sedation
- medium term - mida-
zolam vs haloperidol +
promethazine
Number of part icipants
sedated
Follow-up: 2 weeks
827 per 10001 934 per 1000
(860 to 1000)
RR 1.13
(1.04 to 1.23)
301
(1 study)
⊕⊕©©
Low2,3
-
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Global state: no im-
provement - medium
term
As def ined in each
study
Follow-up: 2 weeks
120 per 10001 260 per 1000
(139 to 486)
RR 2.17
(1.16 to 4.05)
200
(1 study)
⊕⊕©©
Low2,3
-
Global state: need for
additional medication -
medium term
Number of part ici-
pants requiring addi-
t ional medicat ion
Follow-up: 2 weeks
30 per 10001 40 per 1000
(9 to 174)
RR 1.33
(0.31 to 5.81)
200
(1 study)
⊕⊕©©
Low2,3
-
Adverse effects/
events: extrapyramidal
symptoms - medium
term
Number of instances of
extrapyramidal symp-
toms
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Satisfaction with treat-
ment: f rom the per-
spect ive of consumer,
family and informal car-
ers or professionals/
carers at any point dur-
ing the acute manage-
ment stage
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Economic outcomes:
cost-effectiveness
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Assumed risk: mean baseline risk presented for single study. Equates with that of control group.
2Risk of bias: ’serious’ - non-blind, open-label study.
3Imprecision: ’serious’ - small sample size.
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Benzodiazepines + antipsychotics compared to same benzodiazepines for psychosis- induced aggression or agitation
Patient or population: people with psychosis-induced aggression or agitat ion
Settings: hospitals (USA, China)
Intervention: benzodiazepines + ant ipsychot ics
Comparison: same benzodiazepines
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Same benzodiazepines Benzodiazepines+ an-
tipsychotics
Tranquil-
lisation or asleep: se-
dation - medium term-
+ haloperidol - medium
term
Number of part icipants
sedated
Follow-up: 24 hours
Moderate5 RR 0.84
(0.59 to 1.19)
110
(2 studies)
⊕⊕©©
Low1,2
-
556 per 1000 467 per 1000
(328 to 661)
Global state: no im-
provement - + haloperi-
dol - medium term
As def ined in each
study
Follow-up: 24 hours
Low RR 0.96
(0.76 to 1.20)
113
(3 studies)
⊕⊕©©
Low1,2
-
677 per 1000 650 per 1000
(515 to 812)
Modertate3
732 per 1000 703 per 1000
(556 to 879)
High
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867 per 1000 832 per 1000
(659 to 1000)
Global state: no im-
provement - lorazepam
+ risperidone vs lo-
razepam - medium
term
As def ined in each
study
Follow-up: 12 hours
700 per 1000 602 per 1000
(315 to 1000)
RR 0.86
(0.45 to 1.64)
20
(1 study)
⊕⊕©©
Low1,2
-
Global state: need for
additional medication -
+ haloperidol - medium
term
Number of part ici-
pants requiring addi-
t ional medicat ion
Follow-up: 24 hours
Low RR 1.02
(0.79 to 1.32)
103
(3 studies)
⊕⊕©©
Low1,2
-
0 per 1000 0 per 1000
(0 to 0)
Moderate4
500 per 1000 510 per 1000
(395 to 660)
High
774 per 1000 789 per 1000
(611 to 1000)
Adverse effects/
events: extrapyramidal
symptoms - + haloperi-
dol - medium term
Number of instances of
extrapyramidal symp-
toms
Follow-up: 24 hours
24 per 10006 46 per 1000
(4 to 483)
RR 1.94
(0.18 to 20.30)
83
(2 studies)
⊕⊕©©
Low1,2
-
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Satisfaction with treat-
ment: f rom the per-
spect ive of consumer,
family and informal car-
ers or professionals/
carers at any point dur-
ing the acute manage-
ment stage
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Economic outcomes:
cost-effectiveness
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Risk of bias: ’serious’ - most trials received funding f rom a pharmaceut ical inst itute and there was potent ial risk of select ion
bias.
2Imprecision: ’serious’ - conf idence intervals for best est imate of ef fect included both ’no ef fect ’ and appreciable benef it /
harm.
3Assumed risk: calculated f rom the included studies - presented three risks based on the control group risks - ’moderate’ risk
equates with that of control group (73.2%).
4Assumed risk: calculated f rom the included studies - presented three risks based on the control group risks - ’moderate’ risk
equates with that of control group (50%).
5Calculated f rom the included studies - ’moderate’ risk equates with that of control group (55.6%).
6Calculated f rom the included studies - ’moderate’ risk equates with that of control group (2.4%).
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Benzodiazepines + antipsychotics compared to same antipsychotics for psychosis- induced aggression or agitation
Patient or population: people with psychosis-induced aggression or agitat ion
Settings: hospitals (US, China, Brazil)
Intervention: benzodiazepines + ant ipsychot ics
Comparison: same antipsychot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Same antipsychotics Benzodiazepines+ an-
tipsychotics
Tranquilli-
sation or asleep: seda-
tion - medium term - +/
vs haloperidol
Number of part icipants
sedated
Follow-up: 12 hours
Moderate5 RR 1.75
(1.14 to 2.67)
172
(3 studies)
⊕©©©
Very low1,2,3
-
256 per 1000 448 per 1000
(292 to 683)
Low
100 per 1000 175 per 1000
(114 to 267)
High
380 per 1000 665 per 1000
(433 to 1000)
Global state: no im-
provement - +/ vs
haloperidol - medium
term
As def ined in each
study
Follow-up: 36 hours
Moderate4 RR 1.17
(0.93 to 1.46)
185
(4 studies)
⊕⊕©©
Low1,2
-
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521 per 1000 610 per 1000
(485 to 761)
Low
33 per 1000 39 per 1000
(31 to 48)
High
933 per 1000 1000 per 1000
(868 to 1000)
Global state: need for
additional medication
Number of part ici-
pants requiring addi-
t ional medicat ion
Follow-up: 12 hours
See comment See comment Not est imable 67
(1 study)
⊕⊕©©
Low2,3
-
Ad-
verse effects/ events:
extrapyramidal symp-
toms - +/ vs haloperidol
- medium term
Number of instances of
extrapyramidal symp-
toms
Follow-up: 18 hours
Moderate6 RR 0.44
(0.16 to 1.17)
127
(2 studies)
⊕⊕©©
Low2
-
185 per 1000 81 per 1000
(30 to 216)
Satisfaction with treat-
ment: f rom the per-
spect ive of consumer,
family and informal car-
ers or professionals/
carers at any point dur-
ing the acute manage-
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
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ment stage
Economic outcomes:
cost-effectiveness
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
+/vs : with or versus; CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Inconsistency: ’serious’ - high levels of heterogeneity.
2Imprecision: ’serious’ - conf idence intervals for best est imate of ef fect included both ’no ef fect ’ and appreciable benef it /
harm.
3Risk of bias: ’serious’ - funded by pharmaceut ical inst itutes.
4Calculated f rom the included studies - presented three risks based on the control group risks - ’moderate’ risk equates with
that of control group (52.1%).
5Calculated f rom the included studies - presented three risks based on the control group risks - ’moderate’ risk equates with
that of control group (25.6%).
6Calculated f rom the included studies - ’moderate’ risk equates with that of control group (18.5%).
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B enzodiazepines + antipsychotics compared to antipsychotics + antipsychotics for psychosis- induced aggression or agitation
Patient or population: people with psychosis-induced aggression or agitat ion
Settings: n/ a
Intervention: benzodiazepines + ant ipsychot ics
Comparison: ant ipsychot ics + ant ipsychot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Antipsychotics+ an-
tipsychotics
Benzodiazepines+ an-
tipsychotics
Tranquilli-
sation or asleep: seda-
tion - medium term
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Global state: no im-
provement - medium
term
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Global state: need for
additional medication -
medium term
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Adverse effects/
events: extrapyramidal
symptoms - medium
term
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Satisfaction with treat-
ment: f rom the per-
spect ive of consumer,
family and informal car-
ers or professionals/
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
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carers at any point dur-
ing the acute manage-
ment stage
Economic outcomes:
cost-effectiveness
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B enzodiazepines + antipsychotics compared to antihistamines + antipsychotics for psychosis- induced aggression or agitation
Patient or population: people with psychosis-induced aggression or agitat ion
Settings: psychiatric emergency department (Brazil)
Intervention: benzodiazepines + ant ipsychot ics
Comparison: ant ihistamines + ant ipsychot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Antihistamine + an-
tipsychotics
Benzodiazepines+ an-
tipsychotics
Tranquilli-
sation or asleep: seda-
tion - medium term
Number of part icipants
sedated
Follow-up: 12 hours
33 per 10005 400 per 1000
(55 to 1000)
RR 12.00
(1.66 to 86.59)
60
(1 study)
⊕©©©
Very low3,4
-
Global state: no im-
provement - medium
term
As def ined in each
study
Follow-up: 12 hours
0 per 10001 0 per 1000
(0 to 0)2
RR 25.00
(1.55 to 403.99)
60
(1 study)
⊕©©©
Very low3,4
-
Global state: need for
additional medication -
medium term
Number of part ici-
pants requiring addi-
t ional medicat ion
Follow-up: 12 hours
- The mean global im-
pression: need for ad-
dit ional medicat ion -
medium term in the in-
tervent ion groups was
0 higher
(0 to 0 higher)
- 60
(1 study)
⊕©©©
Very low3,4
Skewed data - see ’data
and analysis’.
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Adverse effects/
events: extrapyramidal
symptoms - medium
term
Number of instances of
extrapyramidal symp-
toms
Follow-up: 12 hours
167 per 10005 100 per 1000
(27 to 382)
RR 0.60
(0.16 to 2.29)
60
(1 study)
⊕©©©
Very low3,4
-
Satisfaction with treat-
ment: f rom the per-
spect ive of consumer,
family and informal car-
ers or professionals/
carers at any point dur-
ing the acute manage-
ment stage
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
Economic outcomes:
cost-effectiveness
See comment See comment Not est imable 0
(0)
See comment No study reported this
outcome.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Assumed risk: mean baseline risk - only one trial reported with 0 events in the control group and 12 events in the intervent ion
group.
2Corresponding risk: one trial reported 12 events in the intervent ion group (40%).
3Risk of bias: ’serious’ - study funded by pharmaceut ical inst itutes, potent ial risk of select ion bias, performance bias and
attrit ion bias.4
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4Imprecision: ’very serious’ - only one study reported data for this outcome, data were skew.
5Assumed risk: mean baseline risk presented for single study. Equates with that of control group.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
Comparison 1: Benzodiazepines versus placebo
See Summary of findings for the main comparison. There was
some evidence that lorazepam was superior to placebo in terms of
improvement and behaviour in the medium but not short term,
although these data came from a single small study with very
serious risk of bias and were, therefore, graded as very low quality
evidence. There was no clear evidence of a difference between
groups in tranquillisation, mental state, adverse events or leaving
the study early.
It is understandable that placebo-controlled trials in this area are
uncommon as withholding treatment from people in such a dis-
tressed state can be considered unethical. Therefore, evidence from
RCTs that benzodiazepines are superior to placebo is insufficient.
Comparison 2: Benzodiazepines versus antipsychotics
See Summary of findings 2. Overall, there was very low- to low-
quality evidence of no difference between benzodiazepines and
antipsychotics in terms of global state (e.g. clinical improvement
or need for additional medication) or sedation, or both. However,
there as low-quality evidence from single small studies showing a
clear difference between groups, One small study found that olan-
zapine was superior to lorazepam in terms of clinical improvement
(n = 150, Lorazepam 2001, RO and USA). One small study with
high attrition rates found that midazolam can achieve higher rates
of sedation than droperidol (n = 163, Midazolam 2006, AU). On
esmall study found lorazepam can reduce the severity of symp-
toms compared with haloperidol when measured by CGI (n = 37,
Lorazepam 1997b, USA). Due to the high levels of heterogene-
ity between studies and the very low quality of evidence, it was
difficult to make any conclusions from the results on the need
of additional medication comparing benzodiazepines and antipsy-
chotics. Moreover, there was no evidence available looking at the
short-term effect of benzodiazepines and haloperidol on various
outcomes such as sedation, improvement in global state, adverse
effects and need for additional medication.
In addition, low-quality evidence showed that EPS were consid-
erably lower in people receiving benzodiazepines. The data sug-
gest EPS were significantly higher in people receiving antipsy-
chotics and this should be considered in choosing the correct treat-
ment in an emergency situation. In clinical practice, antipsychotics
and mainly typical antipsychotics are often accompanied by anti-
cholinergic treatment thatmay substantially decrease the incidence
of EPS particularly in non-organic psychosis. Therefore, the use
of atypical antipsychotics based on the reduced EPS profile may
be a suitable potential treatment option. Typical antipsychotics
such as haloperidol without accompanying anticholinergics does
not seem acceptable and this is consistent with outcomes of other
relevant reviews (Huf 2009).
There was no difference between groups for mental state and other
adverse events. Considering the above findings, due to the very low
or low quality of evidence, the difference between benzodiazepine
and antipsychotics for acute agitation remain uncertain.
Comparison 3: Benzodiazepines versus antipsychotics
plus antihistamines
See Summary of findings 3. This comparison includedMidazolam
2003, BZ and Lorazepam 2004, IN, which were larger trials. Re-
sults for improvement and global state scores favoured the use of
combined haloperidol/promethazine over lorazepam but all these
data came from Lorazepam 2004, IN; sedation was reported in
both Midazolam 2003, BZ and Lorazepam 2004, IN trials, but
data could not be pooled because of substantial heterogeneity be-
tween the two trials. People receiving midazolam were more likely
to become sedated compared with combined haloperidol/promet-
hazine inMidazolam 2003, BZ, unlike Lorazepam2004, INwhere
people receiving combined haloperidol/promethazine were more
likely to become sedated. Possible reasons for this dramatic het-
erogeneity was discussed in depth in another review (Huf 2009),
but the most likely reason is midazolam is a faster-acting and more
potent benzodiazepine than lorazepam (Larson 1994). Clinically,
sedation caused by combined haloperidol/promethazine was dose
related.
Lorazepam 2004, IN reported the use of physical restraints.
Throughout the course of the trial, people receiving lorazepam
alone were more likely to be mechanically restrained than people
who received combined haloperidol/promethazine. Although re-
straint was not a stated outcome in our protocol and may be of
more relevance to clinicians in countries where the use of mechan-
ical restraints is employed, we feel that it is an important outcome
and should be considered in future reviews and trials.
In these larger and better-reported trials, adverse effects were infre-
quent but important, and included respiratory depression, nausea
and seizure. Respiratory depression is a very serious potential ad-
verse effect of all benzodiazepines, and occurred in both trials. One
participant in Midazolam 2003, BZ watdmitted with cocaine-in-
duced aggression, a potential mitigating factor.
The above findings were based on low-quality evidence, and results
from future studies are likely to change the findings.
Comparison 4: Benzodiazepines plus antipsychotics
versus same benzodiazepines
See Summary of findings 4. There was little difference between
combined benzodiazepines/antipsychotics compared with benzo-
diazepines alone but the quality of these data was low. The only
significant difference was that sedation was more likely in people
receiving the combination in the short term, although these data
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were from one small trial. Ratings of global state, mental state,
behaviour and adverse effects were all equivocal between groups
- as could be expected in such low power. A real and important
difference could exist, but larger trials are needed before any con-
fident conclusions can be drawn.
Comparison 5: Benzodiazepines plus antipsychotics
versus same antipsychotics
See Summary of findings 5. There were no apparent advantages in
using combined benzodiazepines/antipsychotics compared with
antipsychotics alone in terms of our primary outcome of no im-
provement but there were relatively few data with considerable
heterogeneity. In addition, as each of the included trials defined
’improvement’ differently, it was difficult to interpret how mean-
ingful these data were.
Sedation rates were significantly higher in the combined benzo-
diazepines/haloperidol group compared with haloperidol alone in
the short and medium term although the medium-term data were
heterogeneous. There were no differences between groups in the
incidence of EPS or other adverse effects but these were rated as
low-quality evidence.
Behaviour scores did seem to favour haloperidol when compared
with combined midazolam/haloperidol but these data came from
one small trial (n = 60). This finding may be changed by further
trials.
Comparison 6: Benzodiazepines plus antipsychotics
versus antipsychotics plus antipsychotics
See Summary of findings 6. The only trial to report data for this
comparison provided few data (Lorazepam 1998, SA), with no
documented instances of people leaving the study early, and no
difference in aggression ratings. Therefore, it is difficult to draw
any meaningful conclusions from this comparison; larger, more
informative trials with clearly defined outcomes are needed before
any conclusions can be made.
Comparison 7: Benzodiazepines plus antipsychotics
versus antipsychotics plus antihistamines
See Summary of findings 7. Only one trial reported two relevant
arms (total n = 60), and the quality of evidence was very low
(Midazolam 2011, BZ). There was very low quality evidence that
combined haloperidol/promethazine was significantly better than
combined midazolam/haloperidol in terms of improvement, need
for additional medication, sedation and behaviour. However, as
the quality of the evidence was very low, it was difficult to draw
any meaningful conclusions.
Sensitivity analysis
Although sensitivity analyses were conducted for the ’Risk of bias’
criteria, sequence generation, allocation concealment, blinded out-
come measurement and incomplete data, there were few differ-
ences between trials at high, low and unclear risk of bias. Trials at
low risk of bias for sequence generation, allocation concealment
and blinded outcome measurement were more likely to favour
benzodiazepines over antipsychotics in terms of sedation and low-
ering the risk of EPS. However, these findings were based on rela-
tively few data and should at this stage be interpreted with caution.
Overall completeness and applicability of
evidence
1. Completeness
1.1. Power
1.1.1. Limited power
We only found one trial (n = 102) comparing benzodiazepines
with placebo. Although data were incomplete, we know enough
to suggest that randomisation of benzodiazepine versus placebo
to be ethical only in the most constrained services of such limited
supply that anything but randomisation would be inequitable.
Eleven trials compared benzodiazepines directly with antipsy-
chotics, and most of trials had small sample sizes. When a benzo-
diazepine was compared with combined benzodiazepine/antipsy-
chotic, the five trials had a mean of 50 participants. Even if the
outcome reporting had been comprehensive (taking into account
views of clinicians and participants as well as researchers), the
depth and strength of evidence in this area is very far from com-
plete. Despite an increasing trend to consider atypical antipsy-
chotics as more suitable for rapid tranquillisation than the older
antipsychotics, there were inadequate data to compare atypical an-
tipsychotics with benzodiazepines. Such promotion of the antipsy-
chotics is based more on well-meaning faith combined with an
understandable lack of resistance from industry rather than good
evidence.
The two TREC trials (Tranquilização Rápida-Ensaio Clínico
(Rapid Tranquillisation-Clinical Trial)) that compared benzodi-
azepines with combined haloperidol/promethazine were large (n
= 200 and 301), high-powered trials, recognised for high method-
ological quality in this area of research (NICE 2015). These trials
did not have an emphasis on recording scale-derived data but did
provide useful binary outcomes.
The comparison for combinedbenzodiazepines/haloperidol versus
combined haloperidol/promethazine was very limited (1 RCT, n
= 60) with few data from a single trial with multiple treatment
arms. All outcomes need to be interpreted with great caution.
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1.1.2. No power
The trial search did not identify trials that compared specific ben-
zodiazepines at a high versus low dose; oral versus IM/intravenous;
or low frequency versus high frequency (as defined by each study).
Future research could examine these comparisons to highlight any
potential benefits/efficacy of specifically named benzodiazepines
in the management of psychosis-induced aggression/agitation.
1.2. Outcome measurement
1.2.1. Measures
A major difficulty in synthesising data from trials in this review
was the considerable variability in what and how outcomes were
measured. Several trials reported outcomes that were not within
the specified time period and therefore could not be used.
Given the potential for adverse events with benzodiazepines and
antipsychotics, future trials should ensure that these data are col-
lected and reported. In addition, asmost trials allow for ’as-needed’
repeat doses of these drugs, the number of additional doses or
mean dosage is also an important outcome in these trials.
The trials used a range of modified versions of validated measures
or domain scores, thus, these data could not be synthesised in this
review. If scales are to be used, it is important that they, and the
individual subscales, are validated. Consistent use of measures of
agreed importance is important.
1.2.2. Sedation
There is a need to achieve behavioural control without sedation
(Rocca 2006). This perspective is reflected by sedation being re-
ported as a positive outcome in earlier trials but as negative inmore
recent trials. However, sedation remains important and should be
recorded and value judgements can be made by those who wish to
use the evidence. In future trials, other outcomes such as improve-
ment should be reported, as consensus guidelines have emphasised
that calming an agitated/aggressive person is the key goal in an
acute setting as opposed to rapid tranquillisation (Allen 2005).
2. Applicability
Despite a relatively broad range of inclusion criteria in regard to
participants and settings, results were quite homogenous. Largely,
participants, interventions and situations of administration were
familiar to the average clinical setting and the data seem to be ap-
plicable. Benzodiazepines and antipsychotics were used quite con-
sistently across trials. The majority used lorazepam or haloperidol
in consistent clinically applicable doses. Only six trials used atyp-
ical antipsychotics.
The major sources of heterogeneity were CGI scores when lo-
razepam and diazepam were compared with haloperidol (Analy-
sis 2.6), OASS scores when combined midazolam/haloperidol was
compared with olanzapine and ziprasidone (Analysis 5.6), and se-
dation when lorazepam and midazolam were compared with com-
bined haloperidol/promethazine (Analysis 3.1). There were sev-
eral potential reasons for this heterogeneity. The most identifiable
of these were differences in the types and doses of benzodiazepines
and antipsychotics that were used.
Quality of the evidence
Overall, most quality criteria were poorly reported in the trials in-
cluded in this review. Large, well-designed, clinically relevant and
clearly reported trials are clearly possible (Lorazepam 2004, IN;
Midazolam 2003, BZ), but these are very much the exceptions to
the rule. The randomisation methods and allocation concealment
were poorly reported in the included trials.Most trials did not state
whether they had concealed the group allocation regimen. Some
trials used a double-blind design, however, did not state who was
blinded (e.g. participants, outcome assessor, data analyser). About
30% of trials were supported by pharmaceutical institutes.
The quality of evidence was low to very low, the main reasons for
downgrading the evidence were very small sample size and serious
risk of bias across included studies.
Potential biases in the review process
It is entirely possible that we have not identified small negative
trials and would be most interested if readers know of these.
Agreements and disagreements with other
studies or reviews
The findings of this review agree with other narrative syntheses
of the literature that have concluded that benzodiazepines are at
least as effective as antipsychotics in controlling severely agitated
behaviour (Allen 2000; NICE 2005; Rocca 2006); however, be-
cause benzodiazepines have the potential to cause respiratory de-
pression, their use should be carefully monitored in an environ-
ment suited to manage such cases. The findings are also consistent
with other similar and overlapping reviews (see Implications for
practice: 3. for managers and policy-makers).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with agitation/aggression due to schizophrenia
or schizophrenia-like illnesses
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The intervention selected must be a reasonable and proportionate
response to the risk posed by the person at that particular time.
The aim of rapid tranquillisation is to achieve a state of calm
sufficient to minimise the risk posed to patients or others. To
achieve this state of calmness, various interventions can be used
ranging from de-escalation to pharmacological. Benzodiazepines
are a viable option for care in acute aggression though secondary to
psychotic illness, but much of the data on which practice is based
are poor (although there are exceptions). Many recommendations
for treatment are based on clinician’s experience, expert consensus
or local prescribing practice rather than data from high-quality
trials or well-considered consumer feedback. We think that the
situation is changing but certainly more well-designed, conducted
and reported trials are needed.
2. For clinicians
The data suggest that there is no difference between benzodi-
azepines and antipsychotics in particular relation to sedation but
data are limited and not of high quality. Moreover, low-quality
evidence of differences between benzodiazepine and olanzapine
exists even if not for every outcome. Using a combined benzo-
diazepine/antipsychotic does not seem to confer any advantage
over use of either drug alone. There is some evidence that newer
antipsychotics may be more beneficial than benzodiazepines but
data are very limited.
3. For managers or policy-makers
Lack of high-quality evidence leaves managers and policy makers
with difficult decisions to make. There is currently insufficient
clinical evidence to suggest that the benzodiazepine group of drugs
(alone or in combination with antipsychotics) is clearly superior
to antipsychotics in reducing acute psychotic behaviour.
Implications for research
1. General
Adherence to the CONSORT statement would probably have re-
sulted in this review being more conclusive (Moher 2001). Clear
descriptions of randomisation would have reassured users of these
trials that selection bias had been minimised and well-described
and blinded outcomemeasurement could have encouraged greater
confidence in the control of performance and detection bias. The
use of validated binary outcomes should take preference over con-
tinuous results because they are easier to interpret and better re-
porting of validated rating scales would have providedmore usable
data. The reporting of outcomes with their means and standard
deviations, again, would have providedmore usable data and facil-
itated synthesis of findings. When presenting data in a graph, the
exact numbers and standard deviations should also be reported.
2. Specific
2.1. Reviews
Although our original protocol specified a focus on rapid tran-
quillisation for acute psychosis, but by restricting our analyses up
to 48 hours, other potential serious adverse effects may have been
overlooked. For further reviews on this topic, or the update of this
review in the future, we recommend a less rigid time restriction
on long-term effects of benzodiazepines to attain a more accurate
consideration of the outcomes and other adverse effects (see Table
5).
2.2. Research
2.2.1. Methods
There is a need for better evidence regarding the relative effective-
ness of benzodiazepines and antipsychotics, particularly regarding
the reporting of both short-term and long-term adverse effects.
We did identify large, well-designed and clearly reported trials in
this area (TREC Vellore; TREC-II Brazil).
2.2.2. Interventions
More trials comparing the atypical antipsychotics, such as IM
clozapine or olanzapine, with benzodiazepines are needed. Ad-
ditional trials that compare combined benzodiazepines/antipsy-
chotics with either drug alone are still needed, particularly where
the newer antipsychotics are used. Because dosages could be ad-
justed on an as-needed basis in the majority of trials, it is difficult
to make conclusions about what doses of which drugs are most
suitable for managing psychosis-induced aggression or agitation.
As the ability to adjust doses would seem to be the only ethical
option in longer-term trials, these data also need to be reported in
future trials.
2.2.3. Outcomes
Standardised, validated scales that are acceptable to recipients of
this care, clinicians working in the field, researchers and people
working with regulatory authorities are needed to measure out-
comes in future trials. Possible outcome measures should include
measures of violence, degree of sedation, acceptability of the med-
ication and adverse effects, all recorded over a suitable timescale
to match the pharmacokinetic properties of the drugs. This will
mean selective reporting biases are more likely to be eliminated
and better-quality meta-analyses possible. One way to address this
fundamental issue would be to develop and employ a standardised
set of outcome measurements, or ’core outcome sets.’ This may be
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achieved through the COMET (Core Outcome Measures in Ef-
fectiveness Trials; www.comet-initiative.org/) Initiative that seeks
to identify a standardised set of outcomes, with consensus on how
these are to be defined and measured.
2.2.4. Suggested design of trial
We realise that design of suitable trials takes time and a great
deal of care but we have spent some considerable period studying
the relevant existing trials and, therefore, suggest an outline of a
suitable trial design (Table 6).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alprazolam 1992, USA
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 72 hours.
Setting: hospital - psychiatric emergency service, US.
Participants Diagnosis: all participants fulfilled DSM-III-R criteria for schizophrenia
n = 28.
Age: mean 33 years.
Gender: 11 men, 17 women.
Ethnicity: black (n = 23).
Consent: gave informed consent.
History: not stated.
Inclusion: 18-60 years old, actively psychotic with a minimum score of 12 on the abbre-
viated BPRS
Exclusion: coexisting major axis disorder, significant medical illness, pregnancy, use of
non-prescription psychoactive drug or alcohol in previous 72 hours
Interventions Benzodiazepines plus antipsychotics vs same antipsychotics.
1. Alprazolam 1 mg oral tablet + haloperidol 5 mg oral concentrate, mean 3.2 doses (n
= 14)
2. Haloperidol 5 mg oral concentrate + placebo tablet, mean 2.1 doses (n = 14)
Repeat dose given within first 24 hours if psychotic subscale was ≥ 11. Total dose
administered on day 1 repeated days 2 and 3. Each participant received a minimum of
2 doses
Outcomes Global state: no improvement*.
Mental state: mean endpoint score (BPRS and BPRS-psychosis subscale)
Adverse effects/events: use of medication for EPS.
Hospital and service outcomes: discharged.
Unable to use -
Global state: level of positive psychiatric symptoms (SAPS); level of negative psychiatric
symptoms (SANS) (no data within 48 hours)
Adverse effects/events: EPS (no useable data).
Notes *’Improvement’ - undefined; this result included the number of participants who demon-
strated lower mean baseline scores on the SAPS and BPRS subscale and were subse-
quently discharged before the completion of the study
Risk of bias
Bias Authors’ judgement Support for judgement
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Alprazolam 1992, USA (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised - participants were ’randomly
allocated;’ however, no further description
of randomisation provided
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind - the investigators who ad-
ministered the scales were blind to each
other’s ratings, and trial author DMM was
blind to the dose and schedule of treatment.
Both investigators were blind to drug as-
signment
Rating scales: trial author JGB adminis-
tered the BPRS-psychosis subscale, SANS,
SAPS and trial author DMM administered
the full-scale version of the BPRS - ratings
were not a self-report or completed by an
independent rater
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up: 69%.
9 participants were permitted to leave the
study early for ’humanitarian reasons,’ as
they had sufficiently improved to allow for
early discharge. In this case, a final set of
ratings were administered before discharge,
and the resultswere included in the analyses
High attrition rate but last observation car-
ried forward used for the analysis
Selective reporting (reporting bias) Unclear risk Use of Simpson-Angus Side Effects Profile
and ’another side effects rating scale’ was
mentioned, but no data were reported
Other bias Unclear risk Funding: supported in part by a grant from
The Upjohn Company (now Pfizer). We
are unsure whether Pfizer were involved in
the study design and reporting process
Clonazepam 1993, CA
Methods Allocation: randomised.
Blinding: double blind.
Design: parallel.
Duration: 2 hours.
Setting: psychiatric emergency services, Canada.
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Clonazepam 1993, CA (Continued)
Participants Diagnosis: bipolar (n = 7), chronic schizophrenia (n = 5), schizoaffective disorder (n =
3), brief reactive psychosis (n = 1)
n = 16 (14 were psychiatric inpatients at l’Hôpital Louis-H. Lafontaine, Montreal; 2
were recruited from the emergency department of the Royal Victoria Hospital,Montreal,
Canada)
Age: 18-60 years (mean 35 years).
Gender: 10 men, 6 women.
Ethnicity: not stated.
Consent: participants gave voluntary, informed, written consent; in addition, signatures
from 2 staff psychiatrists were required
History: not stated.
Inclusion criteria: aged 18-60 years with DSM-III diagnosis of bipolar affective illness
(manic phase, schizoaffective disorder, schizophrenia, schizophreniform disorder, brief
reactive psychosis or atypical psychosis) and score of ≥ 4 on 1 of 4 items: hyperactivity,
agitation, intrusiveness and impulsive behaviour on the Target Manic Behaviour Scale
Exclusion criteria: symptoms of organic brain syndromes, drug or alcohol abuse, epileptic
disorders or ECT within past 6 months
Interventions Benzodiazepines vs antipsychotics.
1. Clonazepam 1-2 mg IM, mean dose 5.4 mg + procyclidine placebo, mean dose 15.9
mg (n = 8)
2. Haloperidol 5-10 mg IM, mean dose 19.4 mg + procyclidine, mean dose 12.5 mg (n
= 8)
Given at 0, 0.5 and 1-hour intervals.
Dosage adjusted by blinded psychiatrist; procyclidine given to haloperidol group and
procyclidine placebo given to clonazepam group. No other psychotropic medication was
used during the study
Outcomes Global impression: no improvement*; sedation; mean score (IMPS)
Adverse effects/events: EPS.
Leaving the study early**.
Unable to use -
Global impression: using a modified 9-point CGI-S scale (not validated)
Behaviour: Target Manic Behaviour Symptom Scale (not validated)
Mental state: NOSIE (only selected items/questions from the actual validated tool were
reported)
Notes *’Improvement’ - defined as a reduction of ≥ 50% on the baseline IMPS score
**Both participants who left the study early were included in the statistical analysis by
using the endpoint score at time of exclusion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised participants “were randomly
assigned to one of two drug treatment
groups;” however, no further description of
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Clonazepam 1993, CA (Continued)
randomisation provided
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind - the evaluating psychiatrist
was “blind to treatment allocations” and
determined the exact dose of medication.
The haloperidol group also received procy-
clidinewith each dose - tomaintain double-
blind conditions, the clonazepam group re-
ceived procyclidine placebo with each dose
Rating scales: > 80% completed by a study
psychiatrist, it was unclear whether the
rater was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 88%* - low attrition rate and
last observation carried forward
2 participants withdrew from the study; 1
due to ’parkinsonian reaction’ and 1 due to
’sedation.’
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Funding: “Supported in part through a
grant from Hoffmann La Roche Ltd.” We
are unclear whether Hoffmann La Roche
Ltd were involved in the study design and
reporting process
Clonazepam 1999, CHN
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 24 hours.
Setting: inpatients, Chinese hospital.
Participants Diagnosis: schizophrenia (n = 19), mood disorder (n = 19), schizoaffective psychosis (n
= 6), epileptic mental disorder (n = 1), alcohol-induced psychosis (n = 1) from Chinese
Classification of Mental Disorders (CCMD-2-R)
n = 46.
Age: mean 32 years.
Gender: 32 men, 14 women.
Ethnicity: not stated.
Consent: not stated.
History: not stated.
Inclusion criteria: aggressive people with mental illness.
Exclusion criteria: not stated.
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Clonazepam 1999, CHN (Continued)
Interventions Benzodiazepines vs antipsychotics.
1. Clonazepam 2 mg IM (n = 22).
2. Haloperidol 10 mg IM (n = 24).
Outcomes Behaviour: mean endpoint (OAS).
Mental state: mean endpoint score (BPRS).
Adverse effects/events: EPS, tremor, high heart rate.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subject randomised” - no further descrip-
tion.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated.
Rating scales: unclear who administered
the rating scales.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100%.
Selective reporting (reporting bias) Low risk All measured outcomes were reported.
Other bias Unclear risk Funding: not stated. Unsure whether there
was potential bias
Clonazepam 2007a, CHN
Methods Allocation: randomised.
Blinding: double blinding, not state who was blinded.
Design: parallel.
Duration: 24 hours.
Setting: inpatients, Chinese hospital.
Participants Diagnosis: schizophrenia (CCMD-III).
n = 45.
Age: 18-45 years.
Gender: 20 men and 25 women.
Ethnicity: not stated.
Consent: yes.
History: not stated.
Inclusion criteria: schizophrenia (CCMD-3), aged 18-45 years, ≥ 4 on the agitation
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Clonazepam 2007a, CHN (Continued)
item from BPRS, ≥ 4 on any 1 of the following items from BPRS: unco-operativeness,
hostility, tension, mannerisms and posturing
Exclusion criteria: serious physical illness, substance or alcohol dependence, received the
study drugs 1 month prior to randomisation but with poor response
Interventions Combined benzodiazepines/antipsychotics vs same antipsychotics + placebo vs same
benzodiazepine + placebo
1. Clonazepam 2-6 mg IM + haloperidol 5-15 mg IM (n = 15).
2. Haloperidol 5-15 mg IM + placebo (n = 15).
3. Clonazepam 2-6 mg IM + placebo (n =15).
Participants were administered scopolamine where EPS occurred
Outcomes Mental state: no improvement*.
Mental state: mean score (total score of agitation items on BPRS, positive symptom score
on BPRS)
Adverse effects/events.
Notes * decrease rate of BPRS score < 30%.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised - participants were “randomly
allocated” based on random numbers
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind, not state who was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100%.
Selective reporting (reporting bias) Low risk All measured outcomes were reported.
Other bias Low risk Funding: American John M Davis Fund-
ing. We did not detect any other potential
bias
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Diazepam 1979, IL
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 24 hours.
Setting: Eitanim Psychiatric Hospital, Israel.
Participants Diagnosis: paranoid schizophrenia (n = 9), schizoaffective schizophrenia (n = 9),
schizophrenia subtypes (n = 5), paranoid states (n = 2), mania (n = 5), no diagnosis (n
= 10)
n = 40.
Age: 20-49 years (mean 33 years).
Gender: 27 men, 13 women.
Ethnicity: not stated.
Consent: not stated.
History: previous hospitalisation (mean 3 instances).
Inclusion criteria: newly admitted psychotic people aged 20-50 years after 2 days of drug-
free observation
Exclusion criteria: physical illness.
Interventions Benzodiazepines vs antipsychotics.
1. Diazepam 30-40 mg IV (n = 20).
2. Haloperidol 20-35 mg IV (n = 20).
In the haloperidol group, 10 participants received high-dose haloperidol and 10 partic-
ipants received moderately high-dose haloperidol; these scores were analysed together
Doses were given over a 3-hour period.
All participants were free from neuroleptics for 48 hours before the study began
Outcomes Global impression: sedation; mean score (CGI).
Mental state: mean score (BPRS).
Notes Note: assumptions were made regarding missing SDs data - SDs for the CGI-S and
BPRS mean scores were estimated from the range
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised “patients were randomly as-
signed” to treatment - no further descrip-
tion provided
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Observer blind - it is unclear how trial au-
thors remained blinded to alternation and
decrease of haloperidol dosage
Rating scales: BPRS and CGI were per-
formed by consensus of 2 physicians (trial
authors EL and YL), who were “unaware of
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Diazepam 1979, IL (Continued)
the treatment administered.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Follow-up: 50%.
Reasons for dropout were reported; 16 due
to treatment and 4 due to ’raters’ being un-
available
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Low risk Funding: supported by a grant from the
Gralnick Foundation, High Point Hospi-
tal, Port Chester, NY. We did not detect
any other bias
Flunitrazepam 1999, IL
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 2 hours.
Setting: psychiatric hospital, Israel.
Participants Diagnosis: schizophrenia (n = 19), schizoaffective disorder (n = 7), bipolar (n = 2, DSM-
IV, Axis I Structured Clinical Interview)
n = 28.
Age: 20-60 years (mean 36.8 years).
Gender: 13 men, 15 women.
Ethnicity: not stated.
Consent: need for informed consent waived.
History: not stated.
Inclusion criteria: active psychosis, disruptive or aggressive behaviour; pronounced psy-
chomotor agitation or violent outbursts; hospitalisation in an acute ward
Exclusion criteria: not stated.
Interventions Benzodiazepines vs antipsychotics.
1. Flunitrazepam 1 mg IM, single dose (n = 15).
2. Haloperidol 5 mg IM, single dose (n = 13).
Participants were monitored for 120 minutes.
Outcomes Global impression: no improvement*; sedation.
Adverse effects/events: EPS.
Unable to use -
Behaviour: OAS scores (variance not reported).
Notes *’Improvement’ - defined as reduction of ≥ 50% in the OAS score at 90 minutes
Participants in each group were taking additional medications leading up to the study,
including the following in the haloperidol group: haloperidol 5-10 mg/day (n = 4); per-
phenazine 5-20mg/day (n=5); levomepromazine 50-200mg/day (n= 2); zuclopenthixol
25 mg/day (n = 2); and the following in the flunitrazepam group:
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Flunitrazepam 1999, IL (Continued)
perphenazine 5-20 mg/day (n = 4); haloperidol 5-15 mg/day (n = 6); levomepromazine
75 mg/day (n = 1); zuclopenthixol 25-50 mg/day (n = 4)
4 participants (2 from each group) were also taking mood stabilisers (carbamazepine and
valproic acid) and lorazepam
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participantswere randomised “using a table
of random numbers.”
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not state whether investigators were
blinded.
Rating scales: trial coauthor administered
rating scales used for study. All rating scales
(OAS, BPRS and CGI) were completed by
author NK, who was blind to the study
medications; unclear whether dose adjust-
ment was blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100%.
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Unclear risk Funding: not stated. Unsure whether there
was potential bias
Lorazepam 1989, USA
Methods Allocation: randomised.
Blinding: non-blind.
Design: not stated.
Duration: “more than 60 minutes.”
Setting: metropolitan psychiatric hospital, US.
Participants Diagnosis: manic (n = 22), schizophrenia (n = 16), atypical psychotics (n = 16), miscel-
laneous diagnoses (n = 14)
n = 68.
Age: not stated.
Gender: 41 men, 27 women.
Ethnicity: not stated.
Consent: not stated.
History: not stated.
Inclusion criteria: requiring immediate treatment for agitated or assaultive behaviour
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Lorazepam 1989, USA (Continued)
and had to score > 50 mm on a 100-mm VAS for agitation. All had failed to respond to
non-pharmacological interventions to control agitation
Exclusion criteria: not stated.
Interventions Benzodiazepines + antipsychotics vs same benzodiazepine vs same antipsychotic
1. Lorazepam + haloperidol: haloperidol 5 mg IM + lorazepam 4 mg IM (n = 24)
2. Lorazepam 4 mg IM (n = 23).
3. Haloperidol 5 mg IM (n = 21).
All given as a single dose.
Outcomes Global impression: sedation.
Notes The balance of men/women differed between treatment groups.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; however, no further descrip-
tion of randomisation provided
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-blind, authors stated, “we considered
that the degree of tranquillisation desired
when treating agitated patients is easily as-
certained, and thus we did not use control
subjects and a blind design.”
Rating scales: unclear who administered
rating scales used to determine baseline ag-
itation ratings
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up: 100%.
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Unclear risk Funding: not stated. Unsure whether there
was potential bias
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Lorazepam 1991, USA
Methods Allocation: randomised.
Blinding: double blind.
Design: prospective.
Duration: 48 hours - intervention in an emergency situation; participants in both groups
usually required only 1 parenteral injection for behavioural control during the study pe-
riod (mean number of injections for lorazepam group = 1.13; mean number of injections
for haloperidol group = 1.10)
Setting: locked intensive care unit at Massachusetts Mental Health Center, Boston, US
Participants Diagnosis: schizophrenia (n = 16), bipolar (n = 11), schizoaffective disorder (n = 4),
organic mental disorder (n = 6), other (n = 13)
n = 60*.
Age: mean 34 years.
Gender: not stated.
Ethnicity: not stated.
Consent: not required.
History: not stated.
Inclusion: psychotic participants on a locked intensive care unit who required parenteral
medication to control aggressive, assaultive or disruptive behaviour
Exclusion: known substance abuse documented by positive toxicology screen on admis-
sion
Interventions Benzodiazepines vs antipsychotics.
1. Lorazepam 2 mg IM, mean 1.13 injections (n = 30).
2. Haloperidol 5 mg IM, mean 1.10 injections (n = 30).
Unclear when additional doses were given.
Outcomes Global impression: no improvement*.
Global impression: sedation.
Adverse effects/events: EPS.
Unable to use -
Global impression: CGI (no SD available).
Behaviour: OAS (no SD available).
Mental state: BPRS (no SD available).
Notes *’Improvement’ - defined as a greater than mean decrease in OAS scores at 2 hours
“More bipolar participants received haloperidol by chance.”
*At the time of entering the study:
- n = 4 in the lorazepam group and n = 6 in the haloperidol group were receiving lithium
carbonate
During the study period:
- n = 3 in the lorazepam group and n = 3 in the haloperidol group also received anticon-
vulsants
- n = 3 in the lorazepam group and n = 3 in the haloperidol group also received beta-
blocking agents
- n = 7 in the lorazepam group and n = 3 in the haloperidol group also received benzo-
diazepines
(Separate data analyses were conducted for participants receiving these additional psy-
chotropic medications, but results did not differ.)
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Lorazepam 1991, USA (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised - no further description.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators were likely to have been
blinded as the parenteral medication was
prepared in advance by a member of the
research staff who had no direct clinical re-
sponsibility for the participant
Rating scales: raters were blind to the treat-
ment condition received by the participant.
OAS ratings were obtained by staff nurses.
BPRS ratings were obtained by “trained
study psychiatrists.” Adverse effects and se-
dation were assessed by clinicians who did
not participate in evaluating therapeutic re-
sults
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up: sedation 88%; EPS 67%.
ITT: not stated.
Many participants were unavailable for all
ratings - “the number of patients available
for rating after baseline declined in both
treatment groups because some were dis-
charged or transferred from the locked in-
tensive care unit.”
Selective reporting (reporting bias) Unclear risk Complete data not available - SDs not
available for most reported outcomes
BPRS and CGI data not reported for 48
hours post injection.
Other bias Unclear risk Funding: supported in part by Wyeth Lab-
oratories. Unsure whether Wyeth Labora-
tories were involved in study design and re-
porting process
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Lorazepam 1997a, USA
Methods Allocation: randomised.
Blinding: double blind.
Design: prospective, parallel, multi-centre.
Duration: 24 hours.
Setting: emergency departments in 5 university/general hospitals in the US: University
of Texas Southwestern Medical Center, Dallas; Harbor-UCLA Medical Centre, Los An-
geles; University of Nebraska Medical Center, Omaha; Albert Einstein Medical Centre,
Philadelphia; and Harborview Medical Center, Seattle
Participants Diagnosis: schizophrenia (n = 47), psychosis (n = 27), psychoactive substance abuse (n
= 16), mania (n = 13), schizophreniform disorder (n = 1)
n = 98.
Age: mean 34 years.
Gender: 73 men, 25 women.
Ethnicity: not stated.
Consent: informed consent wherever possible.
History: all participants exhibited psychosis and behavioural dyscontrol (agitated, ag-
gressive, destructive, assaultive or restless behaviour)
Inclusion: presentation to emergency departmentwith psychosis andbehavioural dyscon-
trol to the extent they were capable of harming themselves or others. Score of ≥ 5 on
≥ 3 psychosis/anxiety items from the BPRS
Exclusion: obvious alcohol intoxication, central nervous system depression, allergic hy-
persensitivity, delirium, neuroleptic malignant syndrome, airway obstruction, severe hy-
potension or hypertension, acute narrow-angle glaucoma, benzodiazepine or antipsy-
chotic in previous 24 hours, fluphenazine decanoate in previous 2 weeks, haloperidol
decanoate in previous 4 weeks, pregnancy
Interventions Benzodiazepine + antipsychotic vs benzodiazepine vs same antipsychotic
1. Lorazepam 2 mg IM + haloperidol 5 mg IM, maximum 6 doses (n = 32)
2. Lorazepam 2 mg IM, maximum 6 doses (n = 31).
3. Haloperidol 5 mg IM, maximum 6 doses (n = 35).
Administered over 12 hours with ≤ 6 doses. First 3 injections at least 1 hour apart and
remainder 2 hours apart. Need for subsequent doses made by blinded evaluator. Most
participants had < 3 doses (lorazepam: 74%; haloperidol: 71%; combination: 91%)
Outcomes Global impression: no improvement*; need for additional medication; sedation
Behaviour: mean behaviour score (ABS).
Mental state: mean endpoint score (BPRS psychosis subscale).
Adverse effects/events: EPS; use of medication for EPS; ataxia, dizziness, dry mouth,
speech disorder
Unable to use -
Global impression: CGI (no useable data).
Notes *’Improvement’ - defined as a decrease of 1 from baseline or ≥ 2 from baseline on the
CGI (at 3 hours)
Sample numbers were not clear, as the authors stated that data were only collected if the
participant was awake
Note: assumptions made regarding missing SDs data.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised - eligible participants were
“sequentially assigned using a computer-
generated table of random numbers to re-
ceive one of three therapies.”
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind - “the emergency depart-
ment psychiatrist who treated and rated the
patient remained blinded to the identity of
the patient’s medication throughout treat-
ment.”
Rating scales: administered by emergency
department psychiatrist, who also treated
the participant, but “remained blinded to
the identity of the patient’s medication
throughout.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100%.
The data from2 participants were excluded
from the efficacy analysis, as it was later de-
termined that they had both received pre-
scribed antipsychotic medication shortly
before entering the study. Unclear which
group(s) these 2 participants were excluded
from
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Unclear risk Funding: supported in part by a grant from
Wyeth-Ayerst Research (now Pfizer). Un-
sure whether Pfizer were involved in study
design and reporting process
Lorazepam 1997b, USA
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 4 hours.
Setting: Psychiatric Emergency Service, Eastern Pennsylvania Psychiatric Institute, US
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Participants Diagnosis: schizophrenia (n = 13), bipolar (n = 13), schizoaffective (n = 4), psychotic
disorder not otherwise specified (n = 7)
n = 37.
Age: 18-61 years.
Gender: 26 men, 11 women.
Ethnicity: white (n = 21), African-American (n = 14), Hispanic (n = 2)
Consent: need for informed consent waived.
History: drug abuse or dependence n = 10.
Inclusion criteria: highly agitated people exhibiting psychotic symptoms, judged by
emergency department staff to be an imminent danger to themselves, required restraint,
scored ≥ 5 on ≥ 3 BPRS items and ≥ 4 on CGI
Exclusion criteria: not stated.
Interventions Benzodiazepines vs antipsychotics.
1. Lorazepam 2 mg oral or IM (n = 17).
2. Haloperidol 5 mg oral or IM (n = 20).
Medication administered every 30 minutes for 4 hours ’as needed’ until the participant
was sedated or no longer posed a danger to themselves or staff
Outcomes Global impression: sedation; mean endpoint score (CGI-S).
Mental state: mean endpoint score (BPRS).
Adverse effects/events: EPS.
Notes More bipolar participants received lorazepam (n = 10) than haloperidol (n = 3)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; however, no further descrip-
tion of randomisation provided
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind; however, no further descrip-
tion of blinding provided
Rating scales: symptom ratings were con-
ducted by 1 of 4 raters (psychiatry residents
or psychiatric nursing staff ). Raters were
trained by trial author SF
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100%.
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Low risk Funding: supported in part by a grant
from the National Alliance for Research on
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Schizophrenia and Depression. We detect
no other bias
Lorazepam 1998, SA
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 7 days.
Setting: Sterkfontein Psychiatric Hospital, Krugersdorp, South Africa
Participants Diagnosis: DSM-III-R organic (psychoactive substance) hallucinosis or delusional dis-
order (n = 24), schizophrenia (n = 16), bipolar disorder (n = 14), no diagnosis (n = 6)
n = 60.
Age: 18-45 years.
Gender: 46 men, 14 women.
Ethnicity: not stated.
Consent: signed informed consent obtained - when consent was difficult to obtain,
relatives were called upon to provide consent
History: not stated.
Inclusion criteria: aged 18-45 years, with aggressive and disorganised behaviour
Exclusion criteria: physical illness, pregnancy, abnormal routine blood tests
Interventions Benzodiazepines + antipsychotics vs antipsychotics + antipsychotics
1. Lorazepam 4 mg IM + haloperidol 10 mg oral (n = 30).
2. Clothiapine 40 mg IM + haloperidol 10 mg oral (n = 30).
Dose repeated 6 hourly ’if warranted.’
Outcomes Behaviour: mean aggression score (OAS).
Leaving the study early.
Unable to use -
Mental state: mean score (BPRS) (no data within 48 hours).
Extrapyramidal adverse effects (SAS) (no data within 48 hours)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised - no further description pro-
vided.
Allocation concealment (selection bias) Unclear risk Not stated: medication administered as
“determined by the emergency room nurs-
ing and physician staff.”
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Medications administered using “double
blind procedures.” Not stated who was
blinded
Rating scales were completed by 1 of 4 peo-
ple who were “trained” by study author
(SF)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100%.
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Unclear risk Funding: not stated. Unsure whether there
was potential bias
Lorazepam 1998, USA
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 3 hours.
Setting: psychiatric emergency service, US hospital.
Participants Diagnosis: bipolar (n = 9), psychosis (n = 4), paranoid schizophrenia (n = 3), brief reactive
psychosis (n = 1), undifferentiated schizophrenia (n = 1), substance-induced (n = 2)
n = 20.
Age: mean 36 years.
Gender: 13 men, 7 women.
Ethnicity: not stated.
Consent: waiver of informed consent obtained.
History: not stated.
Inclusion criteria: aged 18-50 years presenting to psychiatry emergency service with
acutely agitated behaviour that met clinical criteria for chemical restraint, defined by a
minimum score of 4, with a score of ≥ 2 on at least 1 OAS item, and a minimum rating
of 50 on a 100-point VAS reflecting agitation and hostility (n = 20)
Exclusion criteria: pregnancy, HIV positive, history of seizures, severe head trauma,
psychopathology due to suspected general medical condition or those whose symptoms
related to drug or alcohol abuse
Interventions Benzodiazepine + antipsychotic vs same benzodiazepine.
1. Lorazepam 2 mg IM + haloperidol 5 mg IM (n = 9).
2. Lorazepam 2 mg IM (n = 11).
(Repeated once at 60 minutes if participants were still severely agitated.)
Outcomes Global impression: no improvement*; need for additional medication
Adverse effects/events: EPS.
Leaving the study early.
Unable to use -
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Global impression: CGI (variance was not reported).
Behaviour: mean aggression score (VAS) (variance was not reported); OAS scores (vari-
ance was not reported)
Notes *’Improvement’ - defined as participants who demonstrated a decrease in ≥ 4 points on
OAS scale
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised - “Participants were assigned
to treatment according to computer-gener-
ated forced randomisation blocks of four.”
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind - “a member of nursing staff,
independent of patient assessment or treat-
ment, prepared and coded each injection of
equal volume.”
Rating scales: administered by an investiga-
tor - unclear whether this investigator was
an independent rater
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100%.
Selective reporting (reporting bias) High risk Authors changed criteria for ’improvement’
on the VAS post-study, after analysis had
takenplace. Full data not reported (i.e. con-
tinuous data for rating scales). Ratings for
CGI, VAS and OAS taken at 30, 60, 120
and 180 minutes but no data were reported
Other bias Unclear risk Funding: not stated. Unsure whether there
was potential bias
Lorazepam 2001, RO and USA
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 24 hours.
Setting: hospitals in Romania and US.
Participants Diagnosis: manic, mixed with psychotic features (52.3%; n = 105/201), mood congruent
(87.5%; n = 176/201), rapid cycling (52.2%; n = 105/201)
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n = 201.
Age: mean 40 years.
Gender: 107 men, 94 women.
Ethnicity: white (n = 146), black (n = 32), other (n = 23).
Consent: written informed consent.
History: age of onset mania or hypomania (mean 23.8), depression (mean 22.6), mixed
episode (mean 24.7)
Inclusion criteria: aged ≥ 18 years with DSM-IV bipolar disorder (manic or mixed),
deemed by a physician to have agitation severe enough to receive injections, minimum
total PANSS-EC score of 14, and ≥ 1 individual item score of ≥ 4
Exclusion criteria: not stated.
Interventions Benzodiazepines vs antipsychotics vs placebo.
1. Lorazepam 2-5 mg IM (n = 51).
2. Olanzapine 10-25 mg IM (n = 99).
3. Placebo (first and second injections were placebo, the third injection was olanzapine
10 mg; participants requiring the third injection were excluded from 24-hour analysis,
n = 21, n = 51)
Participants received 1-3 doses over 3-20 hours based on the clinical judgement of the
investigator
Outcomes Global impression: no improvement*; sedation; need for additional medication; mean
change (CGI-S)
Behaviour: mean behaviour score (ABS).
Mental state: mean change (PANSS and PANSS-EC).
Adverse effects/events: EPS, use of medication for EPS, dizziness, vomiting, nausea
Leaving the study early.
Unable to use -
Agitation-Calmness Evaluation Scale (not validated - developed by trial sponsors)
Notes *’Improvement’ - defined as a reduction of ≥ 40% on the PANSS-EC subscale
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised - no further description.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind - no further description.
Rating scales: Agitation-Calmness Evalua-
tion Scale - single-item9-point scale, devel-
oped by trial sponsors Eli Lilly and Com-
pany (results not included). Unclear who
administered the rating scales used
78Benzodiazepines for psychosis-induced aggression or agitation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lorazepam 2001, RO and USA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 91.6%.
ITT analysis used (last observation carried
forward).
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias High risk Funding: study sponsored by Eli Lilly and
Company - Lilly Research Laboratories,
Lilly Corporate Center, Indianapolis, Indi-
ana, US
Lead trial author KM and coauthors FZ,
SD, MT, KK, RR, DW, PT and AB were
each employed by trial sponsors Eli Lilly
and Company at time of the study
Lorazepam 2004, IN
Methods Allocation: randomised.
Blinding: open.
Design: parallel.
Duration: 2 weeks.
Setting: Department of Psychiatry, ChristianMedial College, Vellore, Tamil Nadu, India
Participants Diagnosis: schizophrenia (n = 37), acute psychosis (n = 22), mania (n = 97), depression
(n = 19), substance misuse (n = 10), other (n = 15)
n = 200.
Age: mean 32.2 (lorazepam group); mean 30.9 (combination group)
Gender: 119 men, 81 women.
Ethnicity: not stated.
Consent: consent was obtained from a responsible relative if participants refused, or
lacked capacity to consent to treatment by virtue of severe mental illness. Relatives were
fully informed and written consent obtained
History: not stated.
Inclusion criteria: where treating clinician felt that participants needed acute IM sedation
due to agitation and dangerous behaviour; where treating physician did not feel that
either intervention would pose an addition risk to the participant
Exclusion criteria: participants without a responsible relative were excluded
Interventions Benzodiazepines vs antipsychotics plus antihistamines.
1. Lorazepam 4 mg IM (n = 100).
2. Haloperidol 10 mg IM + promethazine 25/50 mg IM (n = 96 received 50 mg; n = 4
received 25 mg, drawn into the same syringe, n = 100)
All doses were given at the discretion of the treating physician
Outcomes Global impression: clinical improvement*; need for additional medication, sedation,
mean score (CGI)
Adverse effects/events: airway management, nausea.
Hospital and service outcomes: discharged.
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Leaving the study early: loss to follow-up.
Unable to use -
Use of physical restraints (not in remit of review).
Leaving the study early (no data within 48 hours).
Notes *’Improvement’ - defined as ’clinically improved’ under the CGI - improvement scale
dichotomised; much and very much improved
Participants in each group were receiving other medications at the time of entering the
study: anticonvulsants (n = 15), anticholinergics (n = 14), antidepressants (n = 17),
antipsychotics (n = 53), benzodiazepines (n = 23), beta-blockers (n = 1), lithium (n =
14)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised; ’pragmatic’ - computer-gen-
erated randomnumbers list in varying sized
blocks < 10
Allocation concealment (selection bias) Low risk A table of allocation sequence independent
of block size was produced. Tables were
then sent to a colleague independent of the
TREC team who ensured that the correct
drugwas in the consecutively numbered lo-
cal pack before it was sealed. These packs
were constructed of cardboard, were identi-
cal and were sealed firmly with tape, across
which the consecutive number was written
Blinding (performance bias and detection
bias)
All outcomes
High risk Investigators not blinded, as blinding was
kept until point of treatment assignment,
which minimised selection bias
Rating scales: study co-ordinators, who
were blind to interventions given, under-
took ratings
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 100% in lorazepam group at
4 hours; 99% in combination group at 4
hours
Missing data were reported at each level of
assessment (total n = 12)
Selective reporting (reporting bias) Low risk All measured outcomes were reported.
Other bias Low risk Funding: funded by intra-
mural research grants from Fluid Research
Fund (Christian Medical College, Vellore)
, and Cochrane Schizophrenia Group gen-
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eral fund. We detected no other potential
bias
Lorazepam 2006, USA
Methods Allocation: randomised.
Blinding: double blind.
Design: prospective.
Duration: 90 minutes.
Setting: university affiliated emergency department, US.
Participants Diagnosis: schizophrenia (n = 13), substance abuse (n = 8), bipolar (n = 4), personality
disorder (n = 2), schizoaffective (n = 1), not stated (n = 2)
n = 30.
Age: mean 40 years.
Gender: 23 men, 7 women.
Ethnicity: not stated.
Consent: informed consent required.
History: not stated.
Inclusion criteria: aged 18-65 years, agitated or acutely psychotic (or both) people who
required immediate treatment for symptom reduction
Exclusion criteria: medically unstable conditions, inability to provide informed consent,
known allergy or adverse reaction to study drugs, pregnancy, administration of sedatives
or antipsychotics in the emergency department prior to enrolment
Interventions Benzodiazepines + antipsychotics vs same benzodiazepines.
1. Lorazepam 2 mg IM + placebo oral (n = 10).
2. Lorazepam 2 mg IM + risperidone 2 mg oral (n = 10).
3. Lorazepam 2 mg IM + haloperidol 5 mg oral (n = 10).
Outcomes Global impression: no improvement*; need for additional medication
Mental state: mean score (BPRS) (skew); mean score (PANSS) (skew)
Leaving the study early.
Notes *’Improvement’ - defined as number of participants who returned for the 24-hour follow-
up visit and demonstrated a marked improvement on both BPRS and PANSS
30% of participants tested positive on the urine screen for marijuana or cocaine; 33%
of participants had positive blood alcohol levels
Pilot study.
SDs calculated using the mean and confidence intervals.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to one
of three double-blind groups” - no further
description
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Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind - no further description.
Rating scales: administered by trained
study evaluators, with inter-rater reliabil-
ity assessed by independent evaluation of a
video-taped mode
Incomplete outcome data (attrition bias)
All outcomes
High risk Follow-up: 91%; 2 people withdrew after
providing consent and before trial com-
menced and 1 participant was unable to
stay awake after intervention, therefore,
scores of interview not included in data
analysis
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Unclear risk Funding: study funded by a grant from
Janssen Pharmaceutica. Unsure whether
Janssen Pharmaceutica was involved in the
study design and reporting
Lorazepam 2009, SK
Methods Allocation: randomised.
Blinding: not stated.
Design: parallel.
Duration: 120 minutes.
Setting: South Korea.
Participants Diagnosis: acute psychotic agitation.
n = 37.
Age: ≥ 18 years.
Gender: not stated.
Ethnicity: not stated.
Consent: not stated.
History: not stated.
Inclusion criteria: men and women, ≥ 18 years, DSM-IV diagnosis of schizophrenia,
schizophreniform disorder, brief psychotic disorder, or schizoaffective disorder, bipolar
disorder; andwhohad an excited component score≥ 14on the PANSSwith a score of≥ 4
on at least 1 item (1- to 7-point scale). Psychotic disorderswere brief psychotic disorder (8.
1%), schizophreniform disorder (8.1%), schizophrenia (45.9%), schizoaffective disorder
(2.7%), bipolar disorder (35.1%)
Exclusion criteria: not stated.
Interventions Benzodiazepines + antipsychotic vs same antipsychotics.
1. Haloperidol 5 mg IM (n = 10).
2. Olanzapine* 10 mg IM (n = 12).
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3. Haloperidol 5 mg IM + lorazepam 4 mg IM (n=15).
Outcomes Adverse events.
Unable to use -
PANSS-EC,CGI-S, CGI-I (no data reported), seclusion state (need to contact the author
and confirm whether it should read ’sedation state’)
Notes Only abstract available. We tried to contact the author, but received no reply
*We did not use the data from this group as it did not meet our inclusion criteria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk Only abstract is available, no full text. Un-
sure whether there was selective reporting
Other bias Unclear risk None known.
Lorazepam 2010, IN
Methods Allocation: randomised.
Blinding: open.
Design: parallel.
Duration: 24 hours.
Setting: Institute of Mental Health, Hyderabad, India.
Participants Diagnosis: acute psychotic agitation.
n = 60
Age: not stated.
Gender: not stated.
Ethnicity: not stated.
Consent: not stated.
History: not stated.
Inclusion criteria: not stated.
Exclusion criteria: not stated.
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Interventions Benzodiazepines vs antipsychotics + antihistamines.
1. Lorazepam 4 mg IM (n = not stated).
2. Haloperidol 10 mg IM + promethazine 50 mg IM (n = not stated)
Outcomes Unable to use -
ABS, CGI-S, CGI-I, requires restraints, additional medication, being tranquil, asleep
and adverse events (no data reported)
Notes Only abstract available. We tried to contact the author, but received no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk As only abstracts were available, we did not
know how many outcomes were reported
in the full text
Other bias Unclear risk Not stated.
Midazolam 2003, BZ
Methods Allocation: randomised.
Blinding: open.
Design: parallel.
Duration: 2 weeks.
Setting: 3 public psychiatric hospitals, Rio de Janeiro, Brazil
Participants Diagnosis: psychosis (n = 219), substance misuse (n = 51), not stated (n = 30)*
n = 301.
Age: mean 38 years.
Gender: 146 men, 155 women.
Ethnicity: not stated.
Consent: not required fromparticipant in the emergency setting; if relatives were present,
they were fully informed and consent was requested
History: 9% of participants included had no previous psychiatric attendance
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Inclusion criteria: where treating clinician was uncertain of which treatment to imple-
ment where participants needed acute IM sedation due to agitation and dangerous be-
haviour
Exclusion criteria: where treating clinician believed 1 treatment represented an additional
risk for the participant
Interventions Benzodiazepines vs antipsychotics + antihistamines.
1. Midazolam 15 mg IM (n = 150).
2.Haloperidol 5-10mg IM (n = 77 received 5mg; n = 71 received 10mg) + promethazine
50 mg IM (n = 147 received 50 mg; n = 1 received 25 mg, drawn into the same syringe,
n = 148)
The benzodiazepine antagonist flumazenil was made available at each centre for use in
the event of midazolam toxicity
Outcomes Global impression: sedation**.
Adverse effects/events: seizure, airway management.
Leaving the study early.
Unable to use -
Global impression: sedation (no data within 48 hours).
Hospital and service outcomes: discharged (no data within 48 hours)
Notes *1 participant unaccounted for in diagnosis.
**The primary interest of this trial was defined as ’tranquillised or asleep by 20 minutes’ -
participants were considered tranquillised when they were calm and peaceful, i.e. neither
agitated nor restless, and not showing threatening verbal behaviour or physical aggression
against objects, other people or themselves
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised - ’pragmatic’ -Microsoft Excel
used to generate even random numbers less
than 10 - blocks were then applied to a table
of random numbers
Allocation concealment (selection bias) Low risk Table of allocation sequence independent
of block size was produced. Tables were
then sent to a colleague independent of the
TREC team who ensured that the correct
drugwas in the consecutively numbered lo-
cal pack before it was sealed. These packs
were constructed of cardboard, were identi-
cal, and were sealed firmly with tape, across
which the consecutive number was written
Blinding (performance bias and detection
bias)
All outcomes
High risk Investigators were not blinded as the blind-
ing was kept until point of treatment as-
signment, which minimised selection bias
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Doses of medication administered were “at
the treating doctors discretion.”
Rating scales: raters were nurses/doctors
not involved in the management of the
emergency - unknown to treating clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up: 99%.
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Low risk Funding: jointly funded by Fundação Os-
waldo Cruz, the Cochrane Schizophrenia
Group, the British Council, CAPES (Co-
ordenação de Aperfeiçoamento de Pessoal
deNível Superior) and FAPERJ (Fundação
de Amparo à Pesquisa do Estado do Rio de
Janeiro). We did not detect any other po-
tential bias
Midazolam 2006, AU
Methods Allocation: randomised.
Blinding: double blind.
Design: not stated.
Duration: 100 minutes.
Setting: emergency department of a large metropolitan Australian university hospital
Participants Diagnosis: mental illness (ICD-10 codes F09-F69 and F99, n = 100), no diagnosis (n =
53)
n = 170.
Age: 15-67 years (median 34 years).
Gender: 98 men, 55 women*.
Ethnicity: not stated.
Consent: not required.
History: not stated.
Inclusion criteria: adults, aged 18-65 years, acutely agitated because of mental illness and
required medication restraint
Exclusion criteria: hypersensitivity to either drug, pregnancy, readily reversible causes for
agitation, agitation believed to be due to acute alcohol withdrawal
Interventions Benzodiazepines vs antipsychotics.
1. Midazolam 4 mg + saline solution 1 mg IV (n = 74).
2. Droperidol 4 mg + saline solution 1 mg IV (n = 79).
Participants were given the 5 mg doses every 5 minutes until adequate sedation was
achieved. For participants weighing < 50 kg, dose was 2.5 mg. Physicians could choose
subsequent therapy if adequate sedation was not achieved with the full 20 mg dose
86Benzodiazepines for psychosis-induced aggression or agitation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Midazolam 2006, AU (Continued)
Outcomes Global impression: sedation; need for additional medication.
Adverse effects/events: low blood pressure, airway management, vomiting, seizure, hy-
poxia, low heart rate, EPS
Leaving the study early.
Notes *Numbers for gender for the 170 originally randomised participants were not given, only
numbers from 153 available for analysis were given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables and serially num-
bered study packs.
Allocation concealment (selection bias) Low risk Codes from study packs remained with the
pharmacy until study was complete
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind; blinding was maintained
by returning sealed envelopes contained in
study pack. It is stated, however, that “if
necessary for patient treatment, unblinding
of the drug could be achieved by opening
[the sealed envelope];” unclear whether this
was done
A blinded explicit review of the partici-
pant’s medical record was performed after
discharge
2 participants from each treatment group
(n = 4) were treated on an ’unblinded’ basis
- no further details are given
Rating scale: not stated who administered
rating scales.
Incomplete outcome data (attrition bias)
All outcomes
High risk Follow-up: 90%.
Data from 17 study packs were lost, so only
data from the remaining 153 participants
were used
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Low risk Funding: supported by a postgraduate
scholarship from the National Health and
Medicine Research Council and a re-
search grant from the Australasian College
for Emergency Medicine (Morson Taylor
Award). We did not detect any potential
bias
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Methods Allocation: randomised.
Blinding: double.
Design: not stated.
Duration: 12 hours.
Setting: psychiatric emergency department of Santa Casa de Sao Paulo, Brazil
Participants Diagnosis: bipolar (n = 62), psychotic disorder (n = 88).
n = 150.
Age: 18-50 years, mean 32.1 years.
Gender: 91 men, 59 women.
Ethnicity: not stated.
Consent: informedwritten consent - before and after participation in the study,whichwas
reviewed and approved by the institutional review board. Written consent was obtained
before admission to the emergency unit by a legal guardian and after 12 hours by the
participant (when he/she was able to understand the information) or by the guardian
History: agitation caused by psychotic or bipolar disorder.
Inclusion: signs of agitation, aged 18-50 years, bipolar (manic or mixed episode) or
psychotic disorder diagnosis (DSM-IV-TR criteria), OASS total score ≥ 20 and OAS
with ≥ 4 positive items
Exclusion: disorders due to drug abuse, organic disorder, anxiety or personality disorder
(DSM-IV-TR criteria), failure to agree to participate in study, incapability of completing
all steps of the study and unstable clinical disease
Interventions Benzodiazepines + antipsychotics vs antihistamines + antipsychotics vs same antipsy-
chotics vs different antipsychotics
1. Midazolam 15 mg IM + haloperidol 5 mg IM (n = 30).
2. Promethazine 50 mg IM + haloperidol 5 mg IM (n = 30).
3. Olanzapine 10 mg IM (n = 30).
4. Ziprasidone 20 mg IM (n = 30).
5. Haloperidol 5 mg IM (n = 30).
After the initial dose, only additional doses of combined haloperidol/promethazine could
be used according to clinical judgement. If a participant needed another intervention,
he/she was immediately removed from study
Outcomes Global impression: no improvement*, need for additional medication mean dose (skew)
, numbers sedated, sedation (RSS change scores)
Behaviour: mean aggression change (OAS), mean behaviour change (OASS agitation
scale)
Adverse effects/events: hypotension, EPS.
Notes *’Improvement’ - defined as the number of participants with < 10 points on the OAS
and OASS after 12 hours
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised - allocation by “permuted
blocks - each drug regimen was assigned
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to blocks of five patients and distributed
in this order: olanzapine, ziprasidone,
haloperidol plus promethazine, haloperi-
dol plus midazolam and haloperidol alone.
This assignment was repeated until the to-
tal number of subjects (150) was reached.”
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double blind - study medications were
packaged in identical colour-coded boxes
Rating scales were repeatedly administered
by 2 raters - unclear whether these were
independent raters
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up: 100%.
Selective reporting (reporting bias) Low risk All measure outcomes were reported.
Other bias Unclear risk Funding: not stated.
General: ECT: electroconvulsive therapy; EPS: extrapyramidal symptoms; IM: intramuscular; IV: intravenous; ITT: intention-to-treat;
n: number of participants; SD: standard deviation; TREC: Tranquilização Rápida-Ensaio Clínico (Rapid Tranquillisation-Clinical
Trial).
Diagnostic tools:DSM: Diagnostic and Statistical Manual of Mental Disorders; CCMD: Chinese Classification of Mental Disorders;
ICD-10: The International Statistical Classification of Diseases and Related Health Problems, 10th Revision.
Rating Scales: Behaviour : ABS; Agitated Behaviour Scale; OAS; Overt Aggression Scale; OASS; Overt Agitation Severity Scale; VAS;
visual analogue scale; Global state : CGI; Clinical Global Impression; CGI-S; Clinical Global Impression Severity Scale; RSS; Ramsey
Sedation Scale; Mental state : BPRS; Brief Psychiatric Rating Scale; IMPS; Inpatient Multidimensional Psychiatric Scale; NOSIE;
Nurses’ Observation Scale for Inpatient Evaluation; PANSS; Positive and Negative Syndrome Scale; PANSS-EC; Positive and Negative
Syndrome Scale-Excited Component; SANS; Scale for the Assessment of Negative Symptoms; SAPS; Scale for the Assessment of
Positive Symptoms; Adverse effects: SAS; Simpson-Angus Scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arana 1986 Allocation: not randomised - controlled design.
Chen 2012 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: ziprasidone + clonazepam vs olanzapine.
Outcomes: no useable data - all exceeded 48 hours.
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Currier 2000 Allocation: randomised.
Participants: acutely agitated psychotic participants.
Intervention: risperidone + lorazepam vs haloperidol + lorazepam
Currier 2004 Allocation: randomised.
Participants: acutely agitated psychotic patients.
Intervention: risperidone + lorazepam vs haloperidol + lorazepam
Davis 2008 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: haloperidol vs clonazepam vs haloperidol + clonazepam
Outcomes: no useable data.
Deng 2004 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: risperidone + clonazepam vs chlorpromazine.
Outcomes: no useable data - all exceed 48 hours.
Esmailian 2015 Allocation: randomised.
Participants: acutely agitated people presenting with medical diseases, drug poisoning or trauma
Ge 2004 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: risperidone + clonazepam vs haloperidol.
Outcomes: no useable data - all exceed 48 hours.
Gharabawi 2003 Allocation: randomised.
Participants: people requiring sedation for medical diseases, drug poisoning or trauma
Guz 1972 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: haloperidol + lorazepam vs haloperidol + placebo
Outcomes: no useable data - all exceed 48 hours.
Han 2005 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: clonazepam + risperidone vs clozapine.
Hankoff 1962 Allocation: randomised.
Participants: acutely agitated people with and without schizophrenia
Intervention: chlorpromazine vs chlordiazepoxide vs meprobamate vs placebo
Outcomes: no useable data - all exceed 48 hours.
Hanlon 1970 Allocation: randomised.
Participants: acutely disturbed psychiatric patients.
Intervention: fluphenazine + chlordiazepoxide vs fluphenazine + imipramine
Outcomes: no useable data - all exceed 48 hours.
90Benzodiazepines for psychosis-induced aggression or agitation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
He 2011 Allocation: randomised.
Participants: acutely agitated people with and without schizophrenia
Intervention: aripiprazole + clonazepam vs haloperidol + aripiprazole
Outcomes: no useable data - all exceed 48 hours.
Hou 2011 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: lorazepam + risperidone vs haloperidol + promethazine
Huf 2007 Allocation: randomised.
Participants: acutely agitated psychotic patients.
Intervention: haloperidol vs haloperidol + promethazine.
Hwang 2012 Allocation: randomised.
Participants: people with schizophrenia displaying moderate to severe agitation
Intervention: olanzapine vs haloperidol + lorazepam.
Isbister 2010 Allocation: randomised.
Participants: acutely disturbed/aggressive/agitated behaviour believed to be secondary to psychotic illnesses
Kang 2006 Allocation: randomised.
Participants: schizophrenia.
Interventions: quetiapine + clonazepam vs chlorpromazine vs clozapine
Outcomes: no usable data - all exceed 48 hours.
Kinon 2002 Allocation: randomised.
Participants: people with schizophrenia or related disorder displaying acute behavioural agitation
Intervention: olanzapine (+ as needed lorazepam) vs haloperidol (+ as needed lorazepam)
Kinon 2004 Allocation: randomised.
Participants: acutely agitated people with schizophrenia, schizophreniform or schizoaffective disorder
Intervention: olanzapine (+ as needed lorazepam) vs haloperidol (+ as needed lorazepam)
Lenox 1992 Allocation: randomised.
Participants: bipolar illness, manic type - not acutely psychotic
Liang 2003 Allocation: not randomised.
Martel 2005 Allocation: randomised.
Participants: people requiring emergent sedation in emergency department - aggression was not psychosis-induced
(agitation was ascribed to alcohol intoxication in 94% of participants)
Mei 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: quetiapine + clonazepam vs haloperidol + scopolamine
Outcomes: no usable data - all exceed 48 hours.
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NCT00797277 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: olanzapine vs haloperidol + lorazepam.
NCT00859872 Allocation: randomised.
Participants: acutely agitated people with schizophrenia or schizoaffective disorders
Intervention: risperidone plus clonazepam vs haloperidol.
Nestoros 1982 Allocation: randomised.
Participants: people with schizophrenia - not acutely psychotic
Nobay 2004 Allocation: randomised.
Participants: aggression was not psychosis-induced (violent and severely agitated people)
Richards 1998 Allocation: randomised.
Participants: agitated people without psychosis.
Simpson 2003 Allocation: not randomised - a prospective, naturalistic study
Stevens 1992 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: haloperidol + lorazepam vs haloperidol.
Outcomes: no usable data - all exceed 48 hours.
Tang 2007 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone + clonazepam vs haloperidol + scopolamine
Outcomes: no usable data - all exceed 48 hours.
Veraksa 2016 Allocation: randomised.
Participants: acutely psychotic people with schizophrenia.
Intervention: benzodiazepines vs valproic acid.
Wan 2005 Allocation: randomised.
Participants: agitated/aggressive people with schizophrenia.
Interventions: risperidone + clonazepam vs haloperidol vs chlorpromazine
Outcomes: no usable data - all exceed 48 hours.
Wang 2004 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: clonazepam + risperidone vs clozapine vs haloperidol
Wetzel 1997 Allocation: randomised.
Participants: participants with retarded catatonia.
Wu 2006 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: clonazepam + risperidone vs haloperidol.
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Wyant 1990 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: midazolam vs haloperidol.
Outcomes: no usable data.
Yang 2003 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: clonazepam + risperidone vs clozapine vs haloperidol
Yang 2006 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: quetiapine (+ as needed lorazepam) vs haloperidol
Yu 2006 Allocation: not randomised.
Zhang 2007 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: clonazepam + olanzapine vs haloperidol.
Zhang 2008 Allocation: randomised.
Participants: agitated/aggressive people with schizophrenia.
Interventions: quetiapine + clonazepam vs haloperidol.
Outcomes: no usable data - all exceed 48 hours.
Zhong 2006 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: clonazepam + risperidone vs haloperidol.
Zhou 2012 Allocation: randomised.
Participants: agitated/aggressive people with schizophrenia.
Interventions: risperidone + clonazepam vs haloperidol.
Outcomes: no usable data - all exceed 48 hours.
Zhou 2014 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: clonazepam + ziprasidone vs haloperidol.
Zhu 2005 Allocation: randomised.
Participants: acutely agitated people with schizophrenia.
Intervention: sodium valproate + risperidone vs clonazepam + risperidone
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D A T A A N D A N A L Y S E S
Comparison 1. Benzodiazepines versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
sedation
1 102 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.42, 6.61]
1.1 medium term 1 102 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.42, 6.61]
2 Behaviour: 1. mean change score
(Agitated Behaviour Scale, high
= worse)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 medium term 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Global state: 1. no improvement
(> 40% reduction Positive and
Negative Syndrome Scale-
Excited Component (PANSS-
EC))
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 short term 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.69, 1.16]
3.2 medium term 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.40, 0.97]
4 Global state: 2. need for
additional medication
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 medium term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Global state: 3. mean change
score (Clinical Global
Impression Severity Scale, high
= worse)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 medium term 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Mental state: 1. mean change
score (Positive and Negative
Syndrome Scale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 medium term 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Mental state: 2. mean change
score (PANSS-EC, high =
worse)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 medium term 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse effects/events: 1.
extrapyramidal symptoms
(EPS)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 medium term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Adverse effects/events: 2. use of
medication for EPS
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 medium term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Adverse effects/events: 3.
specific
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 dizziness - medium term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 nausea - medium term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 vomiting - medium term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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11 Leaving the study early: 1. any
reason
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
11.1 medium term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Benzodiazepines versus antipsychotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
sedation
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 vs droperidol - short term 1 153 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [1.55, 4.73]
1.2 vs haloperidol - short term 1 44 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.53, 2.59]
1.3 vs haloperidol - medium
term
8 434 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.83, 1.54]
1.4 vs olanzapine - medium
term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.28, 1.98]
2 Behaviour: 2. mean change/
endpoint score (Agitated
Behaviour Scale, high = worse)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 vs haloperidol - medium
term
1 66 Mean Difference (IV, Fixed, 95% CI) 1.80 [-2.39, 5.99]
2.2 vs olanzapine - medium
term
1 149 Mean Difference (IV, Fixed, 95% CI) 2.91 [0.80, 5.02]
3 Behaviour: 4. mean change score
(Overt Aggression Scale, high =
worse)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 vs haloperidol - medium
term
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Global state: 1. no improvement
(> 40% reduction Positive and
Negative Syndrome Scale-
Excited Component (PANSS-
EC))
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 vs olanzapine - short term 1 150 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.95, 1.66]
4.2 vs olanzapine - medium
term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.06, 3.18]
4.3 vs haloperidol - medium
term
5 188 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.71, 1.11]
5 Global state: 2. need for
additional medication
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 vs droperidol - short term 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 vs haloperidol - medium
term
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 vs olanzapine - medium
term
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6 Global state: 3. mean change/
endpoint score (Clinical Global
Impression Severity Scale, high
= worse)
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 vs haloperidol - short term 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 vs haloperidol - medium
term
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 vs haloperidol - medium
term
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 vs olanzapine - medium
term
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Global state: 4. mean
endpoint score (Inpatient
Multidimensional Psychiatric
Scale, high = worse)
1 16 Mean Difference (IV, Fixed, 95% CI) 2.60 [-3.04, 8.24]
7.1 vs haloperidol - medium
term
1 16 Mean Difference (IV, Fixed, 95% CI) 2.60 [-3.04, 8.24]
8 Mental state: 1. no improvement
(decrease rate of Brief
Psychiatric Rating Scale
(BPRS) score < 30%)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.18]
8.1 vs haloperidol - medium
term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.18]
9 Mental state: 2. mean change/
endpoint score (BPRS, high =
worse)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 vs haloperidol - short term 1 37 Mean Difference (IV, Fixed, 95% CI) -3.26 [-10.65, 4.13]
9.2 vs haloperidol - medium
term
3 123 Mean Difference (IV, Fixed, 95% CI) 1.67 [-1.84, 5.18]
10 Mental state: 3. mean endpoint
score (BPRS psychosis subscale,
high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 vs haloperidol - medium
term
1 66 Mean Difference (IV, Fixed, 95% CI) 0.70 [-7.20, 8.60]
11 Mental state: 3a. mean
endpoint score (BPRS positive
subscale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 vs haloperidol - medium
term
1 30 Mean Difference (IV, Fixed, 95% CI) 0.80 [-1.83, 3.43]
12 Mental state: 4a. mean
endpoint score (BPRS-excited
component, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 vs haloperidol - medium
term
1 30 Mean Difference (IV, Fixed, 95% CI) 1.27 [-0.49, 3.03]
13 Mental state: 2a. mean change
score (Positive and Negative
Syndrome Scale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 vs olanzapine - medium
term
1 146 Mean Difference (IV, Fixed, 95% CI) 5.64 [2.20, 9.08]
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14 Mental state: 4. mean change
score (PANSS-EC, high =
worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 vs olanzapine - medium
term
1 149 Mean Difference (IV, Fixed, 95% CI) 2.85 [1.14, 4.56]
15 Adverse effects/events: 1.
extrapyramidal symptoms
(EPS)
8 536 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.06, 0.39]
15.1 vs haloperidol - medium
term
6 233 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.04, 0.41]
15.2 vs olanzapine - medium
term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 1.89]
15.3 vs droperidol - medium
term
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.90]
16 Adverse effects/events: 2. use of
medication for EPS
2 216 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.15, 1.05]
16.1 vs haloperidol - medium
term
1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.17, 1.47]
16.2 vs olanzapine - medium
term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 1.89]
17 Adverse effects/events: 3.
specific
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 vs haloperidol - akathisia
- medium term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
17.2 vs droperidol - airway
management - medium term
1 153 Risk Ratio (M-H, Fixed, 95% CI) 7.47 [0.39, 142.14]
17.3 vs haloperidol - ataxia -
medium term
1 66 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [0.22, 23.71]
17.4 vs droperidol - low blood
pressure - medium term
1 153 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.33, 6.15]
17.5 vs haloperidol - dizziness
- medium term
1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.25, 5.19]
17.6 vs olanzapine - dizziness
- medium term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.60, 3.82]
17.7 vs haloperidol -
drowsiness - medium term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.55]
17.8 vs haloperidol - dry
mouth - medium term
1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.49, 7.24]
17.9 vs droperidol - low heart
rate - medium term
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 8.59]
17.10 vs haloperidol - high
heart rate - medium term
1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.29]
17.11 vs droperidol - hypoxia
- medium term
1 153 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.33, 6.15]
17.12 vs olanzapine - nausea -
medium term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 7.76 [0.89, 67.67]
17.13 vs droperidol - seizure -
medium term
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.14 vs haloperidol - speech
disorder - medium term
1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.11, 2.87]
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17.15 vs haloperidol - tremor
- medium term
1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.69]
17.16 vs droperidol - vomiting
- medium term
1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.17 vs olanzapine - vomiting
- medium term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 13.46 [0.71, 255.70]
18 Leaving the study early: 1. any
reason
3 339 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.70, 3.13]
18.1 vs droperidol - medium
term
1 173 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.60, 3.79]
18.2 vs haloperidol - medium
term
1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.61]
18.3 vs olanzapine - medium
term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 5.82 [0.62, 54.58]
Comparison 3. Benzodiazepines versus antipsychotics plus antihistamines
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquilisation or asleep: 1.
sedation
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 vs haloperidol +
promethazine - immediate
term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.77, 0.99]
1.2 vs haloperidol +
promethazine - short term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.77, 0.95]
1.3 vs haloperidol +
promethazine - medium term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.84, 0.98]
1.4 vs haloperidol +
promethazine - short term
1 301 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.16, 1.49]
1.5 vs haloperidol +
promethazine - medium term
1 301 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [1.04, 1.23]
2 Global state: 1. no improvement
(Clinical Global Impression
(CGI) - improvement scale
dichotomised; much and very
much improved)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 vs haloperidol +
promethazine - immediate
term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [1.36, 2.37]
2.2 vs haloperidol +
promethazine - short term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [1.51, 4.03]
2.3 vs haloperidol +
promethazine - medium term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 2.17 [1.16, 4.05]
3 Global state: 2. need for
additional medication
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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3.1 vs haloperidol +
promethazine - immediate
term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 vs haloperidol +
promethazine - short term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.77]
3.3 vs haloperidol +
promethazine - medium term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.31, 5.81]
4 Global state: 3. mean endpoint
score (CGI, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 vs haloperidol +
promethazine - immediate
term
1 200 Mean Difference (IV, Fixed, 95% CI) 0.49 [0.23, 0.75]
4.2 vs haloperidol +
promethazine - short term
1 200 Mean Difference (IV, Fixed, 95% CI) 0.60 [0.34, 0.86]
4.3 vs haloperidol +
promethazine - medium term
1 200 Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.05, 0.51]
5 Adverse effects/events: 1. specific 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 vs haloperidol +
promethazine - airway
management - medium term
2 501 Risk Ratio (M-H, Fixed, 95% CI) 2.99 [0.31, 28.54]
5.2 vs haloperidol +
promethazine - nausea -
medium term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.77]
5.3 vs haloperidol +
promethazine - seizure -
medium term
1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
6 Hospital and service outcomes:
1. changes in hospital status
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 vs haloperidol +
promethazine - not discharged
- medium term
1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.86, 1.48]
7 Leaving the study early: 1. any
reason
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 vs haloperidol +
promethazine - medium term
2 501 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.06, 2.87]
Comparison 4. Benzodiazepines plus antipsychotics vs same benzodiazepines
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
sedation
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 + haloperidol - short term 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [1.10, 3.35]
1.2 + haloperidol - medium
term
2 110 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.59, 1.19]
2 Behaviour: 1. mean endpoint
score (Agitated Behaviour
Scale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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2.1 + haloperidol - medium
term
1 63 Mean Difference (IV, Fixed, 95% CI) -1.60 [-5.94, 2.74]
3 Global state: 1. no improvement
mean endpoint change in
Clinical Global Impression
score)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 + haloperidol - short term 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.74]
3.2 + haloperidol - medium
term
3 113 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.76, 1.20]
3.3 + risperidone - medium
term
1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.45, 1.64]
4 Global state: 2. need for
additional medication
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 + haloperidol - medium
term
3 103 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.79, 1.32]
4.2 + risperidone - medium
term
1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Mental state: 1. no improvement
(the decrease rate of Brief
Psychiatric Rating Scale
(BPRS) score < 30%)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 + haloperidol - medium
term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.76, 1.32]
6 Mental state: 2a. mean endpoint
score (BPRS, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 + risperidone - short term 1 20 Mean Difference (IV, Fixed, 95% CI) 1.10 [-23.17, 25.37]
6.2 + risperidone - medium
term
1 20 Mean Difference (IV, Fixed, 95% CI) -1.70 [-24.26, 20.
86]
7 Mental state: 2b. mean endpoint
score (BPRS, high = worse,
skew)
Other data No numeric data
7.1 + haloperidol - short term Other data No numeric data
7.2 + haloperidol - medium
term
Other data No numeric data
8 Mental state: 2c. mean endpoint
score (Positive and Negative
Syndrome Scale (PANSS), high
= worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 + risperidone - short term 1 20 Mean Difference (IV, Fixed, 95% CI) 6.40 [-36.50, 49.30]
8.2 + risperidone - medium
term
1 20 Mean Difference (IV, Fixed, 95% CI) 3.20 [-29.41, 35.81]
9 Mental state: 2d. mean endpoint
score (PANSS, high = worse,
skew)
Other data No numeric data
9.1 + haloperidol - short term Other data No numeric data
9.2 + haloperidol - medium
term
Other data No numeric data
10 Mental state: 3a. mean
endpoint score (BPRS
psychosis subscale, high =
worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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10.1 + haloperidol - medium
term
1 63 Mean Difference (IV, Fixed, 95% CI) 1.20 [-6.28, 8.68]
11 Mental state: 3b. mean
endpoint score (BPRS positive
subscale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 vs haloperidol - medium
term
1 30 Mean Difference (IV, Fixed, 95% CI) 0.06 [-2.73, 2.85]
12 Mental state: 4. mean
endpoint score (BPRS-excited
component, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 vs haloperidol - medium
term
1 30 Mean Difference (IV, Fixed, 95% CI) -0.80 [-2.41, 0.81]
13 Adverse effects/events: 1.
extrapyramidal symptoms
(EPS)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 + haloperidol - medium
term
2 83 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [0.18, 20.30]
14 Adverse effects/events: 2. use of
medication for EPS
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 + haloperidol - medium
term
1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.18, 2.99]
15 Adverse effects/events: 3.
specific
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 + haloperidol - akathisia
- medium term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 + haloperidol - ataxia -
medium term
1 63 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.26, 8.11]
15.3 + haloperidol - dizziness
- medium term
1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.12, 3.61]
15.4 + haloperidol -
drowsiness - medium term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.55]
15.5 + haloperidol - dry
mouth - medium term
1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.15, 2.23]
15.6 + haloperidol - speech
disorder - medium term
1 63 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.26, 8.11]
16 Leaving the study early: 1. any
reason
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 + haloperidol - medium
term
2 40 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.34, 1.50]
16.2 + risperidone - medium
term
1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.45, 1.64]
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Comparison 5. Benzodiazepines plus antipsychotics versus same antipsychotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquillisation or asleep: 1.
sedation
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 +/vs haloperidol - short
term
1 45 Risk Ratio (M-H, Fixed, 95% CI) 2.25 [1.18, 4.30]
1.2 +/vs haloperidol - medium
term
3 172 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.14, 2.67]
2 Behaviour: 1. mean endpoint
score (Agitated Behaviour
Scale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 +/vs haloperidol - medium
term
1 67 Mean Difference (IV, Fixed, 95% CI) -0.20 [-5.05, 4.65]
3 Behaviour: 2. mean endpoint
score (Overt Aggression Scale
(OAS), high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 +/vs haloperidol - short
term
1 60 Mean Difference (IV, Fixed, 95% CI) 1.20 [-0.04, 2.44]
3.2 +/vs haloperidol - medium
term
1 60 Mean Difference (IV, Fixed, 95% CI) 2.40 [0.59, 4.21]
4 Behaviour: 3. mean endpoint
score (Overt Agitation Severity
Scale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 +/vs haloperidol - short
term
1 60 Mean Difference (IV, Fixed, 95% CI) 8.5 [7.07, 9.93]
4.2 +/vs haloperidol - medium
term
1 60 Mean Difference (IV, Fixed, 95% CI) 6.7 [5.94, 7.46]
5 Global state: 1. no improvement 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 +/vs haloperidol - medium
term
4 185 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.93, 1.46]
6 Global state: 2. need for
additional medication
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 +/vs haloperidol - medium
term
1 67 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.79, 1.15]
7 Global state: 3. need for
additional medication (mean
dose, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 +/vs haloperidol - medium
term
1 60 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.33, 0.73]
8 Global state: 4. mean change
score (Ramsey Sedation Scale,
high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 +/vs haloperidol - short
term
1 60 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.01, 1.01]
8.2 +/vs haloperidol - medium
term
1 60 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.36, 0.56]
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9 Mental state: 1. no improvement
(the decrease rate of Brief
Psychiatric Rating Scale
(BPRS) score < 30%)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 +/vs haloperidol - medium
term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.18]
10 Mental state: 2. mean endpoint
score (BPRS, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 +/vs haloperidol -
medium term
1 28 Mean Difference (IV, Fixed, 95% CI) 0.01 [-7.26, 7.28]
11 Mental state: 3a. mean
endpoint score (BPRS
psychosis subscale, high =
worse)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 +/vs haloperidol -
medium term
2 95 Mean Difference (IV, Fixed, 95% CI) -1.19 [-4.60, 2.23]
12 Mental state: 3b. mean
endpoint score (BPRS positive
subscale, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 vs haloperidol - medium
term
1 30 Mean Difference (IV, Fixed, 95% CI) 0.86 [-1.62, 3.34]
13 Mental state: 4. mean
endpoint score (BPRS-excited
component, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 vs hoperidol - medium
term
1 30 Mean Difference (IV, Fixed, 95% CI) 0.47 [-1.32, 2.26]
14 Adverse effects/events: 1.
extrapyramidal symptoms
(EPS)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 +/vs haloperidol -
medium term
2 127 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.16, 1.17]
15 Adverse effects/events: 2. use of
medication for EPS
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 +/vs haloperidol -
medium term
2 95 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.27, 1.01]
16 Adverse effects/events: 3.
specific
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 +/vs haloperidol -
akathisia - medium term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.58]
16.2 +/vs haloperidol - ataxia
- medium term
1 67 Risk Ratio (M-H, Fixed, 95% CI) 3.28 [0.36, 29.97]
16.3 +/vs haloperidol -
dizziness - medium term
2 92 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.12, 2.32]
16.4 +/vs haloperidol -
drowsiness - medium term
1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.55]
16.5 +/vs haloperidol - dry
mouth - medium term
2 92 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.32, 4.92]
16.6 +/vs haloperidol -
hypotension - medium term
1 60 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.64, 190.53]
16.7 +/vs haloperidol - speech
disorder - medium term
1 67 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.20, 3.39]
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17 Hospital and service outcomes:
1. changes in hospital status
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 +/vs haloperidol - not
discharged - medium term
1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.9 [0.54, 1.50]
Comparison 6. Benzodiazepines + antipsychotics versus antipsychotics plus antipsychotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Behaviour: 3. mean endpoint
score (Overt Aggression Scale,
high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 + haloperidol vs
clothiapine + haloperidol -
medium term
1 60 Mean Difference (IV, Fixed, 95% CI) -5.83 [-27.60, 15.
94]
2 Leaving the study early: 1. any
reason
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 + haloperidol vs
clothiapine + haloperidol -
medium term
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Benzodiazepines plus antipsychotics versus antipsychotics plus antihistamines
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquilisation or asleep: 1.
sedation
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 + haloperidol vs
haloperidol + promethazine -
medium term
1 60 Risk Ratio (M-H, Fixed, 95% CI) 12.0 [1.66, 86.59]
2 Behaviour: 1. mean endpoint
score (Overt Aggression Scale
(OAS), high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 + haloperidol vs
haloperidol + promethazine -
short term
1 60 Mean Difference (IV, Fixed, 95% CI) -3.30 [-5.25, -1.35]
2.2 + haloperidol vs
haloperidol + promethazine -
medium term
1 60 Mean Difference (IV, Fixed, 95% CI) 1.70 [-0.06, 3.46]
3 Behaviour: 2. mean endpoint
score (Overt Agitation Severity
Scale (OASS) agitation scale,
high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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3.1 + haloperidol vs
haloperidol + promethazine -
short term
1 60 Mean Difference (IV, Fixed, 95% CI) -14.00 [-18.98, -13.
02]
3.2 + haloperidol vs
haloperidol + promethazine -
medium term
1 60 Mean Difference (IV, Fixed, 95% CI) -2.70 [-3.73, -1.67]
4 Global state: 1. no improvement
(number of participants with
< 10 points on the OAS and
OASS after 12 hours)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 + haloperidol vs
haloperidol + promethazine -
medium term
1 60 Risk Ratio (M-H, Fixed, 95% CI) 25.0 [1.55, 403.99]
5 Global state: 2. need for
additional medication (mean
dose, high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 + haloperidol vs
haloperidol + promethazine -
medium term
1 60 Mean Difference (IV, Fixed, 95% CI) 0.63 [0.15, 1.11]
6 Global state: 3. mean change
score (Ramsey Sedation Scale,
high = worse)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 + haloperidol vs
haloperidol + promethazine -
short term
1 60 Mean Difference (IV, Fixed, 95% CI) 0.60 [0.07, 1.13]
6.2 + haloperidol vs
haloperidol + promethazine -
medium term
1 60 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.46, 0.46]
7 Adverse effects/events: 1.
extrapyramidal symptoms
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 + haloperidol vs
haloperidol + promethazine -
medium term
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.16, 2.29]
8 Adverse effects/events: 2. specific 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 + haloperidol vs
haloperidol + promethazine -
hypotension - medium term
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.44, 6.36]
Comparison 8. Sensitivity analysis: benzodiazepines versus antipsychotics - 1. Random sequence generation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquilisation or asleep: 1.
sedation
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 unclear risk of bias 6 340 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.56, 1.26]
1.2 low risk of bias 3 247 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [1.52, 3.25]
2 Global state: 1. no improvement 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 unclear risk of bias 3 214 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.78, 1.63]
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2.2 low risk of bias 3 124 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.80, 1.28]
3 Adverse effects/events: 1.
extrapyramidal symptoms
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 unclear risk of bias 5 285 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.05, 0.47]
3.2 low risk of bias 3 247 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.03, 0.85]
Comparison 9. Sensitivity analysis: benzodiazepines versus antipsychotics - 2. Allocation concealment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquilisation or asleep: 1.
sedation
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 unclear risk of bias 8 434 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.79, 1.48]
1.2 low risk of bias 1 153 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [1.55, 4.73]
2 Global state: 1. no improvement 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 unclear risk of bias 6 338 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.86, 1.32]
3 Adverse effects/events: 1.
extrapyramidal symptoms
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 unclear risk of bias 7 379 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.06, 0.41]
3.2 low risk of bias 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.90]
Comparison 10. Sensitivity analysis: benzodiazepines versus antipsychotics - 3. Blinded outcome measurement
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquilisation or asleep: 1.
sedation
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 high risk of bias 1 44 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.56, 2.34]
1.2 unclear risk of bias 6 424 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.93, 1.94]
1.3 low risk of bias 2 119 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [1.05, 2.64]
2 Global state: 1. no improvement 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 unclear risk of bias 4 224 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.88, 1.59]
2.2 low risk of bias 2 114 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.60, 1.07]
3 Adverse effects/events: 1.
extrapyramidal symptoms
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 unclear risk of bias 6 426 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.05, 0.68]
3.2 low risk of bias 2 106 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.03, 0.48]
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Comparison 11. Sensitivity analysis: benzodiazepines versus antipsychotics - 4. Incomplete outcome data (attrition
bias)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tranquilisation or asleep: 1.
sedation
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 high risk of bias 2 193 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.15, 2.75]
1.2 unclear risk of bias 3 134 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.62, 1.83]
1.3 low risk of bias 4 260 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.83, 2.03]
2 Global state: 1. no improvement 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 unclear risk of bias 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 0.97]
2.2 low risk of bias 5 290 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.98, 1.56]
3 Adverse effects/events: 1.
extrapyramidal symptoms
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 high risk of bias 1 153 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.90]
3.2 unclear risk of bias 2 77 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.65]
3.3 low risk of bias 5 302 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.06, 0.60]
A D D I T I O N A L T A B L E S
Table 1. The benzodiazepine family
Name Code Chemical name
Benzodiazepines
Bromazepam Ro 5-3350 7-bromo-1, 3-dihydro-5-(2-pyridyl)-2H-1,
4-benzodiazepin-2-one
Camazepam SB 5833 7-chloro-1, 3-dihydro-3-hydroxy-1-
methyl-5-phenyl-2H-1, 4-benzodiazepin-2-
one dimethylcarbamate
Chlordiazepoxide Ro 5-0690 7-chloro-2-methylamino-5-phenyl-3H-1, 4-
benzodiazepin-4-oxide
Cinolazepam OX 373 7-chloro-5-(o-fluorophenyl)-2, 3-dihydro-3-
hydroxy-2-oxo-1H-1, 4-benzodiazepine-1-
propionitrile
Clobaza HR 376 H 4723 LM 2717 7-chloro-1-methyl-5-phenyl-1H-1, 5-benzo-
diazepine-2, 4-(3H, 5H)-dione
Clonazepam Ro 5-4023 5-(o-chlorophenyl)-1, 3-dihydro-7-nitro-
2H-1, 4-benzodiazepin-2-one
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Table 1. The benzodiazepine family (Continued)
Clorazepate 4306CB A35.616 dipotassium 7-chloro-2, 3-dihydro-2, 2-oxo-
5-phenyl-1H-1, 4-benzodiazepine-3-
carboxylate
Cp 1414 S - 2-amino-7-nitro-5-phenyl-3H-1, 5-benzo-
diazepin-4-one
Cyprazepam W 3623 7-chloro-2-[(cyclopropylmethyl)amino]-5-
phenyl-3H-1, 4-benzodiazepin-4-oxide
Delorazepam chlordemethyldiazepam - 7-chloro-5-(o-chlorophenyl)-1, 3-dihydro-
2H-1, 4-benzodiazepin-2-one
Diazepam Ro 5-2807 WY 3467 LA III 7-chloro-1, 3-dihydro-1-methyl-5-phenyl-
2H-1, 4-benzodiazepin-2-one
Doxefazepam SAS 643 7-chloro-5-(o-fluorophenyl)-1, 3-dihydro-3-
hydroxy-1-(2-hydroxyethyl)-2H-1, 4-benzo-
diazepin-2-one
Elfazepam SKF 72.517) 7-chloro-1-[2-
(ethylsulfonyl)ethyl]-5-(o-fluorophenyl)-1, 3-
dihydro-2H-1, 4-benzodiazepin-2-one
Ethyl carfluzepate - ethyl ester of 7-chloro-5-(o-fluorophenyl)-2,
3-dihydro-1- (methylcarbamoyl)-2-oxo-1H-
1, 4-benzodiazepine-3-carboxylic acid
Ethyl dirazepate - ethyl 7-chloro-5-(o-chlorophenyl)-2, 3-di-
hydro-2-oxo-1H-1, 4-benzodiazepine-3-car-
boxylate
Ethyl loflazepate CM 6912 ethyl 7-chloro-5-(o-fluorophenyl)-2, 3-dihy-
dro-2-oxo-1H-1, 4- benzodiazepine-3-car-
boxylate
Fletazepam SCH 15.698 7-chloro-5-(o-fluorophenyl)-2, 3-dihydro-1-
(2, 2, 2-trifluoroethyl)-1H-1, 4-benzodi-
azepine
Fludiazepam ID 540 7-chloro-5-(o-fluorophenyl)-1, 3-dihydro-1
methyl-2H-1, 4-benzodiazepine-2-0
Flunitrazepam Ro 5-4200 5-(o-fluorophenyl)-1, 3-dihydro-1-methyl-7-
nitro-2H-1, 4- benzodiazepin-2-one
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Flurazepam Ro 5-6901 7-chloro-1-[2-(diethylamino)ethyl]-5-
(o-fluorophenyl)-1, 3-dihydro-2H-1, 4-ben-
zodiazepin-2-one . dihydrochloride
Flutemazepam - 7-chloro-5-(o-fluorophenyl)-1, 3-dihydro-3-
hydroxy-1-methyl-2H-1, 4-benzodiazepine-
2-one
Flutoprazepam KB 509 ID 1937 7-chloro-1-(cyclopropylmethyl)-5-
(o-fluorophenyl)-1, 3-dihydro-2H-1, 4-ben-
zodiazepin-2-one
Fosazepam HR 930 7-chloro-1-
[(dimethylphosphinyl)methyl]-1, 3-dihydro-
5-phenyl-2H-1, 4-benzodiazepin-2-one
Girisopam GYKI 51.189 EGIS 5810 1-(3-chlorophenyl)-4-methyl-7, 8-
dimethoxy-5H-2, 3-benzodiazepine
Gv 150013 - (R)-N-[(adamantane-1-methyl)-2, 4-dioxo-
5-phenyl-2, 3, 4, 5-tetrahydro-1H-1, 5-ben-
zodiazepin-3-yl]-N-phenylurea
Halazepam SCH 12.041 7-chloro-1, 3-dihydro-
5-phenyl-1-(2, 2, 2-trifluoroethyl)-2H-1, 4-
benzodiazepin-2-one
Iclazepam clazepam (formerly) - 7-chloro-1-[2-(cyclo-
propylmethoxy)ethyl]-1, 3-dihydro-5-phenyl-
2H-1, 4-benzodiazepin-2-one
Lorazepam WY 4036 7-chloro-5-(o-chlorophenyl)-1, 3-dihydro-3-
hydroxy-2-1, 4-benzodiazepin-2-one
Lormetazepam WY 4082 7-chloro-5-(o-chlorophenyl)-1, 3-dihydro-3-
hydroxy-1-methyl-2H-1, 4-benzodiazepin-
2-one
MORF8063 WE 352 1-methyl-5-phenyl-7-(trifluoromethyl)-1H-
1, 5-benzodiazepine-2, 4(3H, 5H)dione
Meclonazepam (3-methylclonazepam) Ro 11-
3128 (meclonazepam, Roche) Ro 11-3624
(steric antipode of meclonazepam)
(+)-(S)-5-(o-chlorophenyl)-1, 3-dihydro-
3-methyl-7-nitro-2H-1, 4-benzodiazepin-2-
one
Medazepam Ro 5-4556 7-chloro-2, 3-dihydro-1-methyl-5-phenyl-
1H-1, 4-benzodiazepine
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Menitrazepam CB 4857 5-(1-cyclohexen-1-yl)-1, 3-dihydro-
1-methyl-7-nitro-2H-1, 4-benzodiazepin-2-
one
Metaclazepam (formerly: Brometazepam) KC 2547 KC 3755 (normetaclazepam (ac-
tive metabolite)
7-bromo-5-(o-chlorophenyl)-2, 3-dihydro-2-
(methoxymethyl)-1-methyl-1H-1, 4-benzo-
diazepine
Nimetazepam S 1530 1, 3-dihydro-1-methyl-7-nitro-5-phenyl-
2H-1, 4-benzodiazepin-2-one
Nitrazepam Ro4-5360Ro5-3059CB4395 (potassium
salt)
1, 3-dihydro-7-nitro-5-phenyl-2H-1, 4-ben-
zodiazepin-2-one
Nordazepam Ro 5-2180 A 101 7-chloro-1, 3-dihydro-3-hydroxy-5-phenyl-
2H-1, 4-benzodiazepin-2-one
Normetrazepam CB 4260 7-chloro-5-(1-cyclohexen-1-yl)-1, 3-
dilhydro-2H-1, 4-benzodiazepin-2-one
Oxazepam WY 3498 8092 CB Ro 5-6789 7-chloro-1, 3-dihydro-3-hydroxy-5-phenyl-
2H-1, 4-benzodiazepin-2-one
Oxazepam hemisuccinate SAS 538 7-chloro-2, 3-dihydro-3-hydroxy-
2-(1H)-oxo-5-phenyl-1, 4-benzodiazepin-3-
yl hydrogen succinate
Pinazepam Z 905 7-chloro-1, 3-dihydro-5-phenyl-1-(2-propy-
nyl)-2H-1, 4-benzodiazepin-2-one
Potassium nitrazepate CB 4335 2, 3-dihydro-7-nitro-2-
oxo-5-phenyl-1H-1, 4-benzodiazepin-3-car-
boxylic acid monopotassium salt
Prazepam W 4020 7-chloro-1-(cyclopropylmethyl)-1, 3-dihydro-
5-phenyl-2H-1, 4-benzodiazepin-2-one
Quazepam SCH 16.134 7-chloro-5-(o-fluorophenyl)-1, 3-dihydro-1-
(2, 2, 2-trifluoroethyl)-2H-1, 4-benzodi-
azepine-2-thione
Reclazepam SC 33.963 2-[7-chloro-5-(o-chlorophenyl)
-2, 3-dihydro-1H-1, 4-benzodiazepin-1-yl]-
2-oxazolin-4-one
Sc 32.855 - 7-chloro-5-(o-chlorophenyl)-1- (4, 5-dihy-
dro-2-oxazolyl)-2, 3-dihydro-1H-1, 4-ben-
zodiazepine
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Sulazepam W3676 7-chloro-1, 3- dihydro-1-methyl-5-phenyl-
2H-1, 4- benzodiazepin- 2-thione
Temazepam ER 115 Ro 5-5345 WY 3917 7-chloro-1, 3-dihydro-3-hydroxy-1-methyl-
5-phenyl-2H-1, 4-benzodiazepin-2-one
Tetrazepam CB 4261 7-chloro-5-(cyclohexen-1-yl)-1, 3-dihydro-1-
methyl-2H-1, 4-benzodiazepin-2-one
Tofisopam EGYT 341 5-ethyl-
7-8-dimethoxy-1-(3, 4-dimethoxyphenyl)-4-
methyl-5H-2, 3-benzodiazepine
Uldazepam U 31.920 2-[(allyloxy)amino]-7-chloro-5-(o-
chlorophenyl)-3H-1, 4-benzodiazepine
Tricyclic benzodiazepines
1-Hydroxytriazolam - 8-chloro-6-(o-chlorophenyl)
-4H-s-triazolo[4, 3-a][1, 4]benzodiazepine-
1-methanol
Adinazolam U 41.123 F (mesylate) U 41.123 (base) 8-chloro-1-[(dimethylamino)methyl]-
6-phenyl-4H-s-triazolo[4, 3-a][1, 4]benzo-
diazepine (mesylate)
Alprazolam U 31.889 8-chloro-1-methyl-6-phenyl-4H-s-
triazolo[4, 3-a][1, 4]benzodiazepine
Climazolam - 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-
imidazo[1, 5-a][1, 4]benzodiazepine
Cloxazolam CS 370 MT 14-411 10-chloro-11b-(o-chlorophenyl)
-2, 3, 7, 11b-tetrahydro-oxazolo[3, 2-d][1,
4]benzodiazepin-6 (5H)-one
Estazolam noralprazolam D 40 TA Lu 7426 Abbott 47631 8-chloro-6-phenyl-4H-s-triazolo[4, 3-a][1,
4] benzodiazepine
Flutazolam MS 4101 10-chloro-11b-(2-flurophenyl)-2, 3, 7, 11b-
tetrahydro-7-(2-hydroxyethyl-oxazolo[ 3, 2-
d] [1, 4] benzodiazepin-6(5H)-one
Gp 55.129 U 40125 8-chloro-6-phenyl-4H-s-triazolo[4, 3-a][1,
4]benzodiazepine-1-methanol
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Haloxazolam CS 430 10-bromo-11b-
(o-fluorophenyl)-2, 3, 7, 11b-tetrahydrooxa-
zolo[3, 2-d][1, 4]benzodiazepin-6(5H)-one
Ketazolam U 28.774 11-chloro-8, 12b-dihydro-2, 8-dimethyl-
12b-phenyl-4H-[1, 3]oxazino[3, 2-d][1,
4]benzodiazepine-4, 7(6H)- dione
Loprazolam RU 31.158 HR 158 (Z)-6-(o-chlorophenyl)-2, 4-dihydro-2-[(4-
methylpiperazin-1-yl)methylene]-8-nitro-
1H- imidazo[1, 2-a][1,~ 4]benzodiazepin-
1-one
Mexazolam CS 386 10-chloro-11b-(o-chlorophenyl)-2,
3, 7, 11b-tetrahydro-3-methyl-oxazolo[3, 2-
d][1, 4]benzodiazepin-6(5)-one
Midazolam Ro 21-3981 (maleate) Ro 21-3981/003
(HCl)
8-chloro-6-(o-fluorophenyl)
-1-methyl-4H-imidazo [1, 5-a][1, 4]benzo-
diazepine maleate (1: 1)
Noradinazolam U 42.352 8-chloro-1-(methylamino)methyl]-6-phenyl-
4H-s-triazolo[4, 3-a][1, 4]benzodiazepine
Oxazolam - 10-chloro-2, 3, 7, 11b-tetrahydro-2-methyl-
11b-phenyloxazolo[3, 2-d][1, 4]benzodi-
azepin- 6(5H)-one
Ru 31.124 - 8-chloro-6-(o-chlorophenyl)-2-
(4-ethylpiperazin-1-yl)methyl]-2, 4-dihydro-
1H-imidazo[1, 2-a][1, 4]benzodiazepin-1-
one (methyl bridge or methylene group uncer-
tain)
Triazolam U 33.030 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-
triazolo[4, 3-a][1, 4]benzodiazepine
Benzodiazepines with atypical mode of action
Arfendazam - ethyl 7-chloro-2, 3, 4, 5-tetrahydro-4-oxo-5-
phenyl-1H-1, 5-benzodiazepine-1-carboxy-
late
Devazepide L 364.718 (former designation) MK 329
(Merck and Co., USA) L 365.031(Merck)
(S)-N-(2, 3-dihydro-1-methyl-2-oxo-
5-phenyl-1H-1, 4- benzodiazepin-3-yl)-in-
dole-2-carboxamideL 365031N-(2, 3- dihy-
dro-1-methyl-2-oxo-5-phenyl-1H-1, 4-ben-
zodiazepin-3-yl)-1H-p-bromobenzamide
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Gyki 52.322 EGIS 6775 1-(4-aminophenyl)-4-methyl-7, 8-
dimethoxy-5H-2, 3-benzodiazepine 2, 3-
L 365260 - (R)-N-(2, 3-dihydro-1-methyl-2-oxo-5-
phenyl-1H-1, 4-benzodiazepin-3-yl)-N’-(3-
methylphenyl)-urea
Ro 15-4513 - ethyl 8-azido-5, 6-dihydro-6-oxo-4H-im-
idazo[1, 5-a][1, 4]benzodiazepine-3-car-
boxylate
Ro 5-4864 - 7-chloro-5-(p-chlorophenyl)-1, 3-dihydro-1-
methyl-2H-1, 4-benzodiazepin-2-one
Tifluadom KC 5103 (+)-tifluadom KC 6128 (San-
doz/Kali- Chemie, BRD) (-)-tifluadom
KC5911
(+/-)-N-[[5-(o-fluorophenyl)-2, 3-di-
hydro-1-methyl-1H-1, 4-benzodiazepin-2-
yl]methyl]-3-thiophenecarboxamide
Fused benzodiazepines
Brotizolam Ladormin (provisional name) We 941 2-bromo-4-(o-chlorophenyl)-
9-methyl-6H-thieno [3, 2-f ]-s-triazolo[4, 3-
a][1, 4]diazepine
Ciclotizolam We 973-BS 2-bromo-4-(o-chlorophenyl)-9-
cyclohexyl-6H-thieno[3, 2-f ]-s-triazolo[4, 3-
a][1, 4]diazepine
Clotiazepam Y 6047 5-(o-chlorophenyl)-7-ethyl-1, 3-dihydro-1-
methyl-2H-thieno[2, 3-e][1, 4]diazepin-2-
one
Etizolam AHR 3219 Y 7131 4-(o-chlorophenyl)-2-ethyl-
9-methyl-6H-thieno [3, 2-f ]-s-triazolo[4, 3-
a][1, 4]diazepine
Lopirazepam D 12524 7-chloro-5-(o-chlorophenyl)-1, 2-dihydro-3-
hydroxy-3H-pyrido[3, 2- e][1, 4]diazepin-2-
one
Premazepam MDL 181 3, 7-
dihydro-6, 7-dimethyl-5-phenylpyrrolo[3, 4-
e][1, 4]diazepin-2(1H)-one
Razobazam Hoe 175 4, 8-dihydro-3, 8-dimethyl-4-phenylpyra-
zolo[3, 4-b][1, 4]diazepine-5, 7(1H, 6H)-
dione
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Ripazepam CI 683 1-ethyl-4, 6-dihydro-3-methyl-8-
phenylpyrazolo[4, 3-e][1, 4]diazepin-5(1H)
-one
Ro 11-7800 - 9-aminomethyl-2-chloro-
4-(o-chlorophenyl)-6H-thieno[3, 2-f ]-s-tria-
zolo[4, 3-a][1, 4] diazepine
Thiadipone CI 718 bentazepam QM 6008 1, 3, 6, 7, 8, 9-hexahydro-5-phenyl-2H-
[1]benzothieno[2, 3-e][1, 4]diazepin-2-one
Zapizolam - 8-chloro-6-(o-chlorophenyl)-4H-pyrido[2,
3-f ]-s-triazolo[4, 3-a][1, 4]diazepine
Zomebazam - 4, 8-dihydro-1, 3, 8-trimethyl-4-phenylpyra-
zolo [3, 4-b][1, 4]diazepine-5, 7(1H, 6H)-
dione
Zometapine CI 781 7, 8-dihydro-1, 3-dimethyl-4-phenyl-6H-
pyrazolo[3, 4-e][1, 4] diazepine
Table 2. Half lives of some benzodiazepines
Benzodiazepine Half-life
1. Long
Chlordiazepoxide 5-30 hours
Clobazam 16-60 hours
Clorazepate 1-2 hours
Diazepam 20-40 hours
Flurazepam 1-2 hours
Ketazolam ~30 hours
Metaclazepam 7-23 hours
Oxazolam ~30 hours
2. Medium/short
Alprazolam 10-15 hours
114Benzodiazepines for psychosis-induced aggression or agitation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Half lives of some benzodiazepines (Continued)
Bromazepam 10-20 hours
Brotizolam 4-7 hours
Clotiazepam 3-15 hours
Loprazolam 6-8 hours
Lorazepam 8-24 hours
Lormetazepam 8-14 hours
Nitrazepam 15-30 hours
Oxazepam 4-15 hours
Temazepam 5-14 hours
3. Extremely short
Midazolam 1-7 hours
Triazolam 1.5-5 hours
Table 3. Reviews focusing on similar participant groups
Focus of review Reference
Aripiprazole for psychosis-induced agitation/aggression Pagadala 2009
Benzodiazepines for schizophrenia Volz 2007
Containment strategies for people with serious mental illness Muralidharan 2006
Chlorpromazine for psychosis-induced agitation/aggression Ahmed 2010
Haloperidol (rapid tranquillisation) for psychosis-induced agita-
tion/aggression
Powney 2011
Haloperidol for long-term aggression in psychosis Khushu 2012
Haloperidol plus promethazine for psychosis-induced agitation/
aggression
Huf 2009
Loxapine for schizophrenia Chakrabarti 2007
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Loxapine inhaler for psychosis-induced aggression or agitation Vangala 2012
Olanzapine IM or velotab for acutely disturbed/agitated people
with suspected serious mental illnesses
Belgamwar 2005
Quetiapine for psychosis-induced aggression or agitation Wilkie 2012
Risperidone for psychosis-induced agitation/aggression Ahmed 2011
Seclusion and restraint for people with serious mental illnesses Sailas 2000
Zuclopenthixol acetate for acute schizophrenia and similar serious
mental illnesses
Gibson 2012
Table 4. High and low attrition studies
Attrition Study % loss Duration Notes
High Alprazolam 1992, USA 31 72 hours -
Clonazepam 1993, CA 12 2 hours -
Midazolam 2006, AU 10 100 minutes -
Diazepam 1979, IL 50 24 hours -
Lorazepam 1991, USA 33 48 hours 33% participants lost to follow-up for EPS outcome and 12%
loss for ’sedation’
Lorazepam 2006, USA 10 90 minutes -
Low Lorazepam 1998, USA 0 7 days -
Flunitrazepam 1999, IL 0 2 hours -
Lorazepam 2001, RO and
USA
4 24 hours -
Lorazepam 1998, SA 0 7 days -
Midazolam 2003, BZ 1 2 weeks -
Lorazepam 2004, IN 0.5 4 hours -
Clonazepam 1999, CHN 0 24 hours -
Clonazepam 2007a, CHN 0 24 hours -
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Lorazepam 1989, USA 0 60 minutes -
Lorazepam 1997a, USA 0 24 hours -
Lorazepam 1997b, USA 0 4 hours -
Midazolam 2011, BZ 0 12 hours -
Unclear Lorazepam 2009, SK Unclear 120 minutes Only abstract available.
Lorazepam 2010, IN Unclear 24 hours Only abstract available.
Trials were considered to have a high attrition rates if it was more than 5% within the first two hours or 25% to 50% overall.
EPS: extrapyramidal symptoms.
Table 5. Suggested design of future reviews
Methods Allocation: randomised, fully described in terms of methods of randomisation and allocation concealment
Blinding: double/single blind, with methods of maintenance of blinding fully described
Setting: psychiatric emergency settings/hospital.
Duration: immediate term (0-15 minutes); short term (15 minutes to 1 hour); medium term (1-48 hours);
long term (≥ 48 hours)
Participants Diagnosis: primary diagnosis of schizophrenia or related disorders, including schizophreniform disorder,
schizoaffective disorder and delusional disorder with psychosis-induced aggression or agitation
Subgroups: dual diagnoses or drug/alcohol use, or both.
Age: adults, with age specified in trial.
Sex: both.
Comparisons a. Benzodiazepines - given alone.
Including: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clo-
tiazepam, cloxazolam, delorazepam, diazepam, estazolam, flunitrazepam, halazepam, loprazolam, lorazepam,
lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam,
pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam or triazolam
Any dose, any means of administration.
Compared with:
1. Other benzodiazepine - given alone.
Any dose, any means of administration.
2. Antipsychotics.
First generation/typical, including: chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, droperidol,
flupentixol/flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine, mesoridazine, molindone,
periciazine, perphenazine, pimozide, prochlorperazine, promazine, promethazine, thioridazine, thiothixene,
trifluoperazine, triflupromazine or zuclopenthixol
Second generation/atypical, including: amisulpride, aripiprazole, asenapine, clozapine, clothiapine, clotiap-
ine, iloperidone, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, remoxipride,
risperidone, sertindole, sulpiride, ziprasidone or zotepine
Any dose, any means of administration.
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3. Other combinations of drugs.
3.1. Benzodiazepines + antipsychotics.
3.2. Antipsychotics + antihistamine/anticholinergic drugs.
Antihistamines include: azelastine, brompheniramine, buclizine, bromodiphenhydramine, carbinoxamine,
cetirizine, cyclizine, chlorpheniramine, chlorodiphenhydramine, clemastine, cyproheptadine, desloratadine,
dexbrompheniramine, deschlorpheniramine, dexchlorpheniramine, dimenhydrinate, dimethindene, diphen-
hydramine, doxylamine, ebastine, embramine, fexofenadine, levocetirizine, loratadine, meclozine, olopata-
dine, orphenadrine, phenindamine, pheniramine, phenyltoloxamine, promethazine, pyrilamine, rupatadine,
tripelennamine or triprolidine.
Any dose, any means of administration.
4. Non-pharmacological approaches.
b. Benzodiazepines plus antipsychotics.
Compared with:
1. Placebo.
2. Antipsychotics.
Any dose, any means of administration.
3. Other combinations.
3.1. Benzodiazepines plus antipsychotics.
3.2. Antipsychotics plus antihistamines.
4. Non-pharmacological approaches.
c. Benzodiazepines (specific named drug) - given alone.
1. High dose (as defined by each study).
2. Low or standard dose (as defined by each study).
d. Benzodiazepines (specific named drug) - given alone.
1. Oral.
2. Intramuscular or intravenous.
e. Benzodiazepines (specific named drug) - given alone.
1. Low frequency (as defined by each study).
2. High frequency (as defined by each study).
Outcomes measures Primary outcomes.
1. Global impression.
1.1. Specific.
1.1.1. No improvement: as defined by each study. If more than 1 measure of improvement was reported,
then improvement in behaviour is used, followed by improvement in mental state, and then improvement in
symptoms
1.1.2. Tranquillisation (feeling of calmness or calm, non-sedated behaviour (or both))
Secondary outcomes.
2. Global impression - CGI.
2.1. General.
2.1.1. No clinically important change in general functioning.
2.1.2. No change in general functioning.
2.1.3. Mean endpoint change in general functioning.
2.1.4. Mean change in general functioning.
2.2. Specific.
2.2.1. Aggression.
2.2.2. Self-harm, including suicide.
2.2.3. Injury to others.
2.2.4. Improvement in self-care or degree of improvement in self-care.
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2.2.5. Sedation (sleepiness and drowsiness).
2.2.6. Compulsory administrations of treatment.
2.2.7. Need for additional medication.
2.2.8. Decrease in medication.
2.2.9. No change in medication dosage.
2.2.10. Mean change/endpoint scores.
3. Behaviour.
3.1. General.
3.1.1. No clinically important change in behaviour.
3.1.2. Mean behaviour score.
4. Mental state - BPRS.
4.1. General.
4.1.1. No clinically important change in general mental state scores.
4.1.2. Mean endpoint general mental state score.
5. Adverse effects/events.
5.1. General.
5.1.1. Incidence of side effects, general or specific.
5.1.2. Severity of symptoms.
5.1.3. Measured acceptance of treatment.
5.1.4. Sudden or unexpected death.
5.2. Specific.
5.2.1. EPS.
5.2.2. Use of medication for EPS.
6. Hospital and service outcomes.
6.1. Hospitalisation.
6.1.1. Time to hospitalisation.
6.1.2. Hospitalisation of people in the community.
6.1.3. Duration of hospital stay.
6.1.4. Changes in services provided by community teams.
6.2. Seclusion.
6.2.1. Time in seclusion.
6.2.2. Changes in hospital status (e.g. changes from voluntary to involuntary care, changes in level of obser-
vation, use of seclusion)
7. Satisfaction with treatment.
7.1. Specific.
7.1.1. Consumers.
7.1.2. Family and informal carers.
7.1.3. Professionals/carers.
8. Economic outcomes.
8.1. Cost-effectiveness.
8.2. Direct costs.
8.3. Indirect costs.
9. Leaving the study early.
9.1. For any reason.
9.2. For reasons treatment related.
9.3. For reasons unrelated to treatment.
9.4. Due to relapse.
9.5. Due to adverse effects.
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Notes -
BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression; EPS: extrapyramidal symptoms.
Table 6. Suggested design of future studies
Methods Allocation: randomised, fully described in terms of methods of randomisation and allocation concealment
Blinding: double/single blind, with methods of maintenance of blinding fully described
Setting: psychiatric emergency settings/hospital.
Duration: follow-up 72 hours.
Participants Diagnosis: primary diagnosis of schizophrenia or related disorders, including schizophreniform disorder, schizoaf-
fective disorder and delusional disorder with psychosis-induced aggression or agitation
Subgroups: dual diagnoses or drug/alcohol use (or both)
Number of participants > 400.
Age: adults, with age specified in trial.
Sex: both.
Interventions 1. Benzodiazepines - given alone.
Including: alprazolam, bretazenil, bromazepam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clo-
tiazepam, cloxazolam, delorazepam, diazepam, estazolam, flunitrazepam, halazepam, loprazolam, lorazepam,
lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam,
pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam or triazolam
Any dose, any means of administration.
Compared with:
a. Other benzodiazepine - given alone.
Any dose, any means of administration.
b. Antipsychotics.
First generation/typical, including: chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, droperidol, flu-
pentixol/flupenthixol, fluphenazine, haloperidol, levomepromazine, loxapine,mesoridazine,molindone, periciazine,
perphenazine, pimozide, prochlorperazine, promazine, promethazine, thioridazine, thiothixene, trifluoperazine, tri-
flupromazine or zuclopenthixol
Second generation/atypical, including: amisulpride, aripiprazole, asenapine, clozapine, clothiapine, clotiapine,
iloperidone, lurasidone, mosapramine, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, risperidone,
sertindole, sulpiride, ziprasidone or zotepine
Any dose, any means of administration.
c. Other combinations of drugs.
i. Benzodiazepines plus antipsychotics.
ii. Antipsychotics plus antihistamine/anticholinergic drugs.
Antihistamines including: azelastine, brompheniramine, buclizine, bromodiphenhydramine, carbinoxamine,
cetirizine, cyclizine, chlorpheniramine, chlorodiphenhydramine, clemastine, cyproheptadine, desloratadine,
dexbrompheniramine, deschlorpheniramine, dexchlorpheniramine, dimenhydrinate, dimethindene, diphenhy-
dramine, doxylamine, ebastine, embramine, fexofenadine, levocetirizine, loratadine, meclozine, olopatadine, or-
phenadrine,phenindamine,pheniramine,phenyltoloxamine,promethazine,pyrilamine, rupatadine, tripelennamine
or triprolidine.
Any dose, any means of administration.
d. Non-pharmacological approaches.
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Table 6. Suggested design of future studies (Continued)
2. Benzodiazepines plus antipsychotics.
Compared with:
a. Placebo.
b. Antipsychotics.
Any dose, any means of administration.
c. Other combinations.
i. Benzodiazepines plus antipsychotics.
ii. Antipsychotics plus antihistamines.
d. Non-pharmacological approaches.
Outcomes 1. Global impression: no improvement (as defined by each study. If more than 1 measure of improvement was
reported, then improvement in behaviour was used, followed by improvement inmental state, and then improvement
in symptoms)
2. Global impression; general/specific (including tranquillisation/sedation/need for additional medication/decrease
in medication/injury to others/self-harm/aggression or agitation/compulsory administration of treatment)
3. Behaviour: no clinically important change in behaviour.
4. Mental state: no clinically important change in general mental state scores
5. Adverse effects/events (including incidence of specific adverse effects/severity of symptoms/death/EPS/use of
medication for EPS)
6. Hospital and service outcomes (including time to hospitalisation/duration of hospital stay/seclusion/time in
seclusion/changes in hospital status/use of mechanical restraints)
7. Satisfaction with treatment.
8. Economic outcomes.
9. Leaving the study early.
Notes Any outcomes measured using scale-derived data should be interpreted in such a way as to make clear the real-life
relevance of changes in scale score
EPS: extrapyramidal symptoms.
WH A T ’ S N E W
Last assessed as up-to-date: 3 August 2016.
Date Event Description
13 September 2017 New citation required but conclusions have not
changed
Newdata found in update search have not altered over-
all conclusions of review
3 August 2016 New search has been performed Search updated and 3 studies were added to ’Stud-
ies awaiting classification’ section of the review. Re-
structuring of outcomes to be consistent with outcome
structure for other aggression reviews in Cochrane
Schizophrenia
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H I S T O R Y
Protocol first published: Issue 2, 2001
Review first published: Issue 4, 2005
Date Event Description
20 August 2015 Amended Search was updated and 75 references were added to
’Classification pending section’ of the review
18 March 2013 New citation required and conclusions have changed Minor changes to conclusions after new data added to
review.
1 March 2013 New search has been performed Results of update search added. Ten new trials included
bringing the total number of included studies in the re-
view to 21, new comparisons and outcomes added with
new data resulting in minor changes to conclusions
22 October 2008 Amended Converted to new review format.
5 August 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
HZ: data extraction, analysis, writing-up, 2016 update.
SJS: data extraction, analysis, writing-up, 2012 update.
AB: protocol development, data extraction, analysis, writing-up for original version.
TS: study selection, data extraction, writing up, 2016 update.
FC: study selection, data extraction, writing up 2016 update.
SS: data extraction, analysis, writing-up, 2016 update.
SZ: data extraction, analysis, writing-up, 2016 update.
DG: protocol development, data extraction, analysis, writing-up for original version, 2012 and 2016 update.
D E C L A R A T I O N S O F I N T E R E S T
HZ: received a grant for completion of the 2016 update
SJS: received a grant for completion of 2012 update.
AB: none known.
TS: none known.
FC: none known
SS: none known.
SZ: is employed by Review Solutions, a company that completes systematic reviews.
DG: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• The Children’s Hospital at Westmead, Sydney, Australia.
• Central Wandsworth Community Mental Health Team, London, UK.
• St George’s Mental Health NHS Trust, London, UK.
• Western Sydney Local Health District, Australia.
External sources
• NHS National R&D Programme on Forensic Mental Health, UK.
• National Institute for Health Research (NIHR), UK.
Cochrane Collaboration Programme Grant 2011; Reference number: 10/4001/15
• National Institute for Health Research (NIHR), UK.
Cochrane Incentive Grant (2017 update)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Minor
1. ’Risk of bias’ tables for each included study have been extended to include random sequence generation (selection bias), allocation
concealment, blinding (performance and detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias)
and other bias.
3. We added ’Summary of findings’ tables to include a summary of the main outcomes of interest for each comparison.
Major
1. In this update, there have been additions to the Types of interventions section, to include recent important research comparing
benzodiazepines (alone or in combination with antipsychotics) with combined antipsychotics/antihistamines. The authors consider
that this is an area of research of fundamental value that merits inclusion in this systematic review, as benzodiazepines were employed
and so should not have been overlooked.
2. Types of outcome measures have been modified/clarified from the original protocol - this decision was not influenced by any
outcomes. Where the protocol did not define the primary outcome of interest, this update specified ’no improvement’ as the primary
outcome. This was to be defined by each trial author, as the review authors considered that numbers of people who did not improve
by use of a particular intervention was of fundamental importance to both service users and care providers.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Aggression [drug effects]; Anti-Dyskinesia Agents [therapeutic use]; Antipsychotic Agents [∗therapeutic use]; Benzodi-
azepines [∗therapeutic use]; Drug Therapy, Combination [methods]; Emergency Treatment [methods]; Haloperidol [therapeutic use];
Lorazepam [therapeutic use]; Psychomotor Agitation [drug therapy]; Psychotic Disorders [∗drug therapy]; Randomized Controlled
Trials as Topic
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MeSH check words
Humans
124Benzodiazepines for psychosis-induced aggression or agitation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
